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Background: Acute and chronic respiratory failure occurs as a 
consequence of an imbalance in the load-capacity-drive relationship of the 
respiratory system.  Despite the high morbidity and mortality of these patients, 
clear clinical strategies for assessment and subsequent management have 
been lacking due to the limited high quality data available.  The aim of this 
thesis was to evaluate novel techniques to monitor patients with acute 
respiratory deterioration as well as the use of specific monitoring and non-
invasive ventilation strategies in patients with chronic respiratory failure, which 
could translate into important clinical benefits. 
Methods: Three clinical physiological studies were performed.  Firstly, a 
randomised controlled trial evaluated an automated novel hybrid pressure-
volume mode of non-invasive ventilation to treat obesity hypoventilation 
syndrome.  Although the primary outcome measure was gas exchange at three 
months, important physiological measures including physical activity, sleep 
quality and their relationship to weight loss were also investigated.  Secondly, 
an observational cohort trial investigated the role of a novel advanced 
physiological biomarker, neural respiratory drive, to identify treatment failure 
and readmission risk in patients admitted to hospital with an acute exacerbation 
of chronic obstructive pulmonary disease.  The third physiological trial 
investigated, in patients with persistent hypercapnic respiratory failure following 
an acute exacerbation of COPD as part of a large randomised controlled trial, 
the efficacy and mechanism of action of home mechanical ventilation and its 
effect on sleep quality compared with standard oxygen therapy.  
Results: The automated volume targeted mode of ventilation demonstrated 
no advantage in physiological and clinical outcomes above a nurse-led 
protocolised standard set up of non-invasive ventilation in the management of 
obesity hypoventilation syndrome.  The trial was the first to demonstrate that the 
management of sleep disordered breathing and chronic respiratory failure in 
obesity hypoventilation syndrome confers an improvement in objectively 
assessed physical activity as well as weight loss, which has important clinical 
implications.  In the second trial, neural respiratory drive was validated as a 
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novel physiological biomarker to monitor acute clinical change during hospital 
treated exacerbations of COPD.  Furthermore, patients in whom neural 
respiratory drive failed to fall in response to treatment prior to hospital discharge 
had a significantly higher risk of hospital readmission within 14 days, again, 
highlighting the important clinical implications of detailed physiological 
observations.  The third physiological trial confirmed previous data indicating 
that an important mechanism of action of home mechanical ventilation in COPD 
is through improvements in central respiratory drive, but this conclusion was 
given greater confidence by the use of advanced physiological monitoring.   
Conclusion: The data presented in this thesis provide clinically important 
information on the physiological targeting of set-up of non-invasive ventilation in 
patients with chronic respiratory failure secondary to obesity hypoventilation 
syndrome and severe COPD.  Important markers of treatment success in the 
management of chronic respiratory failure in obesity hypoventilation syndrome 
have been identified including physical activity, sleep quality and weight loss.  
These data have also established the potential clinical role of advanced 
physiological biomarkers of neural respiratory drive to monitor clinical change 
and to risk stratify patients during acute exacerbations of COPD.  Finally, the 
data in this thesis provides further evidence that the major mechanism of action 
of home mechanical ventilation in hypercapnic COPD patients is the 
modification of central respiratory drive. 
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CHAPTER 1: INTRODUCTION 
The respiratory system maintains oxygen and carbon dioxide homeostasis, 
which is achieved with repetitive cyclical neural activation and subsequent 
contraction of the respiratory muscles.  Contraction of the inspiratory muscles 
causes an increase in intrathoracic volume with a consequent decrease in 
intrathoracic pressure, which generates a subatmospheric pressure gradient 
causing airflow into the lungs.  The efficiency of this respiratory muscle system 
is dependent on the strength and endurance of the respiratory muscles 
(respiratory muscle capacity) working against the resistance and compliance of 
the airways, lung and chest wall (respiratory muscle load).  Respiratory failure 
arises due to an imbalance in the relationship between neural respiratory drive, 
respiratory muscle capacity and respiratory muscle load (Figure 1) and non-
invasive ventilation (NIV) is used to augment alveolar ventilation in patients with 
chronic respiratory failure. 
Figure 1: Respiratory muscle load-capacity-drive relationship  
 
Illustrates the interaction between load, capacity and drive that is essential to produce 
ventilation 
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1.1: Assessment of Patients with Chronic Respiratory Failure 
Few standards currently exist to guide the assessment of patients with chronic 
respiratory failure during the setup of home mechanical ventilation (HMV).  
Empirically, the evaluation of these patients requires little more than 
measurement of arterial blood gas tensions but, in practice, detailed 
physiological assessment of these key areas is often appropriate.  A summary 
of current practice in evaluation has been divided into: 
 Basic clinical assessment 
 Gas exchange 
 Overnight physiological monitoring 
 Respiratory muscle function 
 Neural respiratory drive 
 Pulmonary mechanics 
 Patient-ventilator interaction 
 Health related quality of life 
 Physical activity 
1.1.1: Basic clinical assessment 
The specific assessments in clinic consultations for patients will depend on the 
underlying aetiology of respiratory failure but a variety of issues are commonly 
identified regarding domiciliary ventilation and should be focused on to ensure 
that adequate patient-ventilator interaction and effective ventilation are 
achieved.  The primary goal of the consultation should be for the clinician to 
demonstrate that the overall effect of HMV is acceptable to the patient and this 
can be judged by the adherence of the patient to the nocturnal prescription of 
NIV and by the effect with sustained use on arterial carbon dioxide tensions.  
The majority of home ventilators now have internal monitoring clocks that 
measure and record the total blower hours and/or data cards that can be used 
for the measurement of adherence.  These data should be compared against 
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the patient reported adherence and any discrepancies investigated with the 
patient.  Poor adherence should prompt further questioning to identify areas to 
improve compliance. 
A range of clinical investigations are available to assist with the assessments of 
patients for HMV.  These cover simple bedside tests to more complicated 
invasive testing used in research.  The investigations are summarised below 
indicating those ‘basic’ tests (Table 1) used in routine clinical practice and 
‘advanced’ procedures (Table 2) used in research. 
Table 1: Basic investigations used in the assessment of home mechanical ventilation 
Basic 
Investigation Unit Assessment 
Sniff nasal pressure (SNIP) cmH2O 










Global expiratory muscle 
strength 
Spirometry (FEV1/FVC) l 
Lung volume and airflow 
obstruction, VC an indirect 
measure of respiratory muscle 
strength 
Cough Expiratory Flow l/min 
Global expiratory muscle 
strength 
Arterial Blood Gases Various 




Table 2: Advanced investigations used in the assessment of home mechanical 
ventilation 
Advanced 
Investigation Unit Assessment 
Sniff Oesophageal Pressure cmH2O 
Global inspiratory muscle 
strength 
Cough Gastric Pressure cmH2O 




cmH2O Volitional diaphragm strength 
Twitch Pdi cmH2O 
Non-volitional diaphragm 
strength 
Intrinsic Positive End 
Expiratory Pressure 
cmH2O Threshold load 
Pulmonary Compliance l/cmH2O Resistive load 
Diaphragm EMG%max % Neural Respiratory Drive 
1.1.2: Gas exchange 
Arterial blood gas (ABG) analysis is an important tool in the assessment of 
patients receiving HMV.  The test is simple to perform by skilled operators and 
the results are rapidly available allowing prompt clinical decisions.  Many units 
are now using arterialised earlobe blood gas as an alternative to ABGs.  These 
have been shown to accurately reflect the arterial partial pressure of carbon 
dioxide (PaCO2) and can be less painful than the arterial equivalent.
1  However, 
earlobe blood gasses can poorly reflect the arterial partial pressure of oxygen  
(PaO2), despite high correlation, due to wide limits of agreement tending to 
underestimate PaO2 in the normal range and therefore need to be interpreted 
appropriately or used in conjunction with pulse oximetry.2  A range of 
parameters can be measured by the modern blood gas analysis machines but 
those of most interest are the partial pressures of oxygen and carbon dioxide 
dissolved in the liquid component of blood (PaO2 and PaCO2, respectively) and 
the arterial bicarbonate (HCO3
-) concentration.  These parameters are used to 
define respiratory failure, which is divided into type 1, hypoxic respiratory failure 
(PaO2 < 8 kPa) and type 2, hypercapnic respiratory failure (PaCO2 > 6 kPa). 
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Oxygen  
Oxygen delivery to the tissues is dependent on cardiac output and oxygen 
content of blood.  Whilst the contribution of dissolved oxygen in blood to total 
oxygen content is small it is linked to haemoglobin saturation level and that 
contributes predominantly to oxygen content (CaO2 = 1.34xSaO2x[Hb] + 
0.003xPaO2).  The correction of hypoxia with HMV is via a combination of 
improving hypoventilation, abolishing upper airways obstruction and alveolar 
recruitment.  If there is additional intrinsic lung disease the addition of 
supplementary oxygen may be required to maintain adequate oxygenation.  
Whilst correction of daytime hypoxia has been shown to be beneficial in COPD3 
there is no clear randomised controlled trial evidence for the use of long term 
oxygen therapy (LTOT) in other diseases causing respiratory failure.  In clinical 
practice, the same degree of hypoxia is used for non-COPD disease with LTOT 
prescribed when the PaO2 < 7.3 kPa or with a PaO2 < 8 kPa if there is evidence 
of sleep disordered breathing, cor pulmonale, right heart strain on the 
electrocardiogram and/or a haematocrit level greater than 50%. 
Carbon dioxide 
The main function of HMV is to correct nocturnal hypoventilation and therefore 
is given in the event of hypercapnic respiratory failure.  In contrast to oxygen, 
the majority of carbon dioxide in arterial blood is dissolved in the liquid 
component rather than being protein bound.  Due to the intrinsic properties of 
carbon dioxide, it rapidly crosses and equilibrates across the alveolar-capillary 
membrane and thus is inversely proportional to alveolar ventilation (VA).  VA is a 
product of respiratory rate (RR) and the difference between tidal volume (V t) 
and the physiological dead space (VDS) [VA = (Vt - VDS) x RR].  Thus, 
hypoventilation can occur through increased dead space, decreased tidal 
volume or decreased respiratory rate.  It is therefore possible to manipulate 
these variables using NIV, although one must appreciate that the ventilator 
circuit will produce a small increase in dead space.  However, this is far 




Acid-base balance is integrally linked to PaCO2 homeostasis and the control of 
ventilation.  Unlike hypoxia which directly stimulates ventilation via action of the 
carotid sinus, CO2 mediates its effects on ventilation via alteration in 
intracellular pH detected by peripheral and central chemoreceptors.  Chronic 
(via renal bicarbonate retention) and acute (via the Henderson-Hasselbach 
equation) hypoventilation cause a rise in HCO3
- levels that aim to buffer the 
effect on pH of rising PaCO2.  The presence of respiratory acidosis (pH < 7.35) 
on blood gas analysis indicates an acute deterioration in respiratory failure that 
is yet to be compensated for and indicates the need for prompt treatment.  
1.1.3: Overnight physiological monitoring  
The investigations discussed so far allow the physician to understand the 
interaction between respiratory muscle load, respiratory muscle capacity and 
neural respiratory drive.  However, this is directed to daytime measurements in 
the awake state for diagnosis of the clinical problem.  The assessment of the 
respiratory physiological changes occurring during sleep that alter the 
respiratory muscle load, capacity, drive relationship are required to assess for 
nocturnal ventilatory support.  There are a range of home and hospital systems, 
from simple to advanced, and these are used to: 
1. Diagnose sleep disordered breathing. 
2. Assess the severity of the problem. 
3. Monitor efficacy of treatment. 
Oximetry  
Overnight oximetry offers a simple, non-invasive and robust measure of 
nocturnal oxygenation and is a useful screening test in patients for the presence 
of sleep disordered breathing.  Due to its ease and low cost it has been used 
extensively in obstructive sleep apnoea but is insufficiently sensitive to exclude 
a diagnosis in that condition.4  The use of oximetry in the assessment of HMV 
can provide the clinician with valuable insights into the severity of disease and 
efficacy of treatment without requiring the patient to be admitted into hospital for 
full physiological monitoring studies and an experienced analyst can use these 
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simple studies to diagnose a range of more complex sleep disordered 
breathing. 
Figure 2: Typical examples of oximetry tracings for [A] obstructive sleep apnoea, [B] 
obstructive sleep apnoea and hypoventilation, [C] isolated hypoventilation  
 
Legend: Red, SpO2; blue, heart rate. 
Computerised scoring systems provide automated analysis producing a 4% 
oxygen desaturation index, analysis time spent with oxygen saturations <90% 
and heart rate variability that allow an indication of hypoxic load.  There is 
limited evidence available to set a standard lower level of nocturnal 
oxygenation, although clinical practice would aim for a mean nocturnal oxygen 
saturation levels >88%.5  Although these devices have widespread availability, 
the user should appreciate their limitations.  These limitations are most 
noticeable when patients are receiving nocturnal oxygen therapy, resulting in a 
relatively normal oximetry trace as the hypoventilation and or upper airways 
obstruction may result in minimal changes in oxygen saturations.  Oxygen 
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therapy acts to mask nocturnal desaturation by shifting the position on the 
oxyhaemaglobin dissociation curve to the right away from the steep portion.  
This means that substantially larger variations in ventilation are required to a 
produce a desaturation. 
Transcutaneous capnography 
The hallmark of hypoventilation is an increase in PaCO2.  Immediately from 
sleep onset there is a reduction in tidal volume with an associated increase in 
PaCO2 compared with wakefulness.
6, 7  This relative hypoventilation is further 
exaggerated at the onset of REM sleep due to the generalised muscle atonia.8  
Furthermore there is a degree of permissive hypercapnia with reduced central 
chemosensitivity to carbon dioxide that occurs during REM sleep.9  Previously 
monitoring changes in CO2 required either intermittent arterial sampling 
(sometimes via an indwelling line) or end tidal monitoring, the former is invasive 
and the latter unreliable in obstructive airways disease and during treatment 
with NIV.  The measurement of expiratory CO2 allows an accurate estimation of 
alveolar CO2 which at the end of expiration has equilibrated with arterial blood 
and thus approximates to PaCO2.  However, in obstructive airways disease the 
prolonged expiratory phase often prevents the exhalation of alveolar gas and 
thus the measurement of end-tidal CO2 becomes less accurate.  The advent of 
robust and reliable transcutaneous CO2 (tcCO2) monitoring has allowed for 
improved analysis of nocturnal breathing disorders. The measurement of tcCO2 
is achieved electrochemically using a Severinghuas pH electrode to quantify the 
potentiometric difference between a reference and a measuring electrode.  The 
resultant potential difference is proportional to the negative logarithm of [CO2].  
The technical constraints of the technique must be realised along with the 
appreciation that it is transcutaneous and not arterial values that are being 
measured.  The measurements are taken using a heated electrode, allowing 
increased permeability of the skin to CO2, facilitating measurement.  The 
temperature settings will vary between systems but are usually in the order of 
40-42oC.  This elevation in temperature causes an increase in the local PaCO2 
and combined with the fact that the skin is a metabolically active tissue, 
consuming oxygen and producing carbon dioxide, further increases the 
recorded value.  The commercially available systems correct for this with an 
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automated algorithm that incorporates these factors and produces a value that 
should reflect actual PaCO2.  Clinical studies have shown tcCO2 to reliably and 
reproducibly reflect PaCO2 in a range of clinical situations and conditions 
including critical care and acute NIV as well as in sleep disordered breathing 
and obesity.10-13  The introduction of combined pulse oximeter and tcCO2 
sensors has further increased the usefulness of these devices simplifying the 
amount of monitoring equipment necessary to study respiratory disorders during 
sleep.  The sensors need to be intermittently re-membraned and calibrated at 
the beginning and end of use to ensure accuracy. 
Advanced sleep studies  
Full polysomnography is rarely required in the management of respiratory 
failure, although it can be useful if it is desired to elucidate the cause of 
persistent sleepiness despite therapy.14  The use of transcutaneous carbon 
dioxide, nasal flow and respiratory inductance plethysmography allows full 
assessment of patients prior to initiation and during follow up and is sufficient in 
clinical practice.  These modalities allow full respiratory sleep studies to be 
performed and the appropriate identification of complex sleep disordered 
breathing, differentiating an obstructive from a central apnoea and documenting 
hypoventilation as well as diagnosing periodic breathing abnormalities, such as 
Cheyne-Stokes respiration.  
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Figure 3: Examples of advanced sleep studies demonstrating [A] an obstructive apnoea 
and [B] a central apnoea occurring during non-invasive ventilatory support 
Legend: Pressure, mask pressure; SUM, sum of chest and abdomen respiratory inductance 
plethysmography (RIP); RC, chest RIP; AB, abdominal RIP. 
The differentiation of obstructive from central events is in a sense one of 
exclusion, being made by the absence of respiratory effort in the latter.  This is 
routinely performed by respiratory inductance plethysmography to measure 
abdominal and thoracic excursion.  The technique is widely accepted and is well 
tolerated by patients and easy to perform, however it may over diagnose central 
events.15  Respiratory sleep studies are also helpful in initial titration of NIV 
settings and diagnosing synchronisation issues between the patient and the 
ventilator as well identifying common events, such as ventilator autocycling and 
trigger delay. 
1.1.4: Respiratory muscle testing 
Respiratory muscle weakness can be a cause of unexplained breathlessness 
with classical symptoms of diaphragm paralysis including orthopnoea, 
breathlessness in water and breathlessness on exercise.16, 17  Although routine 
imaging techniques may raise the suspicion of diaphragm paralysis the 
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sensitivity and specificity of these tests are poor and should not be relied upon 
to make a diagnosis.18  Profound respiratory muscle weakness initially leads to 
nocturnal hypoventilation prior to diurnal hypercapnia becoming established and 
this may be used as an early detector of need for nocturnal ventilatory support 
in at risk populations.19, 20  Tests of respiratory muscle strength are used in the 
diagnosis of unexplained hypercapnic respiratory failure and abnormalities 
require further testing to ascertain whether there is a generalised systemic 
neuromuscular problem or whether it is isolated to the diaphragm.  The latter 
can often be a consequence of neuralgic amyotrophy.  Isolated unilateral or 
bilateral diaphragm weakness can produce sleep disordered breathing but 
usually requires the presence of another pathological process in order to cause 
respiratory failure requiring NIV.21-23 
Non-invasive 
A simple test of respiratory muscle strength is change in VC from sitting to 
supine.  However, other more specific tests, including SNIP and MIP are 
available that better predict the presence of sleep disordered breathing and 
need for NIV, particularly in patients with NMD.19, 24  Both these pressure 
measurements can be performed using handheld devices with a nasal bung or 
mouth piece, respectively. Sniff nasal inspiratory pressure (SNIP) and mouth 
inspiratory pressure (MIP) reflect overall respiratory muscle strength and are 
generally performed from FRC.  Although the early literature reported that MIP 
testing should be performed from residual volume (RV)25 more recent work has 
shown that it is reasonable to simplify the procedure by measuring peak 
pressure from FRC.26  Previous work has shown good correlation between 
airway pressure (Paw) and oesophageal pressure (Poes) during sniff manoeuvres 
in patients without significant airways obstruction.27  Due to the wide normal 
range of MIP values and the technical difficulty some patients have with 
performing the procedure, particularly those with bulbar dysfunction, SNIP may 
provide a better method of excluding significant respiratory muscle weakness 
without the need for invasive testing.28  Although providing a reliable 
assessment of respiratory muscle function in patients with bulbar dysfunction19 
it should be realised that SNIP also has its limitations, in particular in COPD 
when airflow obstruction can prevent rapid equalisation of pressure between the 
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alveoli and upper airway giving a falsely low reading.29  However, multiple tests 
to assess respiratory muscle strength are required to exclude weakness in 
symptomatic patients.30, 31  Details on the test protocols can be found in the 
European Respiratory Society and American Thoracic Society statement on 
respiratory muscle testing.32 
Due to the passive nature of expiration normally the focus of respiratory muscle 
testing is usually on the inspiratory muscles.  Expiratory muscle function may be 
assessed non-invasively using maximum expiratory pressure (MEP) with 
pressure measured at the mouth in an analogous fashion to MIP during a forced 
expiration (from TLC) manoeuvre.  It is important to prevent the subject from 
using buccal manoeuvres to alter the mouth pressure.  As with MIP, MEP has a 
wide normal range meaning low readings should be interpreted within a clinical 
evaluation.  Other simple and commonly used tests of the expiratory muscles 
include cough peak expiratory flow (cough PEF) and whistle Pmo.  If invasive 
assessment of the expiratory muscles is being performed a voluntary cough 
Pgas is measured to assess muscle function or if involuntary assessment is 
required a twitch T10 can be recorded. 
A cough PEF can be performed using a standard peak flow meter attached to a 
face mask and usually requires little or no coaching to produce acceptable 
technique.  It must be realised that although this test indicates expiratory 
muscle performance the pressure and force generated depends on lung 
volumes and coordinated bulbar function to rapidly open and close the glottis 
during cough pressure generation and release.  Therefore, values obtained will 
be reduced in patients with inspiratory muscle weakness due to inability to 
perform deep inspiration prior to cough initiation and in those patients with 
bulbar dysfunction as well as those with true expiratory muscle weakness.33  
Patients with a cough PEF <180 ml/min have been shown to be unable to 
independently clear secretions.34  These patients can augment cough response 
with manual physiotherapy and using insufflation-exsufflation devices35 and this 
augmented cough level is associated with improved prognosis independent of 
VC or breathing pattern.34 
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The normal ranges for voluntary respiratory manoeuvres are provided in Table 
3. 








148 ± 24 122 ± 25 
SNIP 
 
105 ± 24.5 94 ± 21 
MIP (FRC) 106 ± 22 87 ± 21 
MIP (RV) 114 ± 27 88 ± 18 
Units given as cmH2O and are mean±SD.  Abbreviations: Pdi – transdiaphragmatic pressure, 
SNIP – sniff nasal inspiratory pressure, MIP – mouth inspiratory pressure, FRC – functional 
residual capacity, RV – residual volume.  Data adapted from 28, 36. 
Invasive 
As both SNIP and MIP are volitional tests, a low value does not necessarily 
indicate inspiratory muscle weakness but could represent inadequacy in 
performing the test.  Therefore, if the non-invasive testing value is equivocal or 
a more accurate assessment is needed, invasive respiratory muscle testing can 
be performed.  These require both a technically skilled operator as well as more 
specialised, but commercially available, equipment.  Testing requires the 
insertion of oesophageal catheters to measure Poes and EMGdi and a gastric 
catheter to measure gastric pressure (Pgas).  For these reasons, these tests are 
usually performed in tertiary specialist units.   
Voluntary manoeuvres are performed with maximal sniff efforts, (SniffPoes and 
SniffPdi) and maximal cough effort (CoughPgas) recorded via data acquisition 
software (Figure 4).  The pressures generated will, in part, be affected by lung 
volumes and this should be taken into account when analysing the results.  
Although SniffPdi specifically measures diaphragm function it cannot assess 
hemi-diaphragm function and in order to do so isolation phrenic nerve 
stimulation must be performed.  Currently, this is performed using magnetic 
rather than electrical phrenic nerve stimulation as it is better tolerated and 
easier to perform.37, 38  The measurement of transdiaphragmatic pressure 
following supramaximal phrenic nerve stimulation (TwPdi) is the gold standard 
for demonstrating unilateral (Figure 5) or bilateral diaphragm weakness; normal 
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ranges for phrenic nerve stimulation are provided in Table 4.  Furthermore, 
diaphragm activation can be stimulated centrally via transcranial magnetic 
stimulation.39-41  This allows accurate measurement of nerve conduction time, 
central and peripheral diaphragm fatigue, EMGdi latency and amplitude as either 
compound muscle action potential or motor evoked potential.  These 
measurements are generally used as research tools, although these detailed 
assessments are required for the evaluating patients for intramuscular 
diaphragmatic pacer insertion.42 
Figure 4: Voluntary sniff manoeuvre 
A set of traces showing a maximum sniff manoeuvre in a healthy volunteer with coordinated 
activity of diaphragm and parasternal muscles preceding respiratory system pressure changes. 
Figure shows diaphragm EMG (EMGdi) parasternal EMG (EMGpara) oesophageal pressure 
(Poes), gastric pressure (Pgas) and transdisphragmatic pressure (Pdi). All pressure traces are 
shown in cmH20 and EMG traces in mV after amplification (x1000). 
 
Table 4: Normal ranges for twitch diaphragmatic pressure (TwPdi) performed by 
magnetic stimulation  
 Pressure (cmH2O) 
Bilateral TwPdi 
 
21 ± 5 
Left TwPdi 
 
11 ± 2 
Right TwPdi 8 ± 2 
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Figure 5: Left hemi-diaphragm paralysis on invasive testing 
A set of traces demonstrating left hemidiaphragm paralysis on invasive muscle testing with 
absent Pdi following left phrenic nerve stimulation.  Traces show time of magnetic discharge 
(trig), transdiaphragmatic pressure (TwPdi), oesophageal pressure (Poes) and gastric pressure 
(Pgas).  All pressure traces are shown in cmH20. 
1.1.5: Neural respiratory drive 
The measurement of NRD in vivo is difficult to assess and has be estimated 
using a number of techniques.  The motor output from the respiratory centre 
itself cannot be directly quantified and so surrogate markers are used instead.  
Most simply, ventilation has been used as an estimate of NRD but is of little use 
in disease states as it is affected by the mechanics of the respiratory system.  
Measures of respiratory muscle performance have also been tested but again 
are limited due to the influence exerted by respiratory system mechanics.46  The 
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estimate NRD has been employed in both healthy subjects and COPD 
patients.47, 48  Early work concentrated on the diaphragm EMG (EMGdi) and  
although this does not  represent neural output to the entire of the respiratory 
muscle pump, the diaphragm is the principal respiratory muscle accounting for 
the majority of the work of breathing in healthy individuals.49  EMGdi has been 
assessed using both surface and oesophageal electrodes.  The use of surface 
electrodes to record EMGdi is problematic due to the proximity of the abdominal 
muscles which can induce significant cross-talk.50, 51  The use of surface 
electrodes quantifies costal rather than crural diaphragm activity and the 
contribution of each to respiratory activity, whilst highly correlated, continues to 
be the subject of debate.52  EMGdi measured using an oesophageal electrode 
has been used to quantify NRD in many diverse clinical settings including in 
COPD,53 obesity,54 cystic fibrosis55 and critical care.56  Changes in lung volume 
alter the resting length the respiratory muscles and thus can alter the length-
force relationship, this is particularly true of the diaphragm.57 However, despite 
the initial concerns with regard to changes in EMGdi signal with changes in lung 
volume, recent studies have shown the reliability and reproducibility of this 
technique using multi-pair recording electrodes.53, 58  The use of EMGdi allows 
for quantification of NRD during resting breathing, by relating tidal values to the 
peak EMG recorded during a maximum inspiratory manoeuvre,53 and during 
hypercapnic challenge testing.59 
Respiratory drive may also be assessed from the pressure developed during 
the first 100ms of inspiration (P0.1).
60  Whilst initially thought to accurately reflect 
respiratory motor output and be unaffected by pulmonary mechanics and 
respiratory pattern it is now appreciated that it is governed by the force-length 
relationship of the diaphragm, such as occurs in hyperinflation.61  It is therefore 
often considered using a ratio of the P0.1 during tidal breathing to that produced 
during a maximum inspiratory manoeuvre (P0.1:P0.1max).  Unlike metabolic 
changes, pulmonary mechanics or respiratory muscle strength, changes in P0.1 
have been shown to explain the variance in dyspnoea in individual patients with 
COPD during hypercapnic ventilatory response and exercise testing, 
demonstrating the importance of respiratory drive on the perception of 
breathlessness.62 
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1.1.6: Pulmonary mechanics 
A clear understanding of pulmonary mechanics is essential for the physician to 
enable optimal individualised ventilator settings to be prescribed for the patient.  
Assessment of pulmonary mechanics ranges from basic spirometry, which can 
be routinely used in bedside testing and in clinics with portable meters, to full 
lung function testing with measurements of static and dynamic compliance.  The 
interpretation of respiratory function abnormalities are summarised below with 
particular reference to HMV.  Common patterns of spirometry are found in 
patients requiring HMV with the typical lung function abnormalities found in 
COPD, obesity and neuromuscular disease summarised in Table 5 and Figure 
6A-C. 
Table 5: Typical results of lung function tests in home mechanical ventilation population 
 COPD NMD Obesity 
FEV1 - N / - N / - 
FVC - N / - N / - 
FEV1/FVC - N / + N / + 
TLC + N / - N / - 
RV + - N / + 
RV/TLC + N / + N / + 
DLCO - - N / - 
KCO N / - N / + N / + 
MIP N / - - N 
MEP N - N 
Legend: N, normal; -, decreased; +, increased.  Abbreviations: FEV1 – forced 
expiratory volume in 1s, FVC – forced vital capacity, TLC – total lung capacity, RV – 
residual volume, DLCO – diffusion capacity of carbon monoxide, MIP – mouth 
inspiratory pressure, KCO – diffusion capacity corrected for alveolar volume, MIP – 
maximum inspiratory pressure, MEP – maximum expiratory pressure. 
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Figure 6: Flow volume loops from patients with [A] neuromuscular disease, [B] Chronic 




The pattern of change of lung volumes depends on the underlying disease with 
hyperinflation occurring in COPD and reduced lung volumes in obesity and 
restrictive thoracic disorders, such as chest wall disease and neuromuscular 
disease.  Functional residual capacity (FRC) is the point at which outward 
elastic recoil of the chest wall balances inward recoil of the lungs.  A change in 
FRC may move the patient to an inefficient position on the pressure-volume 
curve increasing work of breathing.63, 64  FRC can be measured via a number of 
techniques including helium dilution, nitrogen washout and arithmetically from 
whole body plethysmography.  Each have potential advantages and 
disadvantages but, in clinical practice, the methods produce similar results 
except when there are large areas of unventilated lung as is the case in some 
patients with bullous emphysema.65  Usually the differences are only important 
when conducting research or considering specialised therapies such as lung 
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volume reduction surgery. It is important to recognise that true FRC can only be 
measured with the respiratory muscles relaxed.  This may not be the case in 
patients with advanced COPD in whom measured FRC may be falsely 
elevated.66 
Basic spirometry, used to measure forced expiratory volume in 1 second (FEV1) 
and forced vital capacity (FVC), is the most commonly encountered measure of 
pulmonary mechanics and is used to monitor progression of a range of 
diseases including COPD and is useful in predicting survival in neuromuscular 
disease, including amyotrophic lateral sclerosis.67  A fall in FVC of greater than 
20% from sitting to supine is abnormal and may indicate significant 
diaphragmatic weakness.23, 68  However, because of the non-linear relationship 
between volume and pressure, tests of respiratory muscle strength that 
measure the pressure generated by the respiratory muscles are a more 
sensitive marker of declining respiratory function than the measurement of lung 
volumes.19, 69  In clinical practice, this will include sniff inspiratory nasal pressure 
(SNIP) and maximal inspiratory pressures (MIP) measured at the mouth, which 
are discussed in the Respiratory Muscle Testing section of this chapter (page 
39). 
Advanced physiological measurements  
The detailed measurement of pulmonary mechanics requires the use of 
specialist equipment and skills (Figure 7) and has become less common in 
routine clinical practice.  The basic mechanics of the respiratory system is the 
action of respiratory muscles to produce negative intrathoracic pressure 
changes that result in airflow.  To study this phenomenon requires the 
measurement of pressure changes throughout the system and the flow 
generated.  This is most commonly achieved with the use of differential 
pressure transducers and a pneumotachograph, the signals from these devices 
are amplified and converted from analogue to digital signals and presented by 
commercially available software packages.  Once digitised the signals can be 
later manipulated and studied to measure pulmonary mechanics.  As pleural 
pressure cannot usually be measured directly,70 mid-oesophageal pressure is 
used as a surrogate marker and is measured with an oesophageal balloon 
catheter inserted per-nasally.71  Pressure measurements are also acquired from 
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gastric balloon catheters, to determine transdiapragmatic pressure, and at the 
mouth in order to calculate the transpulmonary pressure. The use of 
oesophageal catheters also allows the measurement of the diaphragm 
electromyogram (EMGdi) without the disadvantages of poor signals acquired 
from surface electrodes, this is commonly now performed using a single 
combined catheter to ease patient comfort.52 
Figure 7: Patient attending for advanced physiological monitoring 
A patient attending for physiological evaluation including measurement of respiratory muscle 
strength, neural respiratory drive and pulmonary mechanics on and off non-invasive ventilation. 
Illustrates the range of equipment needed for specialist invasive testing. 
Compliance 
Compliance of the respiratory system (Crs) reflects the ease with which pressure 
changes produced by the respiratory muscles change the volume of the lung.  It 
is defined as the change in lung volume per unit change in pressure across the 
respiratory system.  In obese patients, for example, the Crs can be reduced thus 
meaning the lungs are more difficult to inflate and such patients require higher 
levels of pressure support to ensure adequate ventilation.66, 72-74  Patients with 
neuromuscular disease often have a normal or slightly reduced lung and chest 
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wall compliance,75-77 however, due to the loss of muscle mass and thus the 
overall compliance of the respiratory system is often preserved.  Therefore 
these patients can usually be ventilated easily at lower pressures. 
Compliance can be measured as a static or dynamic measure, each providing 
useful physiological data and both having advantages and disadvantages.  The 
measurement of static compliance (Cstat) requires the use of specialised 
equipment, including a body box for plethysmography, and relies on the ability 
of the patient to completely relax their respiratory muscles and make no 
respiratory effort, as the measurements are taken at zero flow to exclude airway 
resistance.  This is, in practice, difficult to achieve in spontaneously breathing 
patients.  Although modified techniques exist to measure Cstat, such as rapid 
airway occlusion, these are still limited in the clinical setting.78  However, 
dynamic compliance (Cdyn), can be achieved easily in spontaneously breathing 
patients, although like Cstat measurements, it does require the insertion of a 
balloon catheter to measure oesophageal pressure (Poes) and rests on the 
assumption that the respiratory muscles are inactive at the point of zero flow.  
The patient simply performs resting breathing through a pneumotachograph 
with an oesophageal balloon in situ.  The integration of the flow from the 
pneumotachograph provides a value for V t and this is divided by the pressure 
change between end inspiration to end expiration (∆Poes).  Values are averaged 
over five to ten stable breaths.  The pressure changes are taken from zero flow 
at end inspiration and end expiration as this should represent points of complete 
relaxation of the respiratory muscles.  During inspiration, a proportion of the 
pressure produced by the respiratory muscles is to overcome surface tension 
and airways resistance and thus Cdyn is measured in the relaxed expiratory 
phase. The main limitation of Cdyn is that it can be inaccurate in obstructive lung 
disease as there remains intrapulmonary airflow at end of inspiration.  
Furthermore, the value is falsely reduced in patients with tachypnoea.79 
Positive end-expiratory oesophageal pressure  
PEEPi occurs due to airflow limitation resulting from the narrowing of airways 
with resultant residual positive pressure in the alveolus, and so also the pleural 
pressure, at the end of expiration.  This results in an increase in the work of 
breathing and has a negative impact on ventilator triggering.  Whilst it is not 
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often measured in the HMV population and is more pertinent in acute ventilation 
in critical care, knowledge of the concept can enhance patient set up for HMV.  
The presence of PEEPi can occur due to a range of processes including: 
1. Insufficient expiratory time to allow pressure equalisation across lung 
units due to airway obstruction e.g. COPD.80 
2. Dynamic airway collapse causing flow limitation e.g. emphysema or 
obesity.54 
3. Pulmonary oedema due to cardiac dysfunction. 
Both static and dynamic PEEPi can be measured and requires the use of 
oesophageal balloon catheter and a pneumotachograph, similar to the 
measurement of compliance.  For the measurement of static PEEP i airway 
occlusion is required at the end of passive expiration.  The resultant plateau 
pressure represents the average PEEP i across the whole lung and may vary 
considerably between lung units in disease processes associated with profound 
heterogeneity e.g. emphysema.  Active expiration will cause a falsely high value 
and patients should be coached to avoid this phenomenon.81  Dynamic PEEPi 
can be measured in the spontaneously breathing patient without the need for 
airway occlusion.  The Poes at the end of expiration at the point of zero flow 
represents the lowest level of PEEP i within the lung that is required to be 
overcome in order to instigate flow.  This can therefore be substantially lower 
than static PEEPi, most notably in those with airflow obstruction.  If active 
expiration occurs this can be partly compensated for by subtracting the change 
in gastric pressure (∆Pgas) from the value of PEEPi calculated.
66, 80  In the 
clinical setting failure to correctly titrate EPAP high enough to match patients 
PEEPi can lead to increased work of breathing, discomfort and triggering 
problems, especially in the acute setting.82  Equally an EPAP set too high can 
worsen gas trapping and again lead to patient-ventilator dysynchrony.  PEEPi 
depends on underlying disease and, in general, it is usually absent in 
neuromuscular disease, but can be a significant problem in patients with both 
obstructive airways disease and obesity.83  Significant PEEP occurs in obese 
patients in the supine position due to the pressure exerted by the abdominal 
contents and therefore the position of the patient during measurements must be 
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taken into consideration when interpreting measured PEEP values and setting 
EPAP.54  It must also be noted that EPAP is used to abolish upper airway 
obstruction and maintain airway patency if there is coexistent obstructive sleep 
apnoea. 
Work of breathing 
In the normal state, the respiratory system consumes a small proportion of the 
total oxygen consumption, typically less than 5%, but in illness this can rapidly 
escalate to more than 30% of the total.  Whilst rarely measured in a clinical 
setting unloading the respiratory muscles and reducing work of breathing has 
been shown to be associated with improved ventilator comfort and can be used 
to compare the effectiveness of modes of ventilation.84  Again, measurements 
are taken during spontaneous breathing using a balloon catheter to measure 
Poes and a pneumotachograph with the integration ∆Poes between points of zero 
flow generating the pressure-time product, which correlates with oxygen 
consumption and metabolic work of breathing.85  This technique can show 
changes in work of breathing against changes in respiratory load but with the 
addition of assisted ventilation it can be difficult to interpret as the changes in 
Poes represent, in part, the work performed by the ventilator rather than 
respiratory muscles.84  To accurately measure changes in work of the 
respiratory muscles during ventilation either change in oxygen consumption 
from spontaneous breathing to assisted breathing can be measured or the 
respiratory muscle activity can be measured using the diaphragm 
electromyogram (EMGdi).  These methods allow the physiological effects of 
modes of ventilation to be compared in detail as well as providing insights in to 
the pathological processes involved in patients requiring HMV.  Patients with 
high work of breathing during spontaneous respiration include those with COPD 
and obesity due to the high load on the respiratory system imposed by either 
airflow obstruction and hyperinflation or low chest wall and abdominal 
compliance.  Patients with neuromuscular disease, if no other disease process 
is present, have a low work of breathing and consequently require lower levels 
of respiratory support. 
1.1.7: Patient-ventilator interaction 
The principal areas that need assessment include: 
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1. Interface - mask leak, mouth leak, mask seal, head gear, mask and head 
gear condition and skin pressure areas. 
2. Trigger efficiency – inspiratory and expiratory synchronisation, frequency 
of autocycling, frequency of prolonged inspiratory support. 
3. Pressurisation – symptoms of daytime hypersomnolence and headache, 
worsening breathlessness, continued snoring and signs of cor 
pulmonale, excess or inadequate pressure delivered. 
Sufficient time must be allowed during the initial set up of NIV to individualise 
the ventilator settings.  Furthermore, regular follow up must be undertaken to 
assess adherence to, and efficacy of HMV as a failure to improve gas exchange 
or poor compliance may represent patient-ventilator dysynchrony, progression 
of the underlying disease or ventilator malfunction.  The use of physiological 
targeted set up, using invasive measures of pulmonary mechanics to obtain NIV 
settings that maximally unload the respiratory muscles, has been reported by 
some investigators to improve patient comfort and enhances patient-ventilator 
interaction.82, 84  Whilst some patient-ventilator interactions can be assessed 
clinically others require the use of more invasive physiological testing to assess 
a problem. 
1.1.8: Health related quality of life 
The assessment of health related quality of life (HRQL) has become of 
increasing importance in modern healthcare.  These assessment tools can be 
generic, disease specific or treatment specific.  The use of generic tools allows 
the comparison between groups of patients with different diseases but may lack 
the sensitivity to detect changes in important symptoms in specific 
populations.86  Several questionnaires have been used to measure health 
related quality of life in patients with chronic respiratory failure, such as the 
Chronic Respiratory Questionnaire (CRQ) and St George’s Respiratory 
Questionnaire (SGRQ).87, 88  However, these questionnaires were derived for 
patients with obstructive pulmonary disease and so may not be applicable in 
patients from other diagnostic groups such as obesity hypoventilation syndrome 
(OHS).  Two questionnaires have been validated for measuring health related 
quality of life in patients with chronic respiratory failure receiving domiciliary 
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ventilation: the Severe Respiratory Insufficiency (SRI) questionnaire and the 
Maugeri Foundation Respiratory Failure (MRF) -28 questionnaire.89-91  These 
questionnaires have been shown to be responsive to changes occurring 
following the treatment of chronic respiratory failure with HMV.92, 93 
1.1.9: Physical activity 
The assessment of physical activity has previously been limited to subjective 
self-reported assessments94 or formal exercise testing, such the incremental 
shuttle95 and 6 minute walk tests.96  Recent technological advances have 
allowed the objective measurement of daily physical activity using sensitive 
motion sensors (actigraphs)97 and the estimation of free living energy 
expenditure.98  Actigraphy involves the use of accelerometers to measure 
movement and was initially used to assess the sleep-wake cycle in circadian 
rhythm disorders.99, 100  The devices are usually worn on the wrist when 
assessing sleep but may be worn on the wrist, arm or hip when assessing 
physical activity.101  In the assessment of patients with chronic respiratory 
failure using domiciliary NIV, actigraphy enables both the objective 
measurement of physical activity as well as the sleep-wake cycle. 
The importance of exercise capacity and physical activity in chronic respiratory 
failure is underlined by the prognostic information carried by these 
assessments.  Objectively quantified physical activity has been shown to be a 
strong predictor of all-cause mortality in COPD.102, 103  The 6 minute walk test 
can be used in patients with chronic respiratory failure undergoing HMV to 
stratify mortality with the worst outcomes in those with the most impaired 
exercise performance.104  This relationship is most pronounce in patients with 
COPD in whom skeletal muscle dysfunction is secondary to reduced physical 
activity,105 whereas it is of less prognostic value in OHS in whom exercise 
capacity is relatively preserved.104  The administration of HMV in chronic 
respiratory failure has been shown to improve exercise capacity independently 
of changes in peripheral muscle function.106  The use of actigraphy has become 
increasingly common and has been shown to accurately reflect physical activity 
during household chores and metabolic activity in patients with chronic 
respiratory failure107, 108 and thus is a patient relevant outcome.  Furthermore, in 
patients with COPD low levels of physical activity following an acute 
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exacerbation have been shown to indicate an increased risk of subsequent 
readmission, demonstrating the important clinical relevance of this endpoint.109 
Due to the strong prognostic link, much of the current evidence relates to the 
use of NIV in COPD related respiratory failure.  HMV has been shown to 
improve exercise capacity as part of a structure long term rehabilitation 
programme.110, 111  The study by Duiverman and colleagues examined the 
effects of the addition of HMV to pulmonary rehabilitation in patients with COPD 
and chronic respiratory failure at 1 and 2 year intervals in a randomised 
controlled study.  The primary outcome of the study was HRQL, which showed 
no significant change in the CRQ, a general measure of HRQL but improvement 
in the MRF-28, a HMV specific measure.  However, the study did show 
improvement in exercise capacity, measured by the 6 minute walk test, and 
physical activity, measured by step count in the HMV group.  In addition to the 
use of HMV to improve exercise capacity in COPD NIV has been implemented 
during exercise and recovery to augment the training response.  The rationale 
for this application is that high work of breathing contributes to dyspnoea and 
limits exercise performance in severe COPD.112, 113  The addition of NIV during 
exercise in COPD improves walking distance and decreases dyspnoea.114, 115  
However, there are practical considerations that can limit its utility and thus it 
remains controversial.116   
The importance of physical activity in obesity is empirically clear with the 
limitation to exercise capacity in such obese subjects being multifactorial.117, 118  
A significant contributor to exercise limitation in obesity relates to altered 
pulmonary mechanics.74, 119  Although there have been few data to support 
improvements in exercise capacity induced by HMV in OHS small studies have 
demonstrated the ability of NIV to augment patients performance during 
symptom limited exercise testing.120  In addition to the potential for physical 
activity to augment weight loss in patients with OHS it may in itself improve 
sleep disordered breathing.121  Despite the important link between physical 
activity and obesity no data yet exists to measure the extent of inactivity in 
obesity hypoventilation syndrome or the changes that occur following 
domiciliary NIV. 
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1.2: The Role of Domiciliary Non-Invasive Ventilation in Chronic 
Respiratory Failure 
1.2.1: From the Polio epidemic to the obesity epidemic 
The ability to support patients with ventilatory failure without the need for 
invasive ventilation has been one of the major advances of respiratory medicine 
in recent times.  NIV initially developed as part of critical care for use within the 
intensive care unit but has quickly progressed to be used in specialised 
respiratory units and in the community for a range of pathologies culminating in 
respiratory failure.  Whilst used in critical care to support acute respiratory 
failure technological advances from negative to positive pressure ventilation and 
improvements in patient interfaces have facilitated the use of this technology 
within the domiciliary setting for patients with chronic hypercapnic respiratory 
failure.  The initial clinical demand for application of this technology was in 
neuromuscular disease, particularly following acute poliomyelitis, however, 
subsequent changes in demographics have led to other aetiologies rising in 
predominance.  Domiciliary NIV is now provided for hypercapnic respiratory 
failure associated with both OHS and COPD.  Although these syndromes have 
a common end process, chronic respiratory failure, this develops as a 
consequence of differing pathophysiological mechanisms and this has 
implications for patient assessment and ventilator set up. 
1.2.2: Evidence for domiciliary non-invasive ventilation in neuromuscular 
disease 
Early studies showed that the majority of patients with progressive 
neuromuscular disease die due to respiratory failure.122  This observation made 
the treatment of disorders in this group, such as Duchene’s muscular dystrophy 
and amyotrophic lateral sclerosis, with domiciliary NIV appealing.  The 
physiological data investigating the modes of action has shown improvements 
in the ABG measurement and Epworth sleepiness score (ESS) comparing 
baseline to 3 months post NIV initiation.123  The mechanism of action of NIV in 
this patient group appears to be via improvements in the hypercapnic ventilator 
response (HCVR) with Nickol et al demonstrating no significant change in 
pulmonary mechanics and an improvement in only one measure of respiratory 
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muscle strength following treatment with HMV for 3 months.  In the same study, 
a dose response effect of nightly NIV usage was noted on PaCO2, further 
supporting a true treatment effect.123  
Initial data from retrospective and observational trials showed HMV is well 
tolerated and is associated with improved quality of life measures, fewer in-
patient hospital days and high levels of survival.124-126  The results of these 
studies must be interpreted carefully as there was no control group, historical 
data was used and patients who failed to tolerate NIV often proceeded to 
invasive ventilation.  However, randomised controlled data has been produced 
in this area with Bourke et al studying 92 consecutive patients with amyotrophic 
lateral sclerosis and randomised 41, using a minimisation strategy to reduce 
potential confounders, to NIV or usual care when they reached a pre-set level of 
respiratory dysfunction.127  Criteria for initiation of domiciliary NIV were 
symptomatic hypercapnia or orthopnoea with a MIP <60% predicted.  Control 
(n=19) and NIV (n=22) patients were well matched at entry and all patients were 
followed up until 12 months or death.  Results showed a significant survival 
advantage in the NIV arm over standard care (mean survival in days 219 vs 
171; p=0.006) with improved HRQL indices as measured by the short form 
(SF)-36 questionnaire.  The study had an a priori sub-analysis to examine if a 
survival advantage persisted in those patients with severe bulbar dysfunction.  
No benefit of NIV could be demonstrated with mean survival of 222 days in the 
NIV arm compared with 261 in the control group (p=0.92) in those patient with 
bulbar dysfunction.  However, some quality of life improvement was shown in 
those patients with severe bulbar dysfunction randomised to NIV compared to 
controls.  These data have been used to support the provision of domiciliary 
NIV for patients with neuromuscular disease, however, the optimum timing for 
initiation of ventilation is yet to be established.  The majority of trials have used 
symptomatic daytime hypercapnia or evidence of profound respiratory muscle 
weakness as markers for initiation.  Two studies have investigated the effects of 
earlier intervention in neuromuscular disease in order to better establish 
optimum indication for initiation of HMV.  Raphaël et al recruited 70 patients 
with Duchene’s muscular dystrophy free of daytime respiratory failure in a 
multicentre randomised controlled trial showing no difference in progression to 
58 
ventilatory failure.128  However, of clinical concern was that there was an 
increased mortality in those patients randomised to the NIV arm.  Interestingly, 
the patients were recruited without established respiratory failure and only a 
small minority satisfied criteria for domiciliary NIV by current clinical practice.  A 
more structured approach was adopted by Ward et al by selecting 22 patients 
with daytime normocapnia but nocturnal hypoventilation.20  Patients were 
randomised to either early (n=12) or standard (n=10) initiation of NIV.  Within 
the 24 month follow-up of the trial all bar one patient from the delayed arm had 
required initiation of ventilation based on the development of diurnal 
hypercapnia, with 7 out of the 10 patients starting NIV in the first 12 months.  
The early initiation of therapy to reduce the risk of acute decompensation needs 
to be weighed against the inconvenience and any impact on HRQL of NIV.  This 
trial used a combination of chest wall and neuromuscular disease but it may 
well be most pertinent in the management of neuromuscular diseases due to 
the progressive nature of the disease. 
1.2.3: Evidence for domiciliary non-invasive ventilation in Chronic 
Obstructive Pulmonary Disease 
The evidence for the use of NIV to support ventilatory failure in acute 
hypercapnic exacerbations of COPD is widely accepted and has demonstrated 
improved clinical outcomes compared to conventional management.129-132  
However, the use of domiciliary ventilation in COPD remains controversial.133  A 
number of small physiological trials have demonstrated improvements in gas 
exchange,134-136 health related quality of life,136 pulmonary mechanics134, 135, 137 
and central respiratory drive.137  Larger randomised controlled trials and 
subsequent meta-analyses have failed to translate these small studies into a 
clinical effect, with no significant improvements in clinical primary end points 
demonstrated.93, 138, 139  The most recent and largest randomised clinical trial 
was reported by McEvoy and colleagues.  The data demonstrated a small but 
significant survival advantage in stable hypercapnic COPD patients randomised 
to receive domiciliary NIV compared to standard care at a 2 year time point.140  
However, this survival advantage was only apparent in a post hoc adjusted 
analysis of the data and was subsequently lost using intention to treat analysis.  
Even when using the adjusted data, the outcomes of the Australian trial of non-
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invasive Ventilation in Chronic Airway Limitation (AVCAL) study showed no 
early (<12 months) or long term (>3 years) benefit with the addition of HMV to 
standard care.  Furthermore, randomisation to the NIV arm was associated with 
a poorer quality of life as measured by generic HRQL measures. 
The main criticism of the negative studies in this area is that they have failed to 
adequately titrate the intervention (NIV) to the degree of physiological 
impairment (nocturnal hypoventilation).  The mean pressure support provided in 
these studies is substantially below that which is used in clinical practice and in 
the earlier positive physiological studies.  It is unsurprising that failure to 
adequately ventilate patients in chronic respiratory failure renders the 
intervention unsuccessful.  Recent data from Dreher et al has supported this 
theory with a randomised crossover design trial employed to evaluate high and 
low intensity ventilatory strategies in chronic hypercapnic COPD.141  During the 
high intensity treatment phase, patients had superior control of nocturnal 
hypoventilation than during the low intensity phase.  Interestingly, the patients 
had better compliance with treatment during the high intensity treatment phase, 
in contrary to conventional expectation.  Concerns regarding the effect of a high 
intensity approach on sleep quality have also been addressed, with no 
significant deterioration in sleep architecture seen in high versus low intensity 
NIV.142  However, the data must be interpreted with caution in the most recent 
study as the study population were clinical patients who were all already 
established on high intensity NIV and thus may not reflect an unselected de 
novo population.  The high intensity approach utilises both high inspiratory 
pressures and high back up rates; an approach that could be challenged when 
employed in COPD as it may fail to allow sufficient expiratory time to allow lung 
emptying, potentially exacerbating hyperinflation.  A small randomised 
crossover trial performed by our group has investigated the contribution of 
changes in back up rate during high pressure HMV for hypercapnic COPD.143  
The study randomised patients with stable chronic respiratory failure secondary 
to COPD to either a high pressure and low back-up rate ventilatory strategy 
(PSV) or a high pressure and high back-up rate ventilatory strategy (PCV) for a 
6 week period followed by crossing over to the alternate arm for another 6 
weeks.  12 patients were randomised with 7 completing the whole protocol.  
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Both PSV and PCV produced a similar degree of control nocturnal 
hypoventilation (PSV overnight tcCO2 6.5 ± 1.2 kPa vs PCV overnight tcCO2 6.5 
± 1.3, p=0.985) and daytime gas exchange (PSV PaCO2 7.2 ± 0.8 kPa vs PCV 
PaCO2 7.0 ± 0.8, p=0.190).  There was also similar degrees of objective (PSV 
sleep efficiency 77 ± 12% vs PCV sleep efficiency 73 ± 18, p=0.484) and 
subjective (PSV sleep comfort VAS 57 ± 29 vs PCV sleep comfort VAS 58 ± 29, 
p=0.944) sleep quality.  These data suggest that the high pressure is the 
important feature of the high intensity approach and that there is no additional 
clinical or physiological benefit from adding a high back-up rate.  The equivocal 
nature of the evidence has led to substantial variation in practice across Europe 
in this area.144 
In addition to the failure of earlier trials to maximise the therapeutic benefit of 
HMV with high pressure setup, these trials have also been criticised as they 
have only recruited the most stable of hypercapnic COPD patients.93, 140  There 
has been increasing interest in the use of HMV to target those patients with 
repeated decompensated exacerbations requiring acute NIV.145  Patients who 
have required acute NIV for a decompensated hypercapnic exacerbation of 
COPD have a poor prognosis with high levels of morbidity and mortality.146-148  
These historic outcomes have improved little with recent unselected data 
demonstrating a 1 year mortality of over 50% following the first episode of 
decompensated respiratory failure with the majority of deaths occurring in the 3 
months following hospital discharge.149  A pilot randomised controlled trial has 
been completed that randomised patients to either HMV or CPAP following an 
acute exacerbation requiring NIV.150  Whilst the trial showed a significant 
reduction in episodes of recurrent hypercapnic exacerbations requiring NIV at 1 
year (NIV group 39%, CPAP group 60%, p=0.04) there were no between group 
differences in hospital admissions due to exacerbations of COPD (p=0.48), 
mortality (p=0.86) or PaCO2 (p=0.49).  The specific end-point used in this study 
means limited conclusions can be drawn on any possible clinical benefit.  
Despite the limited evidence in this area the poor prognosis has led some 
centres to routinely offer HMV to patients following an inpatient episode 
requiring acute NIV.  This cohort of patients has been the subject of 
investigation of the clinical and physiological effects of subsequent withdrawal 
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of NIV therapy by Funk et al.151  Patients were initiated on HMV following an 
acute hypercapnic exacerbation and following a 6 month period of stability on 
HMV were subsequently randomised to continuation of HMV or HMV 
withdrawal.  The primary outcome was a clinical deterioration; pre-specified as 
need for escalation of mechanical ventilation, 10% rise in PaCO2 or intractable 
dyspnoea necessitating NIV for relief.  The final criterion was patient rather than 
physician judged.  Patients randomised to the withdrawal group were more 
likely to meet the primary outcome than those who continued to receive HMV 
(continuation group 15%, withdrawal group 77%, p=0.005).  However, if this 
was restricted to the single criterion that applied to both groups, a need for 
escalation of mechanical ventilation, there was no between group difference 
(continuation group 15%, withdrawal group 23%, p value not reported).  There 
were no between group differences in either antibiotic usage (p=0.35) or 
incidence of oral steroid therapy (p=0.59) during the 1 year study period.  The 
use of both subjective and arbitrary criteria to comprise the primary outcome 
limits the interpretation that can be made of the data. 
1.2.4: Evidence for domiciliary non-invasive ventilation in obesity 
hypoventilation syndrome 
The epidemic of obesity in the western world has led to an increase in a range 
of obesity related complications including respiratory problems and sleep 
disordered breathing.152  Whilst OSA is relatively well known by both medical 
and lay people, OHS, despite its high mortality, remains poorly understood and 
under diagnosed.153  OHS was originally described in a case report by 
Auchincloss et al in 1955154 although the commonly used term Pickwickian 
syndrome was not coined until the following year when the condition was linked 
to hypersomnolence.155  The syndrome is now commonly recognised as the 
presence of obesity (BMI > 30 kgm-2), daytime respiratory failure (PaCO2 > 6 
kPa) and sleep disordered breathing in the absence of another identifiable 
cause of hypoventilation.156, 157  While the true population prevalence is 
unknown it is increasingly common with increasing BMI158, 159 and is known to 
be highly prevalent in acute medical attendees153 and patients attending sleep 
disorder services.158  Patients with OHS have a poorer prognosis than similarly 
obese eucapnic patients153 but there has yet to be a randomised controlled trial 
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of NIV compared to sham ventilation or no treatment powered to examine long 
term outcomes.  Current evidence for treatment is based on a collection of 
uncontrolled, non-randomised or short trials involving either CPAP or bi-level 
NIV.  These studies demonstrate short234 and long164 term efficacy of therapy 
with improvements in daytime somnolence,160 health related quality of life92 and 
gas exchange.161  The only randomised controlled comparing domiciliary NIV to 
a control group was recently published by Borel et al.162  In this study lifestyle 
counselling was used as the control due to the difficulties of sham NIV.  Patients 
receiving domiciliary NIV had a greater improvement in PaCO2 (mean 
difference -0.5 kPa, 95%CI -0.8 to -0.1, p=0.015), and sleep architecture, 
although surprisingly no significant between group difference in daytime 
somnolence was demonstrated (Control group ΔESS -2.1, 95%CI -4.5 to 0.4; 
NIV group ΔESS -3.4, 95%CI -6.0 to -0.8; between group p=ns).  Whilst the 
need for treatment in this group to improve symptoms and clinical outcomes is 
generally accepted the optimum ventilatory strategy is yet to be clearly 
elucidated.  There are few trials directly comparing ventilatory modes in OHS 
with Piper et al comparing CPAP to bi-level NIV and Storre et al investigating 
the addition of volume targeted pressure support ventilation, average volume 
assured pressure support (AVAPS), to standard NIV. In the latter study the 
addition of AVAPS was associated with improved nocturnal ventilatory control 
and equivalent improvements in gas exchange and HRQL.92  However, concern 
has been raised regarding the potential for the variable pressure support to 
contribute to increased sleep disruption.163  Piper and colleagues performed a 
randomised controlled trial comparing CPAP therapy and bilevel NIV in obese 
patients with chronic respiratory failure who did not exhibit significant nocturnal 
hypoventilation during CPAP therapy.160  The study showed no significant 
difference in either gas exchange or HRQL following 3 months of therapy.  Due 
to the highly selected cohort of patients enrolled in this trial, the applicability of 
these findings to clinical practice remains unclear and concern is raised when 
examining the findings of the study by Banerjee et al, which demonstrated 
continued severe hypoxaemia in patients with OHS compared to matched 
eucapnic OSA patients when managed with CPAP alone.164  Despite the lack of 
randomised controlled trials there is much evidence to support a survival 
advantage in patients with OHS treated with long term NIV.165, 166  These data 
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raise ethical issues and the controlled trials in the future are likely to require a 
delayed treatment arm and therefore the length of the trial will be limited to 
three months which will adversely impact on our understanding of the long-term 
outcome.  
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CHAPTER 2: HYPOTHESES 
2.1: Translation of Evidence from Bench to Bedside 
The current evidence for advanced physiological measurement and monitoring 
techniques and domiciliary NIV in patients with respiratory failure is variable 
across different acute and long term patient groups and this has led to different 
challenges in each setting.  
Whilst lacking a prospective randomised controlled trial to support long term 
benefits of domiciliary NIV in OHS, there is clear consensus that symptomatic 
benefits of treatment, and probable mortality benefits, renders this unethical.  
However, there is uncertainty as to the optimum ventilatory approach in this 
syndrome, leading to a wide variation in practice; from the use of single level 
CPAP, through to the fixed bilevel devices, to the more advanced ventilatory 
modes.  The use of a mode that can adapt to changing physiological loads 
during sleep may have significant benefit. 
Employing advanced physiological monitoring techniques in patients during an 
acute respiratory deterioration is challenging, but currently we have limited 
approaches to assessing treatment failure and quantifying the risk of 
readmission to hospital.  Therefore, utilising the physiological measure of neural 
respiratory drive as a clinical tool could provide greater understanding of the 
changes in physiology that occur during an exacerbation of COPD as well as 
risk stratifying these patients during their admission. 
The challenge, in the context of chronic respiratory failure secondary to COPD 
is different with the equivocal evidence limiting the current clinical use of the 
intervention.  However, the intuitive benefits of domiciliary ventilation raise the 
potential for successful application if the correct patients and correct ventilatory 
strategy can be selected.  A more detailed knowledge of the pathophysiology of 
chronic respiratory failure, as well as the time course and effect of acute 
exacerbation on the chronic condition, is required to optimise the approach to 
non-invasive ventilation set up in this group. 
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To address these three areas, three physiological trials were performed which 
were based on the pathophysiological mechanisms involved in each specific 
situation, namely an imbalance between respiratory muscle load, capacity and 
drive; these are detailed below. 
2.2: Physiological Trial 1:  Volume Targeted Pressure Support 
Ventilation Compared to Fixed Level Nurse led Protocolised 
Pressure Support in Obese Patients with Chronic Respiratory 
Failure 
The pathophysiological mechanism of chronic respiratory failure in OHS is yet 
to be fully elucidated, however, an imbalance between respiratory muscle load, 
capacity and neural respiratory drive is key. 
2.2.1: Respiratory drive 
Patients with OHS have been shown to have decreased ventilatory responses 
to carbon dioxide compared to eucapnic obese and patients with simple 
OSA.167  The level of NRD, as indicated by EMGdi, are increased in simple 
obesity but in OHS patients there is failure for this to be translated to an 
improved response to CO2.
54, 168  Despite the presence of diurnal hypercapnia, 
patients with OHS can voluntarily hyperventilate in order to become eucapnia 
implying the ventilatory constraints alone are not responsible for this 
phenomenon.169  The presence of sleep disorder breathing promotes sleep 
disruption170 and this itself can impair central respiratory drive by reducing 
HCVR.171-173  The use of NIV in OHS promotes sleep consolidation and may 
therefore act to improve central respiratory drive.162, 164  Uncontrolled studies 
have found that the degree of REM hypoventilation correlates to the daytime 
HCVR and that it can be shown that the HCVR improves following treatment 
with NIV.174, 175  In contrast, the only randomised controlled trial performed failed 
to demonstrate a treatment effect on central respiratory drive, as measured by 
HCVR162, although this may be explained by the selection methods used.  
Patients were recruited from sleep centres and advertisements and enrolled if 
hypercapnic.  However, baseline values were taken 1-2 weeks later when a 
proportion of patients were no-longer hypercapnic (mean PaCO2 control group 
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6.0 ± 0.4 kPa, NIV group 6.4 ± 0.6 kPa) and therefore did not strictly meet the 
criteria for a diagnosis of OHS at this point.  If following the successful treatment 
of OHS with NIV, therapy is withdrawn then the HCVR is attenuated.176  Sleep 
disordered breathing in OHS can be the result of OSA, pure nocturnal 
hypoventilation or a combination of the 2 contributing to nocturnal hypoxia.177  
The presence of prolonged hypoxia occurring during nocturnal hypoventilation 
itself may further exacerbate the reduction in central drive.  Healthy volunteers 
exposed to prolonged mild hypoxia during sleep had significantly dampened 
responses to resistive loads during sleep.178  This impaired ventilatory response 
post apnoea offers another potential avenue for the development of diurnal 
respiratory failure in OHS.  
2.2.2: Respiratory load 
Obesity acts to impair pulmonary mechanics in a number of ways with 
abdominal and thoracic adiposity directly increases the load, as measured by 
pulmonary compliance, on the respiratory system.179  The generation of intrinsic 
PEEP when in the supine posture, as is usual for sleep, creates a threshold 
load in obesity.180  Respiratory mechanics are further impaired by the reduction 
in lung volumes that are associated with moderate and severe obesity.181  
These changes in lung volumes adversely affect pulmonary mechanics by 
increasing airway resistance182 as well as contributing to reducing pulmonary 
compliance.183  Upper airways resistance can also be shown to be higher in 
patients with OHS compared to eucapnic OSA patients.184  These factors all act 
to increases the work of breathing which appears to be more pronounced in 
OHS than in similarly obese eucapnic patients.185, 186  Furthermore, the 
reduction in FRC contributes to ventilation-perfusion mismatching and the 
adoption of a small tidal volume and a rapid respiratory rate.187  The 
normalisation of gas exchange that follows significant weight loss indicates that 
the reduction in this pathological level of load is important in disease 
resolution.188 
2.2.3: Respiratory muscle capacity 
Inspiratory muscle strength and endurance is reported as normal189 or slightly 
reduced190 in simple obesity but markedly impaired in OHS.191  This impairment 
is exaggerated by the supine posture192 and thus more prominent during sleep.  
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Maximum voluntary ventilation is impaired in OHS compared to eucapnic obese 
and this correlates with degree of hypercapnia.193  This loss of respiratory 
muscle capacity may be related to the hypoxia and hypercapnia that are 
hallmark features of OHS.194  
2.2.4: Summary 
The interaction between obesity and sleep disordered breathing further alters 
the load-capacity-drive relationship of the respiratory system.167, 169, 185  This 
relationship differs during changes in body position and sleep stage.54, 195  The 
standard treatment of OHS with fixed CPAP or bi-level NIV does not alter to 
maintain ventilation during these changes.  Newer ventilatory modes have been 
developed that estimate the expiratory tidal volume during ventilation and 
respond by altering the inspiratory pressure provided in order to optimise 
respiratory support.  Storre et al demonstrated that the use of volume targeted 
pressure support mode provided greater control of sleep disordered breathing 
than fixed bi-level pressure support ventilation.92  However, concerns have been 
raised that the variable pressure support may contribute to greater sleep 
disruption.163  These two studies were not designed to minimise the differences 
between the two ventilatory modes and significant differences in the setup 
strategies led to significantly higher delivered pressure support in the volume 
targeted pressure support ventilation group.  It is perhaps expected that these 
higher levels of pressure support provided greater control of nocturnal 
hypoventilation but at the cost of increased sleep disruption. 
The trial reported in this thesis prospectively examined the advantages of the 
use of the volume targeted pressure support mode in the treatment of OHS 
using a single blind randomised controlled trial design with aim of exploring the 
following hypotheses: 
1. Superior control of nocturnal hypoventilation will lead to greater 
improvements in daytime gas exchange. 
2. Volume targeted pressure support ventilation will improve ventilator 
comfort and enhance compliance. 
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3. Improved control of nocturnal hypoventilation will provide greater 
improvements in daytime somnolence and health related quality of life. 
4. Improvements in daytime somnolence will be associated with an 
increase in daytime physical activity and weight loss. 
2.3: Physiological Trial 2: Advanced Physiological Monitoring 
in Patients During Hospital Admissions for Acute Exacerbation 
of Chronic Obstructive Pulmonary Disease 
Acute exacerbations of chronic obstructive pulmonary disease are a major 
economic burden to healthcare systems.196, 197  In addition, exacerbations have 
a significant impact on HRQL with admission avoidance and reduced length of 
hospital admission becoming national targets.198  Recently, healthcare systems, 
including the National Health Service, have focused on providing enhanced 
community care to facilitate early discharge.199-201  Acute care organisations 
have incorporated early warning scores, integrating basic cardiorespiratory and 
other physiological variables into a composite score, as predictors of clinical 
deterioration.  However, the clinical usefulness of such scoring systems remains 
controversial.202-206  All these monitoring systems require accurate 
characterisation of disease severity and response to treatment to identify 
patients that are either deteriorating or only slowly improving to allocate patients 
to higher levels of clinical care.  There are few physiological biomarkers 
available that have sufficient sensitivity and specificity to identify patients failing 
to respond to treatment in acute exacerbations of COPD.207  Whilst the majority 
of cases of respiratory failure due to acute exacerbations of COPD are present 
at admission to hospital a significant minority develop decompensated 
respiratory failure during the ward stay.208  The utilisation of neural respiratory 
drive to measure the clinical response to treatment in acute exacerbations of 
COPD and identify this deterioration has not previously been reported. 
2.3.1: Respiratory drive 
Neural respiratory drive, which reflects the balance between respiratory muscle 
load and capacity, measured using the EMGdi, has been shown to relate to 
disease severity in stable COPD.53  As expected, this technique has been 
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limited in its application, particularly in the acute setting, as it requires the 
placement of an oesophageal electrode to measure EMGdi.  Clinical interest has 
therefore been directed towards measuring the EMG of the parasternal 
intercostal muscles, which can be studied in a less invasive manner.209  The 
chest wall respiratory muscles have increased importance in patients with 
advanced COPD as progressive hyperinflation impacts adversely on diaphragm 
positioning and efficiency,80, 210 which results in a compensatory increase in 
chest wall and accessory respiratory muscle activity.211, 212  In particular, the 
uppermost parasternal intercostal muscles have been shown to be important 
inspiratory muscles.213-215  Furthermore, these parasternal muscles have 
minimal post-inspiratory activity216 with the 2nd intercostal space (ICS) 
parasternal muscle demonstrating similar activity to the diaphragm.217  During 
increasing hyperinflation, as observed during an acute exacerbation of COPD, 
the resting length of the parasternals is less affected than the diaphragm, such 
that the parasternals make a greater contribution to inspiratory pressure 
generation.218  This increase in parasternal activity is also associated with 
higher levels of dyspnoea.219  Previous work has also demonstrated that 
EMGpara, recorded from surface electrodes, has a direct relationship with 
respiratory muscle load.220  Furthermore, it is a measurement that is responsive 
to clinical changes during exacerbations in both childhood asthma221, 222 and 
cystic fibrosis223 following treatment. 
2.3.2: Respiratory load 
Acute exacerbations of COPD produce an acute on chronic increase in the load 
on the respiratory system.224  The changes in load are mediated via changes to 
both inspiratory resistance and dynamic chest wall elastance as well as 
threshold load exerted by intrinsic PEEP.225  This acute increase in load on the 
respiratory system causes a significant increase in the work of breathing with 
transdiaphragmatic pressure changes in patients with acute exacerbations of 
COPD being double that of stable counterparts.226, 227  These effects can be 
further exacerbated by dynamic hyperinflation resulting from severe flow 
limitation impairing expiratory flow time.228 
2.3.3: Respiratory muscle capacity 
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The volitional and non-volitional pressure generating capacity of the inspiratory 
muscles is reduced in COPD.229  However, hyperinflation produces a 
mechanical disadvantage for the diaphragm negatively affecting its pressure 
generating capacity.230  Therefore, when lung volumes are taken into account 
the pressures generated by COPD patients are similar to those of healthy 
subjects.57  The metabolic properties of the respiratory muscles in patients with 
COPD, in particular the diaphragm, have been demonstrated  in vitro231 to have 
a favourable shift to fatigue resistant fibres,232 suggesting only a limited role of 
respiratory muscle weakness in the development of respiratory failure in COPD. 
2.3.4: Summary 
Complex physiological assessment of the respiratory system during acute 
exacerbations of COPD is unlikely to become a clinical tool due to the 
necessary expertise needed and the invasive nature of the procedures.  The 
use of 2nd intercostal space parasternal muscle EMG (EMGpara) to monitor 
respiratory-drive during exacerbations offers an opportunity to detect early 
treatment failure and the need for ventilatory support. 
We designed a prospective observational study measuring NRD using EMGpara 
to investigate the sensitivity and specificity for detecting clinical deterioration 
during an acute exacerbation.  The study was designed to answer the following 
hypotheses: 
1. NRD, as measured by EMGpara, is reproducible in stable COPD. 
2. Changes in NRD precede standard measures of clinical deterioration 
during acute exacerbations of COPD. 
3. Failure of NRD to fall during treatment of an acute exacerbation of COPD 
prior to hospital discharge predicts readmission risk. 
2.4: Physiological Trial 3: Physiological Effects of Home 
Mechanical Ventilation Compared to Home Oxygen Therapy in 
Patients with Persistent Hypercapnic Following Acute 
Exacerbations of Chronic Obstructive Pulmonary Disease 
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The equivocal data concerning the use of domiciliary NIV in COPD are 
principally attributable to poor trial design.  There has been a failure to 
maximise the chances of a successful trial outcome by ensuring that the trial 
selects the highest risk patients and optimises the intervention.  Patients 
presenting with acute decompensated hypercapnia have a poor prognosis with 
high rates of readmission and death146, 147 making them ideal candidates for a 
therapeutic intervention.  The majority of published trials titrated inspiratory 
pressure to comfort or subjective relief of dyspnoea during wakefulness, 
providing less than optimal levels of ventilatory support.93, 138, 140  None of these 
trials showed significant improvements in gas exchange in the intervention 
group, implying failure to adequately augment ventilation.  It is unsurprising 
therefore that the trials did not show significant clinical advantages in the 
therapeutic group as in effect they were receiving sub-therapeutic or sham 
intervention.  Trials involving higher levels of pressure support and reporting 
significant improvements in gas exchange have involved high inspiratory 
pressures.135, 136 
As already alluded to earlier in this chapter much of the equivocal data from 
large clinical trials of HMV in COPD have been criticised due to their failure to 
correct nocturnal hypoventilation.  The advent of high intensity ventilation for 
COPD has been supported by data that  has been shown it to better control 
nocturnal hypoventilation than lower intensity non-invasive ventilation.141  
Although the effects on sleep quality are unclear the data suggests that the 
control of hyponocturnal ventilation is likely to have an equivocal or even 
beneficial effect on sleep quality.136, 142  The previous work by both Dreher et al 
and Meecham-Jones et al used overnight in-hospital polysomnography to 
compare the disruptive effects of nocturnal NIV on sleep quality.136, 142  Whilst 
this allows detailed exploration of sleep architecture it requires extensive 
monitoring for a single night within hospital.  Despite the inability of actigraphy 
to record detailed sleep staging it has the advantage of allowing the monitoring 
of patients for prolonged periods in their own home, which better reflects the 
patients usual sleep pattern and sleep quality.  Three main hypotheses have 
been suggested to explain the improvement in daytime gas exchange of HMV in 
COPD patients with chronic hypercapnic respiratory failure: 
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1. Resetting central respiratory drive. 
2. Improving pulmonary mechanics. 
3. Resting fatigued respiratory muscles. 
The relative merits of each hypothesis are discussed below. 
2.4.1: Respiratory drive 
Due to the increased respiratory muscle load, patients with COPD have an 
increased level of NRD as measured by EMGdi, HCVR and P0.1.
53, 233  However, 
COPD patients with chronic hypercapnia fail to increase NRD levels in response 
to further carbon dioxide stimulus.233  This reduction in central chemosensitivity 
is considered to be a major cause of persistent hypercapnia and it can be 
modified by even short periods of daytime NIV137 and it is inversely correlated 
with changes in daytime PaCO2, supportive of a mechanistic role in mediating 
the change.134  The measurement of central respiratory drive can be 
challenging and two main methods have been used: the hypercapnic ventilator 
response (HCVR)234 test and measurement of P0.1.
60  Both tests have been 
shown to improve following HMV in hypercapnic COPD134, 137, 235, 236 with the 
former demonstrated to be reliable and reproducible in severe COPD237 whilst 
the performance of the latter measurement in this patient group has been 
variable.238  However, the reliability and reproducibility of HCVR has been 
questioned as ventilatory response is influenced by mechanical factors, such as 
airflow limitation and changes in lung volume, which are altered in COPD as 
ventilation increases and lung empting is incomplete.239  Researchers often 
corrected the HCVR to either forced expiratory volume in one second (FEV1)
137 
or maximum voluntary ventilation (MVV)240 in an attempt to account for the 
mechanical limitations of the test and variations in body size.  The use of 
changes in NRD, measured using diaphragm and parasternal EMG, during 
hypercapnic challenge testing may better represent central drive than the use of 
minute ventilation.  Blunting of the respiratory drive leads to nocturnal 
hypoventilation and significant sleep disordered breathing.241  Patients with both 
COPD and significant sleep disordered breathing have a poor prognosis if left 
untreated and outcomes are improved by control of the sleep disordered 
breathing.242  Variation in neural respiratory drive appears an important element 
of exercise restriction in severe COPD and its modification offers the potential to 
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improve exercise capacity and thus physical activity.243  Indeed changes in 
dyspnoea following pulmonary rehabilitation programmes have been shown to 
correlate with changes in objectively measured physical activity.244 
2.4.2: Respiratory load 
COPD is characterised by significant increases in the load on the respiratory 
system.  A major contributor to this is a modification in the operating lung 
volumes with static hyperinflation which places the respiratory system on a less 
efficient part of the pressure-volume curve.  The airflow limitation that is the 
hallmark of COPD can further exacerbate this problem, especially as during 
exercise minute ventilation increases, which leads to dynamic hyperinflation.228  
The degree of hyperinflation as measured by the inspiratory capacity/total lung 
capacity (IC/TLC) ratio provides a global indication of respiratory load and, more 
importantly, it has been shown to have prognostic value in stable COPD.245  
Improvements in the degree of hyperinflation following treatment with NIV have 
been demonstrated with the degree of improvement correlating with 
improvements in gas exchange.134, 137  Long term use of NIV has also been 
shown to reduce load by improving dynamic lung compliance (Cdyn),
236 dynamic 
intrinsic positive end expiratory pressure (dynPEEPi),
236 airflow obstruction,135 
and resting respiratory pattern.235, 236  However, the changes observed have 
been inconsistent across the studies.  The mechanical constraints imposed by 
both static and exercise induced dynamic hyperinflation appear to be the most 
significant limiting factor in endurance exercise capacity in COPD.113  Thus, 
improvements in this area offer the opportunity to release this critical constraint 
allowing improved exercise performance. 
2.4.3: Respiratory muscle capacity 
Initial theories regarding the mechanism of action of NIV in COPD revolved 
around the idea of ‘resting’ the fatigued respiratory muscles.  More recent work 
has indicated that the respiratory muscles in COPD are at a cellular level more 
efficient than healthy controls231 and this is thought to be due to a fibre shift 
from type 2 fatigue sensitive glycolytic fibres to type 1 fatigue resistant oxidative 
fibres within the muscle.232  Furthermore, there has been a failure to 
demonstrate diaphragm fatigue in vivo in COPD patients,246 even in those 
patients requiring mechanical ventilation.247  All the studies to date have not 
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shown any clinically meaningful changes in respiratory muscle function 
following treatment with NIV in severe hypercapnic COPD.93, 137, 138, 248, 249 
2.4.4: Summary 
Whilst much data has been published reporting the physiological changes 
occurring following the initiation of domiciliary NIV, interpretation of the data has 
been limited by the lack of a comparative control group in the studies.134, 137  
Three studies have attempted to use control groups to examine the 
physiological changes caused by HMV.  However, these studies have been 
limited by the use of either a non-randomised design235 or application of NIV in 
a hospital rather than the domiciliary setting,135, 236 as well as of being of 
relatively short duration.  These methodological flaws limit the conclusions that 
can be drawn from these physiological data.  The lack of a clear clinical 
response to HMV in COPD provides a robust case for a physiological 
randomised controlled trial. 
A randomised controlled trial comparing standard care (home oxygen therapy) 
to standard care with the addition of domiciliary NIV will allow the following 
hypotheses to be tested: 
1. The principal physiological mechanism of action of domiciliary NIV in 
hypercapnic COPD is a combination of improved central chemosensitvity 
and enhanced pulmonary mechanics. 
2. Changes in central respiratory drive using NRD, measures such as 
EMGdi and EMGpara, provides greater physiological understanding than 
traditional measures of ventilation output (Ve). 
3. Sleep quality is similar in patients treated with home oxygen therapy and 
domiciliary NIV. 
4. Daytime physical activity is enhanced in patients treated with domiciliary 
NIV compared patients treated with home oxygen therapy. 
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CHAPTER 3: MATERIALS & METHODS 
3.1: Ethical Approval 
All of the studies described had prior ethical approval from either King’s College 
Hospital or St Thomas’ Hospital ethics committee: 
 Study 1 – 07/H0804/140 
 Study 2 – 05/Q0703/82 
 Study 3 – 09/H0802/2 
3.2: Patient Recruitment 
3.2.1: Study 1 
Patients referred to the Lane Fox Respiratory Unit, Guy’s and St Thomas’ 
Hospital and the Sleep and Ventilation Unit, Royal Brompton Hospital with 
stable OHS or transferred following acute decompensated respiratory failure 
secondary to OHS were screened for study inclusion. 
Study inclusion criteria were: 
 Obesity with a BMI >40 kg/m2 
 Daytime stable respiratory failure with PaCO2 >6 kPa and pH >7.35 
 Absence of another identifiable cause of hypoventilation 
 Ratio of FEV1 to FVC >0.70 and FVC <70% predicted 
Exclusion criterion was: 
 An inability to provide written informed consent 
3.2.2: Study 2 
Stable COPD patients were recruited from the pulmonary rehabilitation 
programme at St Thomas’ Hospital.  Patients admitted to a medical ward via the 
accident and emergency department at St Thomas’ Hospital with a primary 
diagnosis of an acute exacerbation of COPD were offered enrolment in the 
study. 
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3.2.3: Study 3 
Patients referred to the Lane Fox Respiratory Unit, St Thomas’ Hospital and the 
Sleep & Ventilation Unit, Royal Brompton Hospital with persistent hypercapnia 
following a recent admission with decompensated acute on chronic respiratory 
failure secondary to an acute exacerbation of COPD were screened for 
suitability for participation.  In addition, patients recruited from Aintree University 
Hospital and Leeds University Hospital were offered participation in the 
actigraphy assessed sleep quality sub-study. 
Inclusion criteria were: 
 An inpatient admission with an acute hypercapnic exacerbation of COPD 
 A greater than 20 pack year smoking history 
 FEV1 of less than 50% predicted 
 FEV1/FVC less than 60% 
 At least 2 weeks following resolution of acute hypercapnic acidosis 
(PaCO2 >7 kPa, pH >7.3) 
 Chronic hypoxia (PaO2 <7.3 kPa or <8 kPa with secondary polycythaemia, 
pulmonary hypertension, peripheral oedema or significant nocturnal 
hypoxia (SpO2 <90% for >30% sleep time) 
Exclusion criteria were: 
 Inability to wean off NIV prior to discharge/transfer (persistent 
hypercapnic respiratory failure with pH <7.30 despite adequate NIV) 
 Patient requiring daytime NIV or >6 hours of nocturnal NIV 
 Development of worsening hypercapnic respiratory failure with 
acidosis during initiation of oxygen therapy (ABG – pH <7.30 taken 2-
4 hours after waking) 
 Primary diagnosis of restrictive lung disease causing hypercapnia 
 Significant symptomatic OSA contributing to patient morbidity 
 Assessment more than 4 weeks from resolution of index exacerbation 
 BMI >35 kgm-2 
 Need for invasive mechanical ventilation during acute admission 
 Unable to tolerate NIV (if given) during acute illness 
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 Unstable coronary artery syndrome 
 Renal replacement therapy 
 Inability to consent/comply with trial protocol (as determined by site 
PI) 
 Aged <18 years 
 Pregnancy 
3.3: Anthropometrics 
3.3.1: Basic anthropometrics 
Height and weight were measured in patients wearing light clothing and without 
shoes.  Waist measurement was taken at the midpoint between the lower costal 
margin and the iliac crest.  Hip measurement was made at the point of largest 
lateral protrusion of the hips. 
3.3.2: Measurement of fat free mass (FFM) 
Single frequency bioelectrical impedance (Bodystat 1500, Bodystat, Douglas, 
UK) was used to calculate participants’ FFM.  The technique involves passage 
of a small current at 50Hz between surface electrodes placed on the 
extremities.  The unit calculates the voltage drop between the electrodes and 
thus total body impedance.  The test assumes a two compartment model with 
adipose tissue containing little or no water and electrolytes and therefore being 
of high electrical impedance and FFM having a high water and electrolyte 
content and thus low electrical impedance.  Predictive equations can then be 
used that incorporate height, weight, age and gender in order to calculate FFM 
from the measured impedance value.  Generic and disease specific regression 
equations exist to maximise the accuracy of the results with the technique 
validated against other methods of measuring body composition such as dual 
energy x-ray absorptiometry (DEXA).250, 251 
3.4: Health Related Quality of Life 
A range of generic and population specific validated questionnaires were used 
to assess health related quality of life in the studies. 
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3.4.1: St George’s respiratory questionnaire (SGRQ) 
Originally validated in 1992, in patients with both fixed and reversible airflow 
limitation, the questionnaire is self-administered and comprises of 72 
questions.87  Once completed the questionnaire provides a total and 3 sub-
domain scores relating to symptoms, impact (on daily life) and activity.  It has 
been shown to be reproducible and sensitive to changes in disease state.252  
The version of the SGRQ used during this work is provided at the end of this 
work (Appendix A: SGRQ). 
3.4.2: Severe respiratory insufficiency (SRI) questionnaire 
Patients with respiratory failure receiving domiciliary NIV consist of a number of 
different diagnostic categories but suffer with a range of problems related to 
both the underlying disease process and the resultant sleep disordered 
breathing.  The SRI questionnaire comprises of 49 questions producing a 
summary and 7 sub-domain scores.  The questionnaire has been validated in 
the general HMV population and specifically in COPD patients receiving HMV 
and has been shown to be reproducible and correlates to changes in generic 
measures of HRQL.89, 90  The questionnaire was originally formulated in 
German but has also been validated in Spanish and English.253, 254  The English 
version of the SRI is provided in the appendix (Appendix B: SRI questionnaire). 
3.4.3: Epworth sleepiness score (ESS) 
Daytime somnolence can be a feature of all forms of sleep disordered breathing 
and it is distinct from either fatigue or tiredness.  The Epworth sleepiness 
questionnaire was validated in a sleep disorder setting to differentiate the 
pathologically sleepy states that occur in OSA, narcolepsy and idiopathic 
hypersomnolence from simple snoring or a healthy control population, with 
values correlating to sleep latency during polysomnography and multiple sleep 
latency testing.255  The ESS has subsequently been used to monitor response 
to treatment in forms of respiratory failure and sleep disordered breathing.123, 256  
A reproduction of the ESS is provided in the appendix (Appendix C: ESS). 
3.4.4: Chronic respiratory disease questionnaire (CRQ) 
The CRQ was developed for use in clinical trials.  This was because it was 
acknowledged that a disparity existed between pulmonary function testing, 
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physical activity, dyspnoea and functional state in COPD.  The CRQ was initially 
developed as an interviewer administered questionnaire and it was 
subsequently modified to incorporate an individualised dyspnoea component 
and be self-administered.88, 257  As with other HRQL measures in COPD it has 
been demonstrated to be reproducible and responsive to clinical change 
occurring following optimisation of medical therapy or pulmonary rehabilitation.88  
The questionnaire provides scores in 4 domains relating to dyspnoea, emotional 
function, fatigue and mastery (patients control over illness).  The self-
administered individualised CRQ is provided in the appendix at the end of this 
document (Appendix D: CRQ-SAI). 
3.5: Exercise Capacity and Physical Activity 
Physical activity is both a patient centred outcome and implicated in the disease 
process itself in COPD.  Exercise performance is an important prognostic factor 
in COPD and in the HMV population.104, 258 
3.5.1: Incremental shuttle walk test 
The ISWT provides a symptom limited test of maximum exercise performance 
that correlates with 6 minute walking test time.95  The test is performed on a 
10m course and is externally paced by using a beep system which starts with 
long pauses and steadily increasing in frequency over the duration of the test.  
The test is continued until the patient is unable to complete the course at the 
necessary pace or is no longer able to continue.  Performance on the ISWT 
correlates strongly with maximum oxygen consumption259 and has been shown 
to correlate with significant outcomes such as mortality in COPD.260  Data 
indicates that the minimum clinically important difference is 47.5m.261 
3.5.2: Actigraphy 
Physical activity can be assessed by means of wrist worn actigraphs.  The 
Actiwatch 64 (Philips-Respironics, Murrysville, PA, US) and Actiwatch Spectrum 
(Philips-Respironics, Murrysville, PA, US) consist of an accelerometer and 
event button.  They produce an activity count that is proportional to the speed 
and duration of movement during 1 minute epochs.  They allow for the objective 
assessment of physical activity in an unobtrusive way and have been used to 
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monitor physical activity in obesity262 and COPD.263  Watches were fitted on the 
non-dominant wrist in COPD and dominant wrist in obesity and worn for 14 
days, except for short periods for personal hygiene.  The patients completed a 
sleep hygiene diary (Appendix E: sleep hygiene diary) during this time and 
returned it with the watch.  Following the assessment period data were 
downloaded via Actiware 5 (Philips-Respironics, Murrysville, PA, US) allowing 
detailed analysis of patterns of physical activity.  Using a combination of sleep 
diary, event marker and light sensor readings rest periods were set on the 
actigram as shown in Figure 8. 
Figure 8: Example actigram with light, activity and event markers used to place rest 
intervals 
Physical activity was calculated for the time in between the daily major rest 
period, termed ‘daytime’, for a seven day period. The following data was 
produced: 
 Mean activity - mean daytime activity counts per 1 minute epoch 
 Peak activity - mean peak 1 minute epoch daytime activity count 
 Total mobile time - mean daytime total number of 1 minute epochs with 
activity (minutes and percentage daytime) 
 Total immobile time - mean daytime total number of 1 minute epochs 
with no activity (minutes and percentage daytime) 
3.6: Pulmonary Mechanics 
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3.6.1: Pulmonary function testing 
Testing was performed in the pulmonary function laboratories at St Thomas’ 
Hospital and the Royal Brompton Hospital and conducted by departmental staff. 
Spirometric, plethysmographic, gas transfer and lung volumes were obtained 
using standardised testing.264  Predictive values were obtained using European 
Respiratory Society standards.265 
3.6.2: Advanced pulmonary mechanics measurements 
The assessment of detailed pulmonary mechanics requires the measurement of 
flow and of pressure changes across the respiratory system.  The process by 
which these are obtained is detailed below.  Following signal acquisition 
analogue to digital conversion was performed by a Powerlab device 
(ADInstuments, Chalgrove, UK).  Once digitised signals could be viewed and 
manipulated on a personal computer using a commercial software package 
(Labchart v7.2, ADInstuments, Chalgrove, UK). 
Measurement of respiratory pressures  
Differential pressure transducers (MP 45, Validyne, Northridge, CA, US) 
attached via amplifiers to the Powerlab system allowed recording of the desired 
pressures.  The transducers were individually connected via low bore non-
compliant tubing to a nasal bung, oesophageal balloon and gastric balloon.  
This allowed simultaneous measures to be taken across the respiratory system.  
The pressure transducers were calibrated against a digital manometer (Bio-Tek 
Instruments, Winooski, VT, US) using a two-point calibration test.  The system 
was calibrated to atmospheric pressure and then to a second pressure (nasal 
and oesophageal transducer -150cmH2O, gastric transducer +150cmH2O) 
generated via a 50ml syringe and 3 way tap connected to the pressure 
transducer.  Linearity was tested to ensure readings were within 1% across the 
range -150 to 150 cmH2O.  Calibration was performed prior to each patient 
testing. 
Oesophageal and gastric balloon posi tioning  
The measurement of transpulmonary and transdiapragmatic pressure requires 
placement of oesophageal and gastric balloons.71  Following application of 
lubrication and local anaesthetic to the nasal passage a combined balloon 
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catheter is inserted and passed into the oesophagus and stomach, assisted by 
patient swallowing.  Once the catheter is fully inserted both balloons are filed 
with 2mL of air and then aspirated to leave small residual volumes for pressure 
recording and attached to the pressure transducers.  The catheter is slowly 
withdrawn until the Poes value becomes negative during inspiration. The catheter 
is then further withdrawn ~10cm to mid oesophageal level.  Correct positioning 
of the catheter is confirmed by ensuring that Poes ~ Pao during a Mueller’s 
manoeuvre (dynamic occlusion test).266  The catheter is then secured to the 
nose to prevent movement during testing. 
Pressure-volume characteristics of balloon catheters  
The pressure within the balloon catheters during testing is transmitted to the 
differential pressure transducer via the residual air left within them.  Large 
pressure swings can cause sizable volume changes and sufficient air is 
required to allow pressures to be accurately recorded.  The pressure-volume 
characteristics of combined catheters (Guangzhou Yinghui Medical Science & 
Technology Company, Guangzhou, China) were tested as follows.  Firstly the 
air was expelled from the balloon by submersion under water for 5 minutes.  
The balloon was sealed via a 3 way tap and removed and allowed to dry and 
then attached to the pressure transducer.  Air was inserted in 0.1mL increments 




Figure 9: Pressure-volume characteristics for combined catheter balloons 






















Testing indicated that the flat portion of the pressure-volume curve, between 
points X and Y on Figure 9, was between 0.2 and 1.2mL.  To allow for sufficient 
volume change during testing 0.2mL was placed in the oesophageal balloon 
and 0.6mL in the gastric balloon. 
Linearity of the balloon-catheter-transducer system 
To test the balloon-catheter-transducer system to ensure it responded in a 
linear fashion to pressure changes the catheter was placed within a sealed bell 
jar.  The pressure within the bell jar was altered in order to provide the range of 
pressures to be tested and the synchronous readings from the digital 
manometer and the balloon-catheter-transducer system were plotted allowing 
linearity to be demonstrated (Figure 10). 
Figure 10: Balloon-catheter-transducer linearity testing at typical balloon filling volumes 






























Balloon filling volume = 0.2ml






























Balloon filling volume = 0.6ml
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Measurement of flow 
A heated pneumotachograph (model 3830, Hans-Rudolph, Shawnee, KS, US) 
was attached to a low pressure differential pressure transducer spirometer pod 
(ADInstruments, Chalgrove, UK).  Standard operating conditions were 
maintained and calibration performed using a 3L volume syringe (Hans-
Rudolph, Shawnee, KS, US) fitted to the pneumotach via a tight rubber seal 
after the spirometer pod was zeroed.  Several loops were then performed with 
the calibration syringe at differing speeds to allow simulation of several flow 
rates.  Accuracy of inspiratory and expiratory limbs were checked to ensure 
values were within 3% of the injected volume. 
Static and dynamic compliance 
The ease at which pressure changes across the respiratory system produce 
changes in volume is termed pulmonary compliance.  It can be measured in 
either static or dynamic fashion.  The measurement of static compliance 
requires specialist equipment and detailed coaching of patients whereas 
dynamic compliance can be readily calculated during tidal breathing.  Dynamic 
compliance is measured during the expiratory phase by dividing the expiratory 
volume by the oesophageal pressure change from end inspiration to end 
expiration (Figure 11).  The measurement is made during the relaxed expiratory 
phase to ensure that the reading is not influenced by respiratory muscle activity 
and the work required to overcome surface tension during inspiration.267 
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Figure 11: Measurement of dynamic compliance 
Abbreviations: Poes – Oesophageal pressure 
Intrinsic Positive end-expiratory pressure (PEEP i) 
As with compliance, PEEPi can be measured via static or dynamic tests.  
Dynamic PEEPi represents change in oesophageal pressure from the start of 
inspiratory effort, as denoted by a rapid fall in oesophageal pressure, to the start 
of inspiratory flow (Figure 12).  This value represents the lowest regional value 
of PEEP that needs to be overcome in order to start inspiration and so can be 
an underestimate of static PEEP in diseases with considerable heterogeneity.  
This value should be corrected for active expiration by subtracting any rise in 
gastric pressure during the preceding expiratory phase from the value 
obtained.66 
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Figure 12: Measurement of dynamic intrinsic positive end-expiratory pressure 
Abbreviations: Poes – Oesophageal pressure, Pgas – Gastric pressure 
3.6.3: Respiratory muscle strength 
Non-invasive assessment of respiratory muscle strength (Sniff nasal inspiratory 
pressure (SNIP), maximum inspiratory pressure at the mouth (PImax) and 
maximum expiratory pressure at the mouth (PEmax) were carried out using a 
handheld device (Micromedical Ltd, Kent, UK) in accordance with the American 
Thoracic Society-European Respiratory Society guidelines.32  During 
measurement of advanced pulmonary mechanics a full range of respiratory 
muscle tests were completed including sniff, PImax, PEmax, TLC, MVV and 
cough. These advanced tests provide more detailed information including global 
(sniff Poes) and diaphragm specific (sniff Pdi) measures of respiratory muscle 
strength. 
3.6.4: Measures of respiratory drive 
Respiratory drive can be measured during tidal breathing by normalising 
recorded respiratory muscle EMGs to the maximum achieved during respiratory 
manoeuvres.  This normalised EMG%max reduces the effect of between patient 
variation in skin preparation and subcutaneous tissue. 
Measurement of parasternal muscle electromyogram (EMGpara) 
The second intercostal space was identified using bony landmarks and skin was 
prepared with EMG contact gel (Nuprep, DO Weaver and Co, US).  Wet gel 
electrodes (Neuroline 720, Ambu, Denmark) were placed adjacent to the sternal 
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edge in the second intercostal spaces.  The signal was amplified and processed 
using a high differential amplifier with band pass filters set at 10Hz and 2000Hz 
(1902, Cambridge Electronic Design, Cambridge, UK - St Thomas’ Hospital site; 
Octbioamp, ADInstruments, Chalgrove, UK - Royal Brompton Hospital site). 
Additional analogue 50Hz notch filter and AC coupling were used.  Amplified 
signals were passed to an analogue to digital convertor (Powerlab, 
ADInstruments, Chalgrove, UK) and then to a personal computer.  Further 
digital filtering occurred at 20Hz after data acquisition (LabChart v7.2, 
ADInstruments, Chalgrove, UK).  EMGpara recordings were performed with the 
patient relaxed in a chair or semi-recumbent in bed with arms supported.  
EMGpara signals were acquired during resting breathing for at least 5 minutes 
and until more than 2 minutes of stable breathing were recorded, a typical trace 
is provided in Figure 13.   
As described earlier maximum manoeuvres were performed and used as the 
maximum EMGpara measurement.  EMGpara signals were analysed using the root 
mean squared (RMS) of the raw EMGpara signal with a 40ms moving window 
and normalised to the maximum RMS EMGpara value (EMGpara%max) analogous 
to the algorithm previously described for the analysis of EMGdi.
53  Peak RMS 
EMGpara was recorded for each breath, discarding those breaths which were 
contaminated by ECG artefacts.  The value for each breath was normalised for 
the maximum RMS EMGpara obtained and the mean for all valid breaths was 
then calculated.  Whilst EMGpara%max reflects neural drive per breath and has 
been used in stable patients we have also used a neural respiratory drive index 
(NRDI, arbitrary units; AU) that incorporated respiratory rate to develop a 
measurement of neural drive to the respiratory muscles per unit time. 
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Figure 13: Representative trace of raw data during [A] maximum sniff manoeuvre and [B] 




Abbreviations: Pnp – Nasopharyngeal pressure (cmH2O, top row), Flow (l/s, 2
nd
 row), EMGpara – 
Parasternal muscle electromyogram (µV, 3
rd
 row), RMS – Root mean squared (µV, bottom row). 
Measurement of diaphragm electromyogram  (EMGdi) 
A combined respiratory pressure-EMG multipair electrode catheter was used 
which allows for reliable signals to be acquired across a range of lung 
volumes.58  Catheter placement occurred as described earlier in this chapter.  
The raw EMG signals were amplified and processed as described above for 
EMGpara with the multipair design producing 5 channels of data. Positioning was 
optimised to ensure the largest raw EMGdi signals were obtained in the 
outermost channels.  The channel with the largest RMS EMGdi signal for each 
breath was used to calculate the EMGdi%max. 
Figure 14: Example of invasive pulmonary physiology raw data obtained from combined 
balloon-electrode catheter to confirm catheter position 
 
Abbreviations: Poes – Oesophageal pressure, Pgas – Gastric pressure, EMGdi – diaphragm 
electromyogram. 
Measurement of other surface electromyogram (EMG)  
In addition to the obligatory inspiratory muscle EMGs recorded from the 
parasternal and diaphragm surface EMGs were acquired from the right 
sternocleidomastoid and right external oblique abdominal muscles. These 
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groups were chosen in order to obtain surface EMG signals from an accessory 
(sternocleidomastoid) and expiratory (abdominal) muscle.  Bipolar electrodes 
were placed adjacent along the surface landmarks of the relevant muscle at 1/3 
from the distal insertion point for the sternocleidomastoid muscle and 2/3 
between umbilicus and anterior iliac crest for the external oblique abdominal 
muscle.  Maximum EMG signals were obtained during the same inspiratory 
manoeuvres as the parasternal and diaphragm muscles for the 
sternocleidomastoid and during a cough and MEP manoeuvre for the abdominal 
muscles. 
Hypercapnic challenge test  
The HCVR was performed using a modified version of the technique originally 
described by Reed et al234 and validated in COPD by our own group.237  A 
simple circuit was employed to minimise dead space with mouth piece, 
pneumotacch, 3 way valve and 5L douglas bag placed in series.  End-tidal CO2 
(etCO2) measurements were performed using the Capnocheck sleep (Smith 
Medical, WI, US).  Calibration was performed in line with manufacturer 
recommendations and delay from sampling port to output was checked prior to 
each testing and corrected digitally.  Ventilatory parameters were calculated 
breath by breath for the duration of the test (4½ minutes or patient intolerance) 
with the first 30 seconds being discarded from analysis.  A second run was 
performed following a minimum period of 30 minutes rest.  Physiological 
recordings of respiratory muscles were performed during the hypercapnic 
challenge test and plotted via the same method as minute ventilation allowing 
slopes of ∆Ve/∆etCO2 and ∆EMG%max/∆etCO2 to be calculated using linear 
regression.  The mean slope of 2 technically satisfactory runs was used.  To be 
deemed technically satisfactory the runs must have been at least 1 minute in 
duration and demonstrated a linear increase in etCO2 during testing of at least 
1kPa.  The results of technically inadequate tests were omitted.  When the 
resultant slope of a technically satisfactory test was not demonstrably linear (via 
linear regression analysis) a value of 0 was entered to indicate that, within the 
limitations of testing, no response to hypercapnic challenge was present. 
3.7: Assessment of Sleep Disordered Breathing 
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Due to the changes that occur in the respiratory load-capacity-drive relationship 
during sleep it was essential to complete patient assessments with measures 
during sleep. 
3.7.1: Overnight oximetry-capnometry 
A combined oximeter-capnometer device (Tosca 500, Radiometer, Crawley, 
West Sussex, UK) was used to measure oxygen saturations (SpO2) and tcCO2 
during sleep.  Capnometer probes were calibrated at the start and end of sleep 
monitoring and the data was uploaded to a personal computer using Download 
2001 (Stowood Instruments, Beckley, Oxford, UK) allowing for the calculation 
of: 
 4% Oxygen desaturation index 
 Mean SpO2 
 Minimum SpO2 
 Total analysis time with an SpO2<90% (time and percentage) 
 Mean tcCO2 
 Maximum tcCO2 
3.7.2: Advanced sleep studies 
Respiratory polygraph 
The diagnosis and severity of sleep disordered breathing (obstructive and 
central apnoea events and hypoventilation) was performed using the Embletta 
(Embla, Broomfield, CO, US).  This is a multichannel device recording nasal 
flow, respiratory effort via inductance plethysmography, SpO2, heart rate and 
body position.  The device was set prior to each individual recording and a 
system check was performed once the patient set up was complete.  At the end 
of the sleep study the device is downloaded via the Somnologica software 
(Embla, Broomfield, CO, US).  Studies were individually scored detailing the 




Wrist worn actigraphy is described earlier for the monitoring of physical activity.  
These devices are widely used for the monitoring of circadian rhythm 
disturbance in patients with respiratory sleep disorders.268  They have been 
shown to correlate with polysomnogram derived sleep parameters269 and have 
the advantage of providing domiciliary recordings over several days.121  Daily 
rest periods were set as described earlier and subsequent analysis using 
commercial software (Actiware 5, Philips-Respironics, Murrysville, PA, US) 
produced values for: 
 Total sleep time – Total duration, in minutes, of actigraphy defined sleep 
in the rest period, i.e. between lights off and lights on 
 Wake after sleep onset – Total duration, in minutes, of actigraphy defined 
wake between sleep onset and lights on 
 Sleep efficiency – Calculated as the percentage of a rest period with 
actigraphy defined sleep 
 Sleep latency – Time, in minutes, between lights off and sleep onset 
3.8: Set up of home oxygen therapy (HOT) and home 
mechanical ventilation (HMV) for HOT-HMV UK study 
3.8.1: Home Oxygen Therapy (HOT) 
All eligible patients had standardisation of medical therapy to ensure they 
received inhaler therapy with long acting β2-agonist, steroid and long acting 
anti-muscarinic and nebulised or inhaled short acting β2-agonist.  Other 
medication, including oral theophylline remained unchanged and under the 
discretion of the usual care providers. Patients had arterial blood gases (ABGs) 
performed whilst seated and breathing room air for at least 20 minutes.  ABGs 
for assessment of HOT were performed at least 4 hours after waking.  Patients 
with hypoxia (PaO2 < 7.3 kPa or PaO2 < 8 kPa with features of secondary 
hypoxaemia) on ABGs performed at least 2 weeks following resolution of 
respiratory acidosis were deemed to meet the criteria for HOT.   
Features of secondary hypoxaemia: 
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 Polycythaemia 
 P-pulmonale on ECG 
 Pulmonary hypertension 
 Peripheral Oedema 
 Nocturnal hypoxia (>30% sleep time with SpO2 <90%) 
A distinction is required between HOT and long term oxygen therapy (LTOT) 
with the latter requiring a longer period of clinical stability and repeat blood 
gases at least 3 weeks apart in order to qualify for treatment.270  The rationale in 
using HOT as opposed to LTOT was that the study was specifically designed to 
look at a high risk recurrent exacerbator phenotype and previous data had 
shown that in the target population the median length of time to readmission 
was 32 days and so a significant proportion of patients would be readmitted 
before the period of stability would be reached and thus would never reach 
eligibility for the study.271  Oxygen therapy was prescribed for both groups at the 
lowest flow able to correct daytime hypoxia (to achieve SpO2 > 90% and PaO2 > 
8 kPa).  Patients were advised to use HOT for at least 15 hours per day.  All 
patients also received standardised education on oxygen therapy.  
3.8.2: Home Mechanical Ventilation (HMV) setup 
HMV setup was performed as an inpatient using either Harmony 2 machine 
(Philips-Respironics, Murrysville, PA, US) or VPAP III STa machine (ResMed, 
Bella Vista, Australia) using a standardised titration protocol (Appendix F: HOT-
HMV titration protocol) to achieve high pressure ventilation (inspiratory positive 
airways pressure (IPAP) ≥ 25 cmH2O) and control nocturnal sleep disordered 
breathing.  The interface (nasal or full face) was selected according to patient 
preference.  Patients were advised to use HMV for the duration of their night 
time sleep period with an aim of achieving greater than 6 hours nightly use. 
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CHAPTER 4: TARGETED TIDAL VOLUME PRESSURE 
SUPPORT VENTILATION VS. FIXED LEVEL PRESSURE 
VENTILATION IN SUPER OBESE PATIENTS WITH CHRONIC 
RESPIRATORY FAILURE 
4.1: Materials and Methods 
All subjects provided written informed consent prior to enrolment.  The study 
was approved by Guy’s research ethics committee (07/H0804/140) and the 
research was conducted in accordance with the declaration of Helsinki and local 
governance policies (RJ1 08/0074).  The study was registered prospectively on 
a publically accessible database (ISRCTN63940700).  
4.1.1: Study design 
The study was a single (subject) blinded prospective randomised controlled 
trial.  Patients were randomly allocated via minimisation to either standard care 
using nurse-led protocolised fixed bi-level Pressure Support NIV (PS) or the 
addition of AVAPS mode using a BiPAP synchrony device (Philips-Respironics, 
Murrysville, PA, US).  Minimisation was performed using BMI (40-50 kg/m2, 50-
60 kg/m2 or >60 kg/m2), neck circumference (<45 / ≥45 cm), gender (male or 
female) and mode of referral (acute or elective) variables. 
4.1.2: Patient assessment and treatment titration 
Patients underwent baseline spirometry (microplus handheld spirometer, 
Cardinal Health, OH, US), arterial blood gases, anthropometrics including body 
composition (Bodystat 1500, Bodystat Ltd, Isle of Man, UK) and completed 
health related quality of life questionnaires (Severe Respiratory Insufficiency 
(SRI) Questionnaire, Epworth Sleepiness Score (ESS), Fatigue Severity Score 
(FSS) and Visual Analogue Score (VAS) for sleep comfort, fatigue and physical 
activity levels).  Following randomisation patients underwent a titration of 
designated NIV mode using a predetermined protocol with settings altered 
according to the results of overnight oximetry-capnometry (Tosca 500, 
Radiometer, Crawley, UK), see Figure 15 and appendix G. 
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Figure 15: Non-invasive ventilation titration protocol for Average-Volume Assured 
Pressure Support (AVAPS) and fixed level Pressure Support (PS) arms 
Randomisation
AVAPS
IPAP = EPAP+4 – 30 cmH20
EPAP = 8 – 10 cmH20
Vte = 8 – 10 mL/kg (ideal weight)
Ti 30-50% cycle
Resting rate - 4
PS
IPAP = 18 – 22 cmH20
EPAP = 8 – 10 cmH20
Ti 30-50% cycle
Resting rate - 4
Overnight oximetry-capnometry




Increase Vte by 10% to improve 
hypoventilation
Titrate EPAP to abolish 
obstructive events (max 16)
No
Increase PS by 10% to improve 
hypoventilation
Titrate EPAP to abolish 
obstructive events (max 16)
Aims:
Mean nocturnal SpO2 >88%
Fall or rise <0.5 kPa in tcCO2
 
Patients were discharged on the allocated treatment and followed up at 3 
months with repeat baseline investigations including overnight oximetry-
capnometry on allocated treatment. 
Patients had assessment of sleep disruption and daytime activity performed 
using the Actiwatch 64 (Philips-Respironics, Murrysville, PA, US), an 
accelerometer device that has been used previously to measure daytime 
activity in obesity262 and to assess sleep patterns in respiratory sleep 
disorders268.  Equipment limitations restricted the number of patients completing 
the actigraphy data collection section of the protocol.  The accelerometer was 
worn for the 7 days following initiation of domiciliary NIV and the 7 days 
following the 3 month assessment. 
4.1.3: Data analysis and statistics 
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To detect a difference in partial pressure of arterial carbon dioxide (PaCO2) ≥ 
0.5 kPa between intervention groups with a power of 80% at the 5% 
significance level required 42 patients to be randomised on a 1 to 1 basis.  To 
allow for an approximate 20% drop out rate 50 patients were targeted for 
recruitment. 
Data were analysed using independent or paired t-test where appropriate, 
unless data were demonstrably not normally distributed and then a non-
parametric equivalent was used.  For all analyses, a p<0.05 was considered 
statistically significant.  Data analysis was conducted using PASW statistics 18 
(SPSS, Chicago, IL, US). 
Multiple linear analysis was used to model the relationships between change in 
PaCO2 and independent variables.  The analysis used included the principal 
independent variable, compliance or estimated tidal volume per ideal body 
weight along with potential confounders.  Variables selected to act as potential 
confounders for the analysis were treatment allocation, clinical presentation, 
gender and age. 
Normally distributed data are presented as mean ± SD and not normally 
distributed data as median (range). 
4.2: Results 
62 patients were screened for study participation with 50 patients consented 
and randomised, of which 4 further patients (2 from either intervention group) 
were unable to be followed up in the study period.  Further details are provided 
in Figure 16 of study exclusions and withdrawals. 
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Figure 16: Recruitment, exclusions and withdrawals summary for Average-Volume 
Assured Pressure Support (AVAPS) and fixed level Pressure Support (PS) trial 
Screened = 62 Excluded = 12
• Unable to read & write = 6
• Declined = 4
• Deteriorated and intubated = 1
• Unable to provide informed 
consent = 1
Baseline assessment = 50
Randomised AVAPS = 25 Randomised PS = 25
3 month assessment = 23 3 month assessment = 23 
Withdrawn = 1
Did not attend 
follow up = 1
Withdrawn = 1
Did not attend 
follow up = 1
 
4.2.1: Baseline anthropometrics and sleep variables 
No statistically significant differences were demonstrated in any assessed 
variable between randomised groups at baseline (Table 6). 
Table 6: Baseline variables and treatment outcomes for Average-Volume Assured 
Pressure Support (AVAPS) and fixed level Pressure Support (PS) trial 
 AVAPS  Fixed level PS  






Age (years) 53 ± 9   56 ± 11   
98 
 AVAPS  Fixed level PS  






Gender (male / female) 12 / 13   11 / 14   
Presentation  
(Emergency / Elective) 
9 / 16   9 / 16   
BMI (kg/m
2
) 50 ± 8 48 ± 9 0.007 52 ± 8 51 ± 7 0.024 










Neck Circumference (cm) 46 ± 6 46 ± 7 0.340 48 ± 5 48 ± 7 0.084 


















 (mmol/l) 31 ± 3 29 ± 3 0.001 31 ± 4 27 ± 3 0.003 
The p-values refer to paired t-test analysis from initiation to follow up values within each group. 
Abbreviations: BMI – body mass index, FEV1 – forced expiratory volume in 1s, FVC – forced 
vital capacity, PaCO2 – arterial partial pressure of carbon dioxide, PaO2 – arterial partial 
pressure of oxygen, HCO3
-
 – serum bicarbonate. 
4.2.2: Treatment titration 
The median time to achieve satisfactory NIV setup was 2 days (range 1-4 days) 
for both groups.  Nocturnal ventilatory control, assessed by overnight oximetry 
and tcCO2, was similar in both the AVAPS and fixed level PS groups (Table 7).  
Three patients failed to reach the predetermined criteria for satisfactory 
ventilator setup (2/25 PS vs. 1/25 AVAPS; p=0.6) due to an inability to tolerate 
the increase in inspiratory positive airways pressure (IPAP) or tidal volume (V te).  
These patients were discharged on the highest tolerated settings.  
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Supplementary oxygen was required by six patients (4/25 PS vs. 2/25 AVAPS; 
p=0.4). 
Table 7: Discharge oximetry-capnometry results in Average-Volume Assured Pressure 
Support (AVAPS) and fixed level Pressure Support (PS) groups 
 AVAPS Fixed level PS p-value 
4%ODI (events/hour) 22 ± 16 22 ± 17 0.517 
Mean SpO2 (%) 92 ± 3 92 ± 3 0.552 
%TST SpO2 <90% (%) 20 ± 21 15 ± 20 0.630 
Mean tcCO2 (kPa) 7.1 ± 0.7 7.2 ± 1.0 0.952 
Max tcCO2 (kPa) 8.4 ± 0.8 8.4 ± 1.6 0.980 
The p-value refers to comparison between interventions by independent t-test.  Abbreviations: 
ODI – oxygen desaturation index, SpO2 – oxyhaemaglobin saturation, TST – total sleep time, 
tcCO2 – transcutaneous carbon dioxide. 
At discharge, ventilator settings provided a mean IPAP 25 ± 3 cmH2O in the PS 
group and mean Vte 657 ± 96 mL in the AVAPS group.  A small but statistically 
significant difference in mean EPAP was present with 10 ± 2 and 9 ± 1 cmH2O 
in the PS and AVAPS groups respectively (p=0.03).  Mean back up rate was 14 
± 1 breaths per minute in both groups. 
4.2.3: Actigraphy assessed sleep and activity parameters following 
initiation of NIV 
No significant differences were demonstrated between AVAPS and PS groups 
in objective assessment of sleep quality (total sleep time (TST), wake after 
sleep Onset (WASO), sleep efficiency or sleep latency) at baseline or follow up 
(Table 8). 
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Table 8: Actigraphy analysed sleep parameters for the 1st week following initiation of 
non-invasive ventilation compared with the 1st week following the 3 month assessment 
in the Average-Volume Assured Pressure Support (AVAPS) (n=14) and fixed level 
Pressure Support (PS) (n=15) arms 









TST (minutes) 341 ± 80 352 ± 78 0.713 321 ± 52 346 ± 75 0.302 
WASO%TST 
(%) 
23 ± 11 23 ± 17 0.987 27 ± 16 20 ± 13 0.185 
Latency 
(minutes) 
5 ± 3 8 ± 7 0.164 4 ± 2 5 ± 6 0.577 
Efficiency (%) 80 ± 7 80 ± 13 0.894 79 ± 9 81 ± 9 0.416 
The p-value refers to comparison between interventions at each time point by independent t -
test. Abbreviations: TST – total sleep time, WASO – wake after sleep onset. 
4.2.4: Outcome following 3 months of domiciliary NIV 
Gas exchange, health related quality of life, daytime somnolence and 
control of sleep disordered breathing  
There were no between group differences in change in the primary outcome: 
PaCO2, or secondary outcomes: daytime gas exchange, anthropometric 
measures, spirometry, HRQL or daytime somnolence (Table 9, Table 10). 
Table 9: Changes in gas exchange, anthropometrics and spirometry between non-










∆PaCO2 (kPa) -0.6 ± 1.0* -0.6 ± 1.1* 0 (-0.7 to 0.6) 0.867 
∆PaO2 (kPa) 0.2 ± 1.7 0.5 ± 1.6 0 (-1 to 1) 0.519 
∆HCO3
-











∆BMI (kg/m2) -1 ± 2* -2 ± 4* 1 (-1 to 2) 0.497 
∆Fat free mass (kg) -1 ± 6 0 ± 8 -1 (-4 to 3) 0.805 
∆Waist circumference 
(cm) 
-3 ± 5* -2 ± 7 -1 (-3 to 4) 0.676 
∆FEV1 (%predicted) 6 ± 13* 4 ± 14 2 (-6 to 10) 0.588 
∆FVC (%predicted) 6 ± 12* 5 ± 17* 1 (-7 to 10) 0.777 
The p-value refers to comparison between interventions by independent t-test, * indicates a 
significant (p<0.05) within group imporvement. Abbreviations: PaCO2 – arterial partial pressure 
of carbon dioxide, PaO2 – arterial partial pressure of oxygen, HCO3
-
 – serum bicarbonate, BMI – 
body mass index, FEV1 – forced expiratory volume in 1s, FVC – forced vital capacity. 
Table 10: Between treatment group comparison of changes in health related quality of 
life and daytime somnolence from initiation of non-invasive ventilation to follow up at 3 
months 







∆SRI-SS (/100) 11 7 5 (-2 to 12) 0.212 
∆SRI-RC (/100) 15 11 4 (-8 to 16) 0.464 
∆SRI-PF (/100) 8 5 3 (-7 to 14) 0.532 
∆SRI-AS (/100) 15 6 9 (-2 to 20) 0.121 
∆SRI-SR (/100) 5 6 0 (-11 to 10) 0.927 
∆SRI-AX (/100) 17 9 8 (-6 to 22) 0.260 
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∆SRI-WB (/100) 9 4 5 (-5 to 14) 0.338 
∆SRI-SF (/100) 13 8 5 (-8 to 14) 0.429 
∆VAS-sleep comfort 
(/100) 
13 20 8 (-8 to 23) 0.332 
∆VAS-activity (/100) 8 0 -9 (-26 to 9) 0.324 
∆VAS-fatigue (/100) 19 13 -6 (-23 to 11) 0.480 
∆ESS (/24) -5 -6 1 (-2 to 5) 0.428 
∆FSS (/56) -9 -7 -2 (-11 to 8) 0.752 
SRI: higher score indicates better quality of life, VAS: higher score indicates greater quality of 
life; FSS: higher score indicates greater level of fatigue.  The p-value refers to comparison 
between interventions by independent t-test.  Abbreviations: SRI-SS – severe respiratory 
insufficiency questionnaire summary score, SRI-RC – severe respiratory insufficiency 
questionnaire respiratory complaints domain, SRI-PF – severe respiratory insufficiency 
questionnaire physical function domain, SRI-AS – severe respiratory insufficiency questionnaire 
attendant symptoms and sleep domain, SRI-SR – severe respiratory insufficiency questionnaire 
social relationships domain, SRI-AX – severe respiratory insufficiency questionnaire anxiety, 
SRI-WB – severe respiratory insufficiency questionnaire well-being domain, SRI-SF – severe 
respiratory insufficiency questionnaire social functioning, VAS – visual analogue score, ESS – 
Epworth sleepiness score, FSS – fatigue severity score. 
Significant within group improvements occurred in PaCO2, health related quality 
of life, daytime somnolence and overnight oximetry-capnometry (Table 6, Table 
11 and Figure 17) between baseline and follow up.  Change in daytime PaCO2 
strongly correlated with other clinically important and patient relevant outcomes 
including change in anthropometrics (Δweight r=0.438, p=0.002; ΔFM r=0.619, 
p<0.001; Δwaist circumference r=0.339, p=0.021; ΔFFM r=-0.464, p=0.001), 
nocturnal hypoventilation (Δmean SpO2 r=-0.310, p=0.043; Δmean tcCO2 
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r=0.588, p<0.001), spirometry (ΔFEV1 r=-0.470, p=0.001; ΔFVC r=-0.403, 
p=0.006) and HRQL (ΔSRI-SS r=-0.321, p=0.029). 
Figure 17: Comparison of inter and intra group changes in Average-Volume Assured 
Pressure Support (AVAPS) and fixed level Pressure Support (PS) for [A] mean nocturnal 
oxyhaemoglobin saturation (SpO2), [B] percentage nocturnal recording time with an SpO2 
<90%, [C] mean transcutaneous carbon dioxide (tcCO2) and [D] max transcutaneous 
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Table 11: Health related quality of life pre-post treatment in Average-Volume Assured 
Pressure Support (AVAPS) and Pressure Support (PS) groups 
 AVAPS  Fixed level PS  
 Baseline Follow up p-value Baseline Follow up p-value 
SRI-SS 
(/100) 
55 ± 16 66 ± 19 <0.001 51 ± 14 57 ± 15 0.018 
SRI-RC 
(/100) 
55 ± 20 70 ± 20 0.001 49 ± 24 59 ± 22 0.025 
SRI-PF 
(/100) 
50 ± 24 58 ± 26 0.069 42 ± 20 47 ± 22 0.139 
SRI-AS 
(/100) 
48 ± 17 62 ± 20 0.003 48 ± 19 54 ± 16 0.100 
SRI-SR 
(/100) 
66 ± 20 72 ± 24 0.116 67 ± 20 73 ± 18 0.165 
SRI-AX 
(/100) 
48 ± 24 65 ± 29 0.001 41 ± 23 50 ± 21 0.094 
SRI-WB 
(/100) 
55 ± 19 64 ± 21 0.007 51 ± 16 55 ± 17 0.303 
SRI-SF 
(/100) 








43 ± 24 52 ± 26 0.177 47 ± 23 47 ± 22 0.967 
VAS-fatigue 
(/100) 
39 ± 23 59 ± 27 0.001 42 ± 26 55 ± 28 0.058 
ESS (/24) 11 ± 5 6 ± 5 0.001 13 ± 6 7 ± 5 <0.001 
FSS (/56) 43 ± 14 34 ± 15 0.014 45 ± 16 37 ± 18 0.038 
SRI: higher score indicates better quality of life, VAS: higher score indicates greater quality of 
life; FSS: higher score indicates greater level of fatigue.  The p-values refer to paired t-test 
analysis from initiation to follow up values within each group.  Abbreviations: SRI-SS – severe 
respiratory insufficiency questionnaire summary score, SRI-RC – severe respiratory 
insufficiency questionnaire respiratory complaints domain, SRI-PF – severe respiratory 
insufficiency questionnaire physical function domain, SRI-AS – severe respiratory insufficiency 
questionnaire attendant symptoms and sleep domain, SRI-SR – severe respiratory insufficiency 
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questionnaire social relationships domain, SRI-AX – severe respiratory insufficiency 
questionnaire anxiety, SRI-WB – severe respiratory insufficiency questionnaire well-being 
domain, SRI-SF – severe respiratory insufficiency questionnaire social functioning, VAS – visual 
analogue score, ESS – Epworth sleepiness score, FSS – fatigue severity score. 
Ventilatory parameters 
There were no between group differences in any of the assessed outcome 
variables (Table 6) or ventilator parameters (Table 12). 
Table 12: Ventilator parameters at follow up in Average-Volume Assured Pressure 
Support (AVAPS) and fixed level Pressure Support (PS) groups 
 AVAPS Fixed level PS p-value 
Delivered IPAP (cmH2O) 22 ± 5 23 ± 4 0.402 
Leak (L/min) 53 ± 13 53 ± 19 0.968 
Patient triggered breaths (%) 43 ± 27 45 ± 27 0.759 
Compliance (hours:minutes/day) 4:11 ± 2:53 5:08 ± 2:22 0.230 
Abbreviations: IPAP – inspiratory positive airway pressure. 
NIV showed a dose response effect with a significant correlation between hours 
of use and improvement in daytime PaCO2 (r=-0.370; p=0.012) with the 95% 
confidence interval crossing below 0 with an adherence time of 4 hours (Figure 
18). 
Figure 18: Relationship between ventilator compliance and change in arterial partial 
pressure of carbon dioxide (PaCO2) 
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Abbreviations: AVAPS – average-volume assured pressure support, PS – fixed level pressure 
support. 
A significant linear relationship was demonstrated when comparing the 
ventilator calculated mean Vte over the trial period per ideal body weight and the 
change in daytime PaCO2 (r=-0.398; p=0.006) from baseline to follow up 
(Figure 19).  Multiple linear regression analysis demonstrated no significant 
relationship between any of the potential confounders (treatment allocation, 
clinical presentation, age and gender) and change in PaCO2.  The model 
showed both ventilator adherence and V te per ideal body weight were 
significantly related to change in PaCO2. 
Figure 19: Relationship between change in arterial partial pressure of carbon dioxide 
(PaCO2) during trial period and calculated ventilation per unit of ideal body weight 
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Abbreviations: AVAPS – average-volume assured pressure support, PS – fixed level pressure 
support, Vte – ventilator estimated tidal volume. 
Anthropometrics and physical activity  
32 patients completed actigraphy monitoring analysis at baseline and 28 
patients at follow up.  There were no differences between the AVAPS and fixed 
level PS group at either baseline or follow up in measures of daytime physical 
activity and anthropometric variables (Table 13). 
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Table 13: Changes in actigraphy (n=28) and anthropometric (n=46) variables between 
baseline and 3 months follow up in treatment groups 





∆Weight (kg) -3 ± 5 -5 ± 9 2 (-2 to 7) 0.289 
∆Fat free mass (kg) -1 ± 6 0 ± 8 -1 (-5 to 4) 0.805 
∆Fat mass (kg) -2 ± 7 -4 ± 12 2 (-4 to 8) 0.484 
∆Waist circumference 
(cm) 
-3 ± 5 -2 ± 7 -1 (-4 to 2) 0.676 
∆Mean activity counts 
(counts/day) 
18 ± 64 46 ± 64 -28 (-78 to 22) 0.261 
∆Max activity counts 
(counts/day) 
207 ± 557 414 ± 506 -207 (-624 to 209) 0.315 
∆Immobile time 
(minutes/day) 
-39 ± 96 -41 ± 90 2 (-70 to 75) 0.947 
∆Mobile time 
(minutes/day) 
4 ± 93 24 ± 79 -20 (-88 to 48) 0.545 
 
4.2.5: Combined Average-Volume Assured Pressure Support (AVAPS) and 
fixed level Pressure Support (PS) cohort 
As there were no clinically significant differences demonstrated between the 
AVAPS and fixed level PS modes in either primary or secondary outcomes, a 
single cohort (n=28) was produced to allow a post-hoc analysis of the 
relationship between physical activity and NIV in OHS patients. 
Physical activity and weight loss  
Baseline data showed that patients spent an average of 3 hours 21 minutes ± 1 
hour 33 minutes immobile or asleep during the daytime period.  There were 
significant inverse correlations observed between daytime activity (mean activity 
counts per day), and weight (r=-0.392; p=0.024) and waist circumference (r=-
0.423; p=0.014).  Significant reductions in weight, fat mass and waist 
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circumference were observed following 3 months of NIV, with an associated 
increase in physical activity (Table 14). 
Table 14: Actigraphy (n=28) and anthropometric variables (n=46) at baseline and 3 
months follow up 
 Baseline 
Follow up at 3 
months 
p-value 
Weight (kg) 141 ± 28 137 ± 28 0.001 
Fat free mass (kg) 70 ± 17 69 ± 17 0.593 
Fat mass (kg) 70 ± 21 67 ± 19 0.041 
Waist circumference (cm) 142 ± 15 140 ± 16 0.003 
Mean activity counts 
(counts/day) 
232 ± 100 263 ± 94 0.016 
Max activity counts 
(counts/day) 
1797 ± 507 2100 ± 553 0.006 
Immobile time (minutes/day) 201 ± 93 161 ± 84 0.028 
Mobile time (minutes/day) 771 ± 86 785 ± 110 0.417 
Actigraphy analysed for the 1
st
 week at home following initiation of NIV compared with the 1
st
 
week following the 3 month assessment of NIV. 
There were significant correlations between change in physical activity, as 
measured by change in immobile time, and both the change in fat mass 
(r=0.482; p=0.011) and waist circumference (r=0.456; p=0.015) between 
baseline and follow up assessment (Figure 20). 
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Figure 20: Regression analysis showing relationship between change in anthropometric 
measures ([A] fat mass, [B] waist circumference) and change in physical activity between 
initation of NIV and 3 month follow up 
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Abbreviations: AVAPS – average-volume assured pressure support, PS – fixed level pressure 
support. 
4.2.6: Ventilator Triggering 
Post hoc analysis of ventilator triggering was performed using data downloaded 
from ventilator data cards at the end of the study period.  An arbitrary cut off of 
≤50% and >50% non-triggered ventilator delivered breaths was selected to 
investigate the effect of back up rate pressure controlled ventilation (PCV) 
dependency on clinical outcome.  Baseline data for the groups is provided 
below in Table 15. 
Table 15: Comparison between patients receiving ≤50% pressure control ventilation 
(PCV) and those patients receiving >50% PCV at baseline i.e. patient triggering greater 







Age (years) 52 ± 9 56 ± 11 0.277 
Gender (male / female) 7 / 10 16 / 13 0.840 
PaCO2 (kPa) 6.6 ± 0.4 7.1 ± 0.8 0.018 
BMI (kg/m
2
) 52 ± 8 51 ± 8 0.669 
FEV1 (% predicted) 57 ± 15 54 ± 15 0.558 








ESS 11 ± 6 13 ± 6 0.400 
SRI - SS 51 ± 16 54 ± 16 0.532 
Mean nocturnal SpO2 
(%) 
93 ± 3 92 ± 3 0.105 
Mean nocturnal tcCO2 
(kPa) 
7.0 ± 0.8 7.2 ± 0.9 0.593 
Abbreviations: PCV – pressure controlled ventilation, PaCO2 – arterial partial pressure of carbon 
dioxide, BMI – body mass index, FEV1 – forced expiratory volume in 1s, FVC - forced vital 
capacity, ESS – Epworth sleepiness score, SRI-SS – severe respiratory insufficiency 
questionnaire summary score. 
The ventilator settings were similar at NIV initiation in each group as shown in 
Table 16. 
Table 16: Comparison of ventilator settings between patients receiving ≤50% pressure 
control ventilation (PCV) and those patients receiving >50% PCV at initiation of on-
invasive ventilation (NIV) 
 PCV ≤50% PCV >50% p-value 
IPAP (cmH2O) 23 ± 3 26 ± 3 0.052 
EPAP (cmH2O) 9 ± 1 10 ± 2 0.047 
Vte (mL) 619 ± 75 661 ± 96 0.301 
Back up rate (bpm) 14 ± 1 14 ± 1 0.223 
Abbreviations: PCV – pressure controlled ventilation, IPAP – inspiratory positive airways 
pressure, EPAP – expiratory positive airways pressure, Vte – estimated tidal volume 
Comparative post hoc analysis showed that patients with a backup rate PCV 
dependency >50% had a greater control of nocturnal carbon dioxide, improved 
daytime carbon dioxide and enhanced health-related quality of life at 3 months 
(Table 17).  These data support the hypothesis that controlled NIV provides 
better nocturnal ventilatory control and improves patient outcome. 
Table 17: Comparison of changes in gas exchange, anthropometrics, health-related 
quality of life and overnight oximetry-capnometry from baseline to 3 months in patients 
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∆PaCO2 (kPa) -0.1 ± 0.7 -1.0 ± 1.1 0.9 (0.3 to 1.5) 0.003 
∆BMI (kg/m2) -0.3 ± 1.5 -2.2 ± 3.2 1.9 (0.2 to 3.6) 0.031 
∆ESS -2 ± 5 -8 ± 6 6 (2 to 9) 0.001 
∆SRI - SS 3 ± 11 13 ± 12 -10 (-2 to -17) 0.010 
∆Mean nocturnal 
SpO2 (%) 
3 ± 6 5 ± 4 -2 (-5 to 1) 0.146 
∆Mean nocturnal 
tcCO2 (kPa) 
-0.3 ± 0.8 -0.9 ± 1.2 0.6 (0.0 to 1.3) 0.049 
Abbreviations: PCV – pressure controlled ventilation, PaCO2 – arterial partial pressure of carbon 
dioxide, BMI – body mass index, ESS – Epworth sleepiness score, SRI-SS – severe respiratory 
insufficiency questionnaire summary score, SpO2 – oxyhaemaglobin saturation, tcCO2 – 
transcutaneous carbon dioxide. 
4.2.7: Clinical Presentation 
NIV Initiation 
Patients presenting acutely had similar baseline anthropometrics, but with a 
greater restrictive ventilatory defect on spirometry and more pronounced 
hypercapnia compared to those patients admitted electively for NIV set up 
(Table 18). 
Table 18: Baseline data based on elective or acute clinical presentation 
 
Elective 
(n = 33) 
Acute 
(n = 17) 
p-value 
Treatment allocation 
(AVAPS / PS) 
17 / 16 8 / 9 0.765 




(n = 33) 
Acute 
(n = 17) 
p-value 
Gender (Male / Female) 16 / 17 11 / 6 0.276 
BMI (kg/m
2
) 51 ± 8 51 ± 8 0.830 
Fat Free Mass (kg) 71 ± 18 71 ± 20 0.944 
Waist Circumference 
(cm) 
140 ± 14 149 ± 19 0.079 
Neck Circumference 
(cm) 
47 ± 5 48 ± 6 0.348 
FEV1 (%predicted) 57 ± 13 47 ± 16 0.017 
FVC (%predicted) 57 ± 12 49 ± 16 0.056 
PaCO2 (kPa) 6.7 ± 0.6 7.3 ± 0.8 0.004 
PaO2 (kPa) 8.7 ± 1.1 8.9 ± 2.2 0.796 
HCO3
-
 (mmol/l) 30 ± 3 32 ± 4 0.149 
Abbreviations: AVAPS – average-volume assured pressure support, PS – fixed level pressure 
support, BMI – body mass index, FEV1 – forced expiratory volume in 1s, FVC - forced vital 
capacity, PaCO2 – arterial partial pressure of carbon dioxide, PaO2 – arterial partial pressure of 
oxygen, HCO3
-
 - serum bicarbonate. 
However, the differences in both gas exchange and spirometry present at 
baseline were no longer significant at 6 week (p=0.36) and 3 month (p=0.94) 
follow up.  There were no significant differences between acute and elective 
groups in terms of length of time to setup (AVAPS 2 day ± 1 day vs. PS 2 day ± 
1 day; p=0.4) or respiratory sleep study measures (Table 19). 
Table 19: Comparison of limited attended respiratory polygraphy data for elective and 
acute clinical presentation at initiation of non-invasive ventilation (NIV) 
 
Elective 
(n = 33) 
Acute 




25 ± 18 17 ± 10 0.085 




(n = 33) 
Acute 
(n = 17) 
p-value 
%TST SpO2 <90% 
(%) 
18 ± 23 16 ± 15 0.708 
Mean tcCO2 (kPa) 6.7 ± 0.7 7.4 ± 1 0.061 
Max tcCO2 (kPa) 8.2 ± 0.8 8.8 ± 1.8 0.120 
Abbreviations: ODI – oxygen desaturation index, SpO2 – oxyhaemaglobin saturation, TST – 
total sleep time, tcCO2 – transcutaneous carbon dioxide. 
Variation in health-related quality of life  
Paradoxically, despite greater disease severity, patients presenting following an 
acute decompensated episode of respiratory failure reported better levels in 
some health-related quality of life measures at enrolment. Subsequently patient 
initiated on treatment following an acute exacerbation had larger improvements 
in some of these measures at follow up compared with those patients 
presenting electively (Table 20). 
Table 20: Health-related quality of life analysed according to elective and acute clinical 
presentation 












SRI-SS (/100) 51 ± 17 58 ± 17 0.002 57 ± 11 71 ± 15
#
 0.003 
SRI-RC (/100) 48 ± 22 61 ± 21 <0.001 62 ± 19
#
 74 ± 21
#
 0.094 
SRI-PF (/100) 49 ± 23 51 ± 25 0.451 40 ± 18 56 ± 24 0.001 
SRI-AS (/100) 44 ± 17 53 ± 17 0.012 58 ± 15
#
 69 ± 17
#
 0.017 
SRI-SR (/100) 64 ± 19 68 ± 22 0.115 75 ± 16 82 ± 16
#
 0.180 
SRI-AX (/100) 43 ± 27 52 ± 26 0.040 47 ± 13 70 ± 23
#
 0.003 
SRI-WB (/100) 50 ± 19 55 ± 19 0.079 62 ± 9
#
 69 ± 17
#
 0.020 
SRI-SF (/100) 60 ± 22 74 ± 19 0.064 56 ± 22 66 ± 23 0.018 
VAS-sleep 35 ± 28 51 ± 23 0.002 40 ± 28 63 ± 26 0.025 
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35 ± 21 50 ± 24 0.003 50 ± 25
#
 72 ± 26
#
 0.046 
ESS (/24) 12 ± 6 7 ± 5 <0.001 12 ± 6 5 ± 5 0.001 
FSS (/56) 46 ± 14 38 ± 16 0.005 41 ± 15 29 ± 16 0.092 
SRI: higher score indicates better quality of life, VAS: higher score indicates greater quality of 
life; FSS: higher score indicates greater level of fatigue.  The table p-value refers to within group 
change from baseline.  
#
independent t-test p<0.05 between group difference.  Abbreviations: 
SRI-SS – severe respiratory insufficiency questionnaire summary score, SRI-RC – severe 
respiratory insufficiency questionnaire respiratory complaints domain, SRI-PF – severe 
respiratory insufficiency questionnaire physical function domain, SRI-AS – severe respiratory 
insufficiency questionnaire attendant symptoms and sleep domain, SRI-SR – severe respiratory 
insufficiency questionnaire social relationships domain, SRI-AX – severe respiratory 
insufficiency questionnaire anxiety, SRI-WB – severe respiratory insufficiency questionnaire 
well-being domain, SRI-SF – severe respiratory insufficiency questionnaire social functioning, 
VAS – visual analogue score, ESS – Epworth sleepiness score, FSS – fatigue severity score. 
Ventilator settings showed a higher set IPAP in the fixed level PS arm in the 
acute (27 ± 3 cmH2O) compared to the elective (24 ± 2 cmH2O) group (mean 
difference 2.8 cmH2O, 95%CI 0.4 to 5.2 cmH2O, p=0.025).  Set Vte was similar 
in both acute and elective groups in the AVAPS arm.  A trend towards 
increased daily ventilator usage was observed in patients presenting acutely 
compared with elective presentation (mean difference 73 minutes, 95%CI -8 to 
154 minutes, p=0.075) that translated into a significantly higher percentage of 
days with a ventilator usage of greater than 4 hours (mean difference 25%, 
95%CI 7 to 45%, p=0.009).  There were no significant between group 
differences demonstrated in changes in gas exchange, respiratory sleep study 
parameters or anthropometric measures between baseline and follow up. 
4.3: Discussion 
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This single-blind randomised controlled trial demonstrated that average-volume 
assured pressure support ventilation has similar efficacy to fixed level pressure 
support ventilation when accompanied by a strict nurse-led protocolised setup 
in reducing daytime carbon dioxide level in super-obese patients with OHS.  
These results are in contrast to previous data suggesting that automated 
variable pressure support provided enhanced nocturnal ventilatory control, but 
at a cost of increased sleep disruption.  The current data represent the largest 
randomised controlled trial in super-obese patients with chronic respiratory 
failure and, as such, these clinical data add to the limited published data 
available.  In addition, these data confirm the findings of previous small studies 
in less obese patients demonstrating the improvements in daytime gas 
exchange, daytime somnolence and HRQL that can be achieved with the use of 
bi-level NIV.  In contrast to previous data, this study indicates that nocturnal 
treatment of chronic respiratory failure in super-obese patients enhances 
daytime physical activity, which is associated with weight loss. 
4.3.1: Critique of method 
Study design 
The study design used was a single blind randomised controlled trial.  The 
primary outcome was objective and all other assessments were conducted in 
accordance with international guidelines, when available, or local policies to 
minimise the chance of assessor bias.  This limitation is constant throughout 
other randomised studies in this area.92, 160  Although the scientific quality of the 
current trial would have been enhanced by the addition of a third control arm, 
the clinical consensus and current evidence strongly support the use of 
domiciliary NIV in patients with significant nocturnal hypoxia and hypercapnia, 
such as were enrolled in this study.  Survival data from observational studies 
have demonstrated that in this patient population NIV confers an advantage and 
therefore we considered that the use of a control arm raised clinical safety and 
ethical concerns.153, 166  This is the largest randomised controlled trial in this 
area and although it was designed with an 80% power there was a lower than 
expected drop out rate.  However the failure to demonstrate treatment 
superiority of volume targeted PSV may have occurred as a result of a type-2 
error. 
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Limitations of assessment methods  
For the purposes of this study, we were focussed on the primary outcome of 
change in PaCO2 and differences in nocturnal ventilatory control between the 
volume targeted and fixed level pressure support, assessed and titrated using 
limited attended respiratory polygraphy.  Whilst it is considered ideal to confirm 
sleep and quantify sleep staging using extended polysomnography, this should 
not detract from the findings of the trial.  Previous studies have shown that 
oximetry-capnometry is an accurate method to monitor change in tcCO2 in 
obese patients during NIV initiation.10, 11, 13, 272  The limitations of extended 
polysomnography to assess ventilator induced sleep disturbance must also be 
highlighted.  This approach only provides a single night assessment in a 
monitored hospital setting with a substantial array of electrocephalic, 
electromyographic and respiratory physiological monitoring equipment attached 
to the patient, all of which may cause sleep disruption.  Notwithstanding the 
difficulties of assessing the disruptive effects of NIV on sleep, we aimed to 
investigate the effect of volume targeted and fixed level PS on nocturnal 
disruption using 7-day actigraphy.  As this technique collects data over multiple 
nights in the home, overcoming the nightly variation occurring with 
polysomnography,273, 274 it has also been suggested to be a superior method of 
assessing treatment associated sleep disruption in OSA.121  Furthermore, 
actigraphy has been shown to be a valid method of assessing the sleep-wake 
cycle in patients with sleep disordered breathing269, 275 and the previously 
reported values for total sleep time, wake after sleep onset and sleep efficiency 
in OHS patients using extended polysomnography are comparable with our 
current data.92, 163  Importantly the intra-device reliability of the Actiwatch-64 
device is high, allowing useful comparison between patients and time points.13  
Actigraphy has the added benefit of providing objective daytime physical activity 
data and in the current study it permitted interrogation of the relationships 
between nocturnal ventilatory control, daytime somnolence, physical activity 
and weight loss. 
4.3.2: Significance of findings 
Efficacy of ventilation 
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Both non-invasive ventilatory modes provided similar control of nocturnal 
ventilation at baseline and follow up.  This was reflected by a similar 
improvement in hypercapnia at 3 months.  These data are in contrast to 
previous studies demonstrating greater reduction in tcCO2 during volume 
targeted pressure support ventilation compared to fixed level PS ventilation.92, 
163  However, neither of the previous trials used a study titration protocol, as 
was used in the current study, to minimise the differences between the groups, 
and thus the ventilator setup favoured higher levels of pressure support 
delivered in the volume targeted pressure support ventilation arm resulting in 
greater carbon dioxide clearance.  In addition to previous published data, the 
data from the current study showed that ≥4 hours nocturnal ventilation was 
required to achieve a reduction in daytime carbon dioxide.  These data are 
highly relevant to clinicians managing super-obese patients to satisfactory 
prescribe bi-level NIV. 
Effects on sleep disturbance  
The present study challenges previous data that showed volume targeted 
pressure support ventilation contributes to sleep disruption during initiation of 
NIV in patients with OHS.163  However, we consider our study design may 
explain this discrepancy because the previous studies employed a cross-over 
design, which is methodologically inferior to 1:1 randomisation.  Specifically 
Janssens et al randomised their patients in a cross-over design to their ‘normal’ 
NIV with or without volume targeted pressure support.  Furthermore, the 
estimated tidal volume was based on the patients’ actual body weight (8-10 
mL/kg) rather than their ideal body weight, which was the method used in the 
current study.  Not unexpectedly, this study design resulted in a significantly 
higher mean IPAP in the volume targeted PS group.  Therefore, in addition to 
the unfamiliar mode of ventilation these patients were provided with ventilator 
settings likely to negatively impact on sleep quality.  In contrast, the current 
study had an a priori protocol for titration that produced similar delivered mean 
PS levels between the groups.  The data suggests therefore, that the 
differences demonstrated in earlier studies were inherent to study design and 
setup protocol rather than the treatment mode per se. 
Improvements in health related quality of life and daytime somnolence  
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Consistent with previous reports, there was a significant treatment effect 
resulting in improvements in both daytime somnolence and HRQL.92, 160  There 
were no differences demonstrated in the magnitude of these improvements 
between groups, as expected, given that the efficacy of venti lation was similar.  
Although a larger mean improvement in HRQL occurred in the volume targeted 
PS treatment arm with more subdomains of the SRI showing within group 
improvements than in the PS arm.  This finding is hypothesis generating and 
could represent greater improvements in HRQL in the volume targeted PS arm, 
however, the trial was not powered to detect such differences and to do this 
would require a substantially larger trial with hundreds of participants that was 
beyond the scope of this current work. 
Improvements in physical activity  
As there were no significant differences demonstrated between the intervention 
groups, we considered that combining them to produce a cohort study is 
scientifically valid and that this provides useful clinical outcome data 
determining the effect on nocturnal ventilatory control in a group of super-obese 
patients with chronic respiratory failure.  A reasonable hypothesis has been that 
there is a direct relationship between enhanced nocturnal ventilatory control and 
improvement in daytime symptoms which, in turn, has a direct relationship with 
an increase in daytime physical activity and weight loss.  However, evidence for 
this has been lacking with few studies objectively assessing physical activity 
following resolution of hypersomnolence in patients with treated sleep-
disordered breathing.  The most recent data from a randomised controlled trial 
in male OSA patients with type 2 diabetes compared daytime physical activity 
using actigraphy in patients who received either therapeutic or sham-CPAP 
showed no within or between group differences in physical activity levels.276  
Our study population differs from that studied by West et al as the patients in 
the current trial were hypercapnic rather than eucapnic as in the earlier study.  
Furthermore, half our cohort were female, and the patients in our cohort were 
substantially more obese.  The West et al study failed to demonstrate an 
improvement in physical activity and there was also no weight loss achieved 
over the duration of the study in the study.  This is in contrast to the significant, 
albeit modest (3%) weight loss in our cohort.  Although this level of weight loss 
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appears minor, weight loss of this magnitude has been shown to be associated 
with improved metabolic measures in diabetic patients.277  It cannot be deduced 
from the data presented whether the changes in activity levels are the cause or 
effect of the weight loss.  However, given the correlation between the changes 
in activity and changes in anthropometric measures as well as the weight loss 
comprising of a change in fat mass rather than as the result of resolution of cor 
pulmonale are supportive of a causal relationship.  Given the role of pulmonary 
rehabilitation in other chronic respiratory disorders this data raises the 
possibility of augmenting the benefits of treatment in OHS by the addition of 
specific rehabilitation.278  The design of future studies of NIV to treat OHS will 
need to include such measurements. 
4.3.3: Ventilatory parameters 
Although it is expected that higher levels of pressure support result in greater 
ventilation, we hypothesised that those patients with lower ventilator triggering 
rates, and thus a higher proportion of pressure controlled breaths delivered by 
the ventilator, would have enhanced nocturnal ventilation.  We indeed observed 
that these patients had marked improvements in nocturnal oximetry and 
capnometry measures, which was reflected in an enhanced improvement in 
HRQL between initiation and follow up compared to those patients who had 
higher triggering rates.  Apart from a modestly higher PaCO2 in the group more 
dependent on pressure control ventilation, the groups were reasonably matched 
at baseline in terms of anthropometrics, spirometry, daytime somnolence and 
health-related quality of life. As a post hoc analysis the conclusions that can be 
drawn from these data are limited, however the data are hypothesis generating 
with the greater improvements in both night time and daytime gas exchange 
and HRQL in patients with greater dependence on back up rate pressure 
controlled ventilation.  This warrants further investigation.  It could be postulated 
that such patients are receiving ventilation that has driven the PaCO2 below 
their apnoeic threshold and that this would be associated with more rapid re-
setting of central respiratory drive and a subsequent improvement in clinical 
outcomes.  This approach could therefore be a more beneficial treatment 
strategy.  Such data informs clinical practice and, in particular, suggests that 
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clinicians might consider using a spontaneous-timed mode of ventilation in 
patients with OHS with a moderate back-up rate. 
4.3.4: Clinical presentation 
Patients with OHS may present both electively via the sleep disorders, bariatric, 
and respiratory services or acutely following an episode of decompensated 
episode of acute on chronic respiratory failure.  It is acknowledged that OHS is 
often a missed diagnosis, but it is less clear whether there are inherent 
demographic and other differences that influence the clinical presentation.  
Patients were transferred following an acute episode after a period of 
stabilisation and we observed a lower vital capacity and worse hypercapnic 
respiratory failure in these patients.  An expected consequence of this was 
higher inspiratory pressures required during NIV set up to establish similar 
nocturnal oximetry and capnometry control. 
Variations in patient self-reported HRQL may, in part, explain the differences 
between elective and acute clinical presentation of our super obese cohort.  
Patients presenting electively had greater impairment in terms of self-assessed 
respiratory complaints, sleep and attendant symptoms, and overall well-being.  
Patients presenting acutely had correspondingly higher levels, implying that 
these patients did not perceive the severity of their illness despite having 
greater physiological derangement at presentation.  This lack of correlation 
between illness perception and physiological impairment is interesting.  A 
rational assumption would be that patients with higher respiratory and sleep 
symptom burden would be more likely to seek medical attention electively, 
prompted by their symptoms, and this was reflected in the current data.  The 
variation in illness perception has significant implication to clinical services 
including emergency and critical care as well as bariatric services as simple 
symptom screening tools may lack sensitivity and specificity to identify the 
patients at risk of acute deterioration.  It may well be that screening spirometry, 
clinic oximetry and nocturnal home oximetry will provide greater sensitivity and 
specificity to screen super obese patients. 
4.3.5: Conclusion 
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These data demonstrate the equivalence of the average-volume assured 
pressure support mode of NIV compared to standard fixed bi-level NIV in terms 
of improvements in daytime gas exchange, nocturnal control of sleep 
disordered breathing, health related quality of life, daytime somnolence and 
daytime physical activity. The similar degree of sleep disruption occurring 
between volume targeted PS and fixed bi-level PS refutes previous suggestions 
of a significant deleterious effect on sleep quality in OHS patients when using 
this mode of NIV. The data is informative for clinical practice confirming the 
importance of adherence at the 4 hour level and that improving daytime PaCO2 
is an important target for therapy. The data on ventilatory triggering is 
hypothesis generating implying that improving central respiratory drive may be 
critical mechanism action of domiciliary NIV in OHS. Finally, the study 
represents the first attempt to objectively assess daytime activity and its 
relationship to treatment in this patient group. The results are exciting with the 
potential to augment the weight loss achieved by NIV with rehabilitation 
strategies, bridging patients to definitive weight loss procedures.102 
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CHAPTER 5: INTER-OCCASION REPRODUCIBILITY OF A 
RESPIRATORY PHYSIOLOGICAL BIOMARKER 
5.1: Materials and Methods 
The background literature of this study can be found on Page 68 of this thesis 
and the details of patient recruitment was described earlier in this thesis on 
Page 75. 
5.1.1: Baseline data 
Following enrolment patients completed the Chronic Respiratory Disease 
Questionnaire (CRQ), Borg score, modified Medical Research Council (MRC) 
score, performed handheld spirometry and had respiratory rate, heart rate and 
oxygen saturations recorded. 
5.1.2: EMGpara measurement 
Patient testing occurred following completion of the pulmonary rehabilitation 
session at least 30 minutes following last exercise and was repeated at the next 
session, 3-4 days later. EMGpara was acquired and processed as described 
earlier in the materials and methods section. 
5.1.3: Data analysis and statistics 
Reproducibility was assessed using Pearson’s correlation coefficient, co-
efficient of variability and Bland-Altman analysis.279  Data that were not normally 
distributed, as defined by the Kolmogorov-Smirnov test, were transformed and 
then analysed as parametric data or if the logarithm of the data remained non-
normal then a non-parametric equivalent was used.  Data analysis was 
conducted using SPSS software (SPSS, Chicago, IL, USA).  All data are 
presented as mean ± SD, unless otherwise stated with a p value <0.05 
considered as statistically significant. 
5.2: Results 
Ten patients with stable COPD were studied with a mean age 75 ± 6.9 years 
(range 66-85 years), 50% male.  Mean FEV1 was 0.97 ± 0.41 L.  The mean 
EMGpara on visit 1 was 8.83 ± 5.29 µV and on visit 2 was 10.09 ± 6.72 µV with a 
Cv of 0.19 ± 0.13.  The mean difference in EMGpara was 1.26 ± 2.45 µV 
123 
between visits with limits of agreement of -3.54 and 6.06 µV.  The mean 
EMGpara%max value on visit 1 was 11.59 ± 5.70% and on visit 2 was 11.96 ± 
5.11% with a Cv of 0.15 ± 0.09.  The mean difference in EMGpara%max was -0.37 
± 2.93% between visits with limits of agreement of -6.12 and 5.38%.  A Bland-
Altman plot of the first and second visit EMG data is provided in Figure 21. 
Figure 21: Bland-Altman comparisons for [A] parasternal muscle electromyogram 
(EMGpara) and [B] percent of maxmium parasternal muscle electromyogram (EMGpara%max) 
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Pearson’s correlation analysis between visit 1 and visit 2 demonstrated a strong 
correlation in both EMGpara (r=0.94; p<0.001) and EMGpara%max (r=0.89; 
p=0.002), see Figure 22.  No significant relationships could be identified 
between FEV1 and either EMGpara (p=0.78) or EMGpara%max (p=0.46) or the 
dyspnoea domain of the CRQ and EMGpara (p=0.17) or EMGpara%max (p=0.37). 
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Figure 22: Correlation between visit 1 and visit 2 for [A] parasternal muscle 
electromyogram (EMGpara) and [B] percent of maxmium parasternal muscle 
electromyogram (EMGpara%max) 















































These data demonstrated that the measurement of parasternal 
electromyography, as a measure of neural respiratory drive, has satisfactory 
inter-occasion reproducibility in stable patients with COPD.  This is a requisite of 
any test and supports the utilisation of EMGpara as a novel respiratory 
physiological biomarker for measuring changes in the respiratory muscle load-
capacity relationship in patients with COPD. 
5.3.1: Critique of the method 
Patient selection 
Stable patients attending pulmonary rehabilitation were chosen as they 
represented a population of patients that were already both clinically stable and 
attending hospital on repeat occasions close together.  Although possible, it 
would seem unlikely that the benefit attributable to pulmonary rehabilitation 
would improve the load-capacity-drive relationship in the short time between the 
two measurements.  Furthermore, this would act to increase the variability and 
thus the true repeatability may be greater.  Again, the use of patients having 
completed the exercise component of the programme may have some residual 
breathlessness related to exertion.  However, patients were tested following the 
education session and thus at least 30 minutes following completion of the 
exercise component of rehabilitation.  Borg scores were measured 
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synchronously with parasternal electromyography and if the Bland-Altman plot 
was restricted to patients in whom the Borg score was the same on both 
occasions (n=8), the reproducibility of EMGpara%max was further enhanced with 
limits of agreement being subsequently narrowed to -3.7% to 5.0%. 
Surface EMGpara measurement 
Although the issues of surface EMG recording are well described,52 we 
acknowledge that contamination from other chest wall muscles cannot be 
excluded.  However, we carefully observed patient and electrode position during 
data acquisition to maximise the contribution of parasternal muscles to the 
inspiratory EMGpara signal and minimising the non-respiratory activity of other 
muscles.  More detailed needle electrode technique could be used to isolate 
parasternal muscle activity,217, 280 but similar to oesophageal measurement of 
diaphragm electrical activity, this invasive technique is not suitable for the acute 
setting. 
Validity and reproducibility of EMGpara 
EMGpara, as a measure of neural respiratory drive, was shown to have 
satisfactory inter-occasion reproducibility in patients with stable COPD.  
Although the degree of variability with EMGpara in COPD patients was greater in 
this study than that shown previously by our own group using EMGdi
53 and 
EMGpara in patients with cystic fibrosis,
55 the inter-occasion correlation was 
>0.80, which is a level that has previously been used to indicate acceptable 
inter-test agreement for surface EMG.220 
5.3.2: Significance of findings 
The data demonstrated that EMGpara is a reproducible measure of neural 
respiratory drive in stable COPD.  This provides the requisite support to use 
EMGpara as a novel physiological technique to investigate the load-capacity-
drive relationship in the acute setting in COPD. 
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CHAPTER 6: A RESPIRATORY PHYSIOLOGICAL BIOMARKER 
TO MONITOR CLINICAL DETERIORATION AND PREDICT 
READMISSION IN ACUTE EXACERBATIONS OF COPD 
6.1: Materials and Methods 
The background literature of this study can be found on Page 70 of this thesis.  
Patient recruitment is as described earlier in this thesis on Page 76.  An acute 
exacerbation of COPD was defined based on clinical features and basic 
investigations.201  Initial patient management was according to standard local 
guidelines with oral corticosteroids, antibiotics and a combination metered-dose 
inhalers and nebulised bronchodilators.  Patients were identified by the COPD 
team and subsequently screened and recruited by the research team, with the 
first EMGpara measurement recorded within 24 hours of hospital arrival.  Repeat 
EMGpara measurements and the clinical dataset were recorded daily until the 
patient was reported as stable and suitable for hospital discharge. 
6.1.1: Baseline data 
Demographic and anthropometric data were collected at patient recruitment.  
Borg score281 and MRC dyspnoea score282, 283 were used to assess subjective 
breathlessness.  HRQL data was obtained using the CRQ.88  Spirometry was 
performed with a handheld device (EasyOne Diagnostic Spirometer, ndd 
Medical Technologies, Switzerland) according to standard guidelines.284, 285  
Repeat measurements were taken daily during admission until patient was 
either discharged or deemed medically fit for discharge.  The patient was 
positioned comfortably and rested for at least 5 minutes; bronchodilator therapy 
was withheld for the previous 4 hours.  Heart rate (HR), oxygen saturations 
(SpO2) and respiratory rate (RR) were measured over one minute.  Clinical data 
(HR, SpO2, RR, temperature, blood pressure and Medical Early Warning score 
(MEWS)286) and the supervising senior clinician’s summary opinion on clinical 
course were recorded from the medical notes and observation charts.  A patient 
was defined as a clinical ‘deteriorator’ or ‘improver’ based on the summary 
opinion of the senior attending respiratory physician (respiratory specialist 
registrar or consultant) and the requirement for increased treatment.  The 
respiratory clinicians were blinded to the EMGpara measurement, which was 
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analysed off line following patient discharge.  EMGpara signals were acquired 
either in a chair or semi-recumbent in bed.  Oxygen therapy was only used 
when the SpO2 was ≤ 88%. 
6.1.2: EMGpara measurements 
Signal acquisition was performed as described in the materials and methods 
section of this thesis on Page 86.  The resting signal was normalised to the 
maximum value obtained from a reproducible maximum sniff manoeuvre to 
produce the EMGpara%max.  To reflect changes in respiratory pattern, the product 
of EMGpara%max and respiratory rate was calculated to produce the neural 
respiratory drive index (NRDI; arbitrary units AU).  Nasal cannulae connected to 
a differential pressure transducer (Validyne DP45, Validyne, Northridge, CA, 
US) identified inspiratory and expiratory phases of breathing.  In addition to 
EMGpara EMG signals were acquired from the right sternocleiodomastoid 
muscle and right internal oblique abdominal muscle. 
6.1.3: Data analysis and statistics 
Relationships between EMGpara, EMGpara%max and NRDI and lung function 
parameters and HRQL data were analysed using regression analysis.  Data 
were analysed using independent or paired t-test where appropriate.  Data that 
were not normally distributed, as defined by the Kolmogorov-Smirnov test, were 
transformed and then analysed as parametric data or if the logarithm of the data 
remained non-normal then a non-parametric equivalent was used.  Data 
analysis was conducted using SPSS software (SPSS, Chicago, IL, USA).  All 
data are presented as mean ± SD or median (range), unless otherwise stated 
with a p-value <0.05 considered as statistically significant. 
6.2: Results 
6.2.1: Change in EMGpara in patients with acute exacerbations of COPD 
30 patients were recruited with a mean age of 72 ± 10 years (47% male).  On 
admission, the median MRC dyspnoea score was 5 (2-5).  The median previous 
admission frequency and length of stay was 3 admissions (0-13) and 6 days (2-
34), respectively.  Baseline data are provided in Table 21 and Table 22.  3 
patients received non-invasive ventilation with all cases initiated in the first 4 
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hours of admission in the emergency department.  9 patients were discharged 
with home oxygen, all were previously prescribed long term oxygen therapy.  
Table 21: Individual baseline admission data for patients admitted with an acute 






















1 64 F 12.6 9.1 238 3 4 26 UTP 
2 73 F 8.4 12.9 271 2 1 21 0.32 
3 57 M 40.0 25.0 799 3 4 32 UTP 
4 70 F 43.1 52.1 1512 4 7 29 0.52 
5 72 M 7.5 11.0 221 1 3 20 1.64 
6 72 F 5.8 21.0 543 3 6 26 UTP 
7 77 M 3.7 11.5 298 2 7 26 0.49 
8 81 F 14.0 21.2 509 2 6 24 0.46 
9 68 F 22.4 20.3 406 1 4 20 UTP 
10 64 M 16.8 25.3 506 1 7 20 0.69 
11 80 F 6.5 13.9 291 4 3 21 0.58 
12 74 F 9.2 14.8 355 2 2 24 0.45 
13 69 F 18.6 16.0 383 2 8 24 0.49 
14 89 F 21.8 36.7 808 2 1 22 0.24 
15 90 M 8.3 14.0 252 1 0.5 18 0.69 
16 79 M 6.4 16.9 422 3 5 25 0.48 
17 85 F 7.5 16.2 390 3 7 24 0.53 
18 72 F 16.4 10.4 249 2 4 24 UTP 
19 72 F 9.5 12.2 231 1 5 19 0.62 
20 75 F 19.8 15.7 378 4 8 24 0.44 
21 63 F 18.4 28.1 534 1 8 19 0.60 
22 72 M 20.9 32.3 550 1 3 17 0.67 
23 75 F 16.3 36.7 770 3 4 21 0.34 
24 83 M 15.7 17.9 287 0 0 16 1.58 
25 43 M 13.3 21.0 440 2 3 21 0.50 
26 64 M 17.4 25.1 527 2 9 21 0.45 























28 85 M 6.2 13.2 304 2 3 23 0.82 
29 63 M 3.0 8.0 144 1 5 18 2.11 
30 80 M 10.5 21.3 426 1 9 20 0.96 















22 ± 4 
0.60 ± 
1.65 
Abbreviations: EMGpara – Parasternal muscle electromyogram, EMGpara%max – percentage of 
maximum obtainable parasternal muscle electromyogram, NRDI – neural respiratory drive 
index, MEWS – medical early warning score, RR – respiratory rate, FEV1 – forced expiratory 
volume in 1s, UTP – patient unable to perform. 
Table 22: Summary of clinical parameters and indices of neural respiratory drive on 
admission 
 Emergency department 
Baseline 
measurements 
MEWS 3 (0-7) 2 (0-4) 
FEV1 (L) - 0.60 ± 1.65 
FVC (L) - 1.53 ± 0.82 
PaO2 (kPa) 10.0 ± 3.5 - 
PaCO2 (kPa) 6.3 ± 1.4 - 
EMGpara%max (%) - 20.3 ± 9.9 
NRDI (AU) - 455 ± 263 
Abbreviations: MEWS – medical early warning score, FEV1 – forced expiratory volume in 1s, 
FVC – forced vital capacity, PaO2 – arterial partial pressure of oxygen, PaCO2 – arterial partial 
pressure of carbon dioxide, EMGpara%max – percentage of maximum obtainable parasternal 
muscle electromyogram, NRDI – neural respiratory drive index. 
24 patients had recordings on 2 occasions, 5 patients had recordings on 3 
occasions and 1 patient had recordings on 4 occasions, producing 37 data 
pairs.  The daily values for sniff EMGpara were highly correlated (r=0.97, 
p<0.001) with minimal bias (Figure 23). 
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Figure 23: Daily repeatability of maximum sniff parasternal muscle electromyogram 
(EMGpara) 
Bland-Altman of sniff EMGpara




































∆Borg score had a significant relationship with ∆EMGpara (r=0.50; p=0.001), 
∆EMGpara%max (r=0.57; p<0.001) and ∆NRDI (r=0.60; p<0.001) and ∆FEV1 (r=-
0.58; p=0.002) as shown in Figure 24.  There was no relationship observed with 
∆SpO2 (p=0.16) or ∆RR (p=0.08).  The indices of neural respiratory drive also 
correlated with changes in respiratory rate.  A non-significant trend was 
demonstrated in the relationship between ∆FEV1 and ∆EMGpara%max (p=0.053) 
and ∆NRDI (p=0.057).  There were no significant changes demonstrated in the 
standard physiological parameters in ‘deteriorators’ between repeat 
assessments, but there were significant increases in the indices of neural 
respiratory drive (mean difference EMGpara%max=6.2, 95%CI 1.7 to 10.7, 
p=0.017; mean difference NRDI=226, 95%CI 165 to 288, p<0.001) and a non-
significant increase in MEWS (p=0.07) between occasions. 
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Figure 24: Comparison of change in Borg score with change in [A] parasternal muscle 
electromyogram (EMGpara), [B] percent of maxmium parasternal muscle electromyogram 
(EMGpara%max), [C] Neural respiratory drive index (NRDI) and [D] Forced expiratory volume 
in 1s (FEV1)* 
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Showing data from 37 pairs of readings generated from consecutive recordings of physiological 
variables in 30 patients. Open circles represent ‘improvers’ and closed circles ‘deteriorators’. 
*data from 26 pairs of data. 
Baseline EMGsc%max was 13.4±8.5% with no statistically significant changes 
occurring during the first 24 hours of admission in either improvers or 
deteriorators. There were no significant relationships between EMGsc%max and 
other markers of NRD, measures of dyspnoea, spirometric measures or in the 
standard clinical variables. 
There were significant differences observed in mean change between 
‘improvers’ and ‘deteriorators’ in all three EMGpara indices.  However, there were 
no significant between group differences in changes in RR, HR, SpO2 or FEV1 
(Table 23).  A significant (p=0.02), but clinically small (0.5), difference was 
observed in MEWS between ‘improvers’ and ‘deteriorators’.  Patients who 
improved had statistically significant reduction in dyspnoea (∆Borg -1.5; 95%CI 
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-0.7 to -2.3, p=0.001), respiratory rate (∆RR -1.8bpm; 95%CI -0.2 to -3.3, 
p=0.027) and increase in FVC (∆FVC 0.22 L; 95%CI 0.05 to 0.40, p=0.013), 
with no statistically significant differences demonstrable in physiological 
variables in the ‘deteriorators’.  
Table 23: Difference between consecutive recordings of measured physiological 
variables in 30 patients from day of baseline measurement to repeat reading 




∆MEWS 0.50 (0 - 1) 0 (-2 - 1)  0.019 
∆RR 4.5 ± 6.0 -1.8 ± 3.8 6.3 (-0.1 to 12.6) 0.051 
∆SpO2 1.2 ± 2.4 0.9 ± 2.7 -0.3 (-2.3 to 2.8) 0.829 
∆FEV1
*
 0.03 ± 0.18 0.06 ± 0.14 0.03 (-0.42 to 0.36) 0.786 
∆EMGpara 7.8 ± 4.9 -1.7 ± 5.5 9.6 (4.4 to 14.8) 0.003 
∆EMGpara%max 6.2 ± 4.3 -3.5 ± 8.1 9.6 (4.5 to 14.8) 0.001 
∆NRDI 226 ± 58 -113 ± 221 339 (234 to 444) <0.001 
*
7 patients were unable to perform spirometry on 1 or more occasions, therefore analysis of 
FEV1 was performed on ‘improvers’ n=20 and ‘deteriorators’ n=3.  Abbreviations: MEWS – 
medical early warning score, RR – respiratory rate, SpO2 – oxyhaemaglobin saturation, FEV1 – 
forced expiratory volume in 1s, EMGpara – Parasternal muscle electromyogram, EMGpara%max – 
percentage of maximum obtainable parasternal muscle electromyogram, NRDI – neural 
respiratory drive index. 
Both ‘improvers’ and ‘deteriorators’ had similar levels of NRD at initial reading 
that were significantly different at the follow up reading 24 hours later (mean 
difference EMGpara%max=8.1, 95%CI 0.2 to 16.0, p=0.046; mean difference 
NRDI=335, 95%CI 163 to 507, p<0.001). Significant differences in NRD did not 
persist in subsequent measurements (Figure 25). 
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Figure 25: Daily changes in [A] percent of maxmium parasternal muscle electromyogram 
(EMGpara%max) and [B] neural respiratory drive index (NRDI) during the course of 
admission between patients designated as ‘improvers’ or ‘deteriorators’ during the first 
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Plotted as mean ± standard error of the mean. 
Receiver operating characteristics (ROC) plots (Figure 26) with change ‘cut offs’ 
>+6.6 for EMGpara%max and >+160AU for NRDI had sensitivities of 83% (95%CI 
54 to 100%) and 100% (95%CI 100 to 100%) and specificities of 96% (95%CI 
88 to 100%) and 100% (95%CI 100 to 100%) for both EMGpara%max and NRDI, 
respectively.  ROC plots of the standard clinical variables either did not 
statistically differ from the null hypothesis or could not produce a ‘cut off’ 
providing sensitivity >80% without reducing specificity to <90% (Figure 26).  The 
best performing routine physiological variable was respiratory rate that provided 
a sensitivity of 83% (95%CI 54 to 100%) and a specificity of 88% (95%CI 74 to 
100%) to detect clinical deterioration using a cut off of an increase in respiratory 
rate of 2 breaths per minute. 
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Figure 26: Receiver Operating Characteristic (ROC) plot of change in [A] percent of 
maxmium parasternal muscle electromyogram (EMGpara%max) and neural respiratory drive 
index (NRDI) and [B] respiratory rate (RR), medical early warning score (MEWS), 
oxyhaemoglobin saturation (SpO2) and forced expiratory volume in 1s (FEV1) for 
detection of clinical deterioration 
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6.2.2: Change in EMGpara between admission and discharge to predict 
readmission 
A significant difference in ∆EMGpara and ∆NRDI between admission (1
st 
measurement within 24 hours of admission) and discharge (final measurement 
within 24 hours of clinical stability) was demonstrated between those patients 
readmitted within 14 days as a consequence of a respiratory deterioration and 
those patients who remained at home.  However, ∆MEWS, ∆FEV1 and number 
of previous admissions did not differ between patients who were and were not 
readmitted (Table 24). 
Table 24: Difference between admission and discharge of measured physiological 
variables in 30 patients either readmitted (n=9) or not readmitted (n=21) within 14 days of 
hospital discharge 




∆MEWS* 0 (-1 - 2) 0 (-3 - 2)  0.5 
∆FEV1
*
 0.09 ± 0.15 0.08 ± 0.10 
0.1 




4 (0 - 14) 3 (0 - 10)  0.1 
∆EMGpara%max 1.98 ± 4.36 -4.05 ± 10.30 
6.03 
(11.5 to 0.54) 
0.03 
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∆NRDI 76 ± 134 -127 ± 305 
203 
(39 to 366) 
0.02 
*
7 patients were unable to perform spirometry on 2 occasions, therefore analysis of FEV1 was 
performed on readmitted n=6, not readmitted n=17.  Abbreviations: MEWS – medical early 
warning score, FEV1 – forced expiratory volume in 1s, EMGpara%max– percentage of maximum 
obtainable parasternal muscle electromyogram, NRDI – neural respiratory drive index. 
ROC plots (Figure 27) were calculated with ‘cut offs’ of a change in EMGpara%max 
>0% and NRDI >50AU during admission producing sensitivities of 67% (95%CI 
36 to 97%) and 67% (95%CI 36 to 97%) and specificities of 62% (95%CI 41 to 
83%) and 71% (95%CI 52 to 91%) for EMGpara%max and NRDI, respectively.  
None of the ROC plots for routine clinical variables differed significantly from the 
null hypothesis (Figure 27). 
Figure 27: Receiver Operating Characteristic (ROC) plot of change in in [A] percent of 
maxmium parasternal muscle electromyogram (EMGpara%max) and neural respiratory drive 
index (NRDI) and [B] respiratory rate (RR), medical early warning score (MEWS) and 
number of previous admission for hospital readmission at 14 days 
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This study has demonstrated that 2nd intercostal space parasternal neural 
respiratory drive index, calculated as a product of EMGpara and RR normalised 
for maximum EMGpara, is a reproducible physiological biomarker in stable 
COPD patients and has greater sensitivity and specificity than standard clinical 
physiological parameters to identify patients failing to respond to treatment for 
acute exacerbations of COPD.  Furthermore, the failure of NRDI to fall during 
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an exacerbation requiring hospitalisation identifies patients who are more likely 
to be readmitted with a further respiratory deterioration. 
6.3.1: Critique of the method 
Patient selection 
The patients recruited were not consecutive admissions and therefore subject to 
selection bias.  Despite this limitation, demographics and severity of patients 
were similar to previously reported data.208  Furthermore, the goal of this study 
was to provide pilot data to demonstrate the feasibility and clinical usefulness of 
using non-invasive EMG monitoring as a physiological biomarker in the acute 
setting.  Although the cohort only had a moderate severity of illness, based on 
the median MEWS, it must be realised that this is a scoring system that is only 
validated in general medical patients.286  MEWS has never been validated in a 
COPD acute exacerbation cohort and even in the general medical patients the 
area under the curve of the ROC curve is <0.7.  MEWS reports cardiovascular 
and respiratory clinical instability with cerebral function and thermal 
dysregulation.  During an acute exacerbation of COPD, patients are unlikely to 
have instability of blood pressure, cerebral dysfunction or thermal dysregulation 
and any patient who was not able to consent (e.g. impaired cognition) was 
excluded from this study.  MEWS is not considered as either a specific or 
sensitive test for estimating the exacerbation severity or monitoring patients with 
acute exacerbation of COPD.  The patients in this study had similar 
exacerbation severity to that of the British Thoracic Society National Audit as 
regards age, although the cohort in the current study had marginally greater 
airflow obstruction and levels of dyspnoea, as measured by MRC score.287  The 
patient population in this study can reasonably be assumed to be representative 
of patients admitted to UK hospitals. 
Surface EMGpara measurement 
Generic issues regarding surface EMGpara measurement are discussed in the 
Chapter  Inter-occasion reproducibility of a respiratory physiological biomarker, 
section 5.3.1: Critique of the method, page 124.  Specifically, during the current 
study we further evaluated the repeatability of the sniff manoeuvre.  It was 
expected that tidal EMGpara values would change in response to treatment but 
that sniff EMGpara as a maximal manoeuvre would not show pronounced daily 
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variability.  As would be expected from a maximal manoeuvre in the context of 
an acute exacerbation, the limits of agreement are relatively wide.  This may, in 
part, be due to the variability in placement, as opposed to true changes in 
muscle activation due to any volitional variation on a daily basis.  There is no 
systematic bias in terms of signal intensity or day-to-day variation in sniff 
EMGpara, and therefore this should not detract from the clinical usefulness of this 
test. 
Validity of surface EMG 
The protocol for the study concentrated on parasternal surface EMG whereas it 
can be argued that for an accurate assessment of respiratory muscle activity to 
be made the measurement of electrical activity of the diaphragm and extra-
diaphragmatic accessory respiratory muscles, such as sternocleidomastoid 
muscle should be obtained.  As part of this study, assessment of 
sternocleidomastoid muscle activity was achieved in a subset of patients.  
However, in contrast to the diaphragm and 2nd intercostal space parasternal 
muscle, which are primarily respiratory muscles, sternocleidomastoid has both 
respiratory and non-respiratory function (e.g. rotational  movement of the head) 
and consequently the non-respiratory activity interfered with respiratory activity 
of sternocleidomastoid preventing accurate and reliable measurements. 
The study took place with support from an established research group with 
extensive experience of measuring diaphragm EMG activity using the 
oesophageal electrode.53  This technique has been shown to be significantly 
superior to surface EMG measurement of diaphragm activity.  However, the 
invasive technique of measuring diaphragm EMG was considered inappropriate 
in patients experiencing an exacerbation of COPD.  Such patients have high 
levels of dyspnoea and anxiety and passing an oesophageal electrode would 
not be possible in routine clinical practice and therefore this would significantly 
limit the usefulness of neural respiratory drive as a physiological biomarker and 
novel clinical assessment tool. 
The use of surface EMGdi is more suited to investigations of healthy subjects 
and stable COPD patients during resting breathing because of the crosstalk 
between muscles contaminating surface diaphragm EMG measurements and 
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variation in skin surface impedance.52  With recruitment of the abdominal 
muscles, during exercise or acute exacerbation, the surface EMGdi signal 
becomes contaminated, reducing the usefulness of this technique.  
Furthermore, there is no standard for position of surface electrodes for 
measurement of EMGdi or readily identifiable landmarks to assist interoccasion 
reproducibility.  In contrast the measurement of EMGpara is assisted by easily 
identifiable surface landmarks facilitating its use as a respiratory physiological 
biomarker.  There is no clear consensus for the positioning of surface 
diaphragm electrodes making comparison between studies difficult.  In addition, 
the surface landmarks for electrode placement are often difficult to locate thus 
making reproducibility poor and failing to minimise the contribution of the nearby 
abdominal muscles, which are often active in severe COPD, especially during 
an exacerbation when flow limitation is at its peak.51, 288, 289  Surface diaphragm 
EMG measures costal as opposed to crural diaphragm activity and whilst the 
two parts of the diaphragm appear to have similar activation and activity it is by 
no means clear that costal diaphragm EMG represents overall diaphragm 
activity during all activities.52  For the reasons stated above, the 2nd intercostal 
space parasternal muscle was used in this study as the principal component of 
NRD, reflecting its attributes as a respiratory muscle with similar activity to the 
diaphragm with easily identifiable landmarks and minimal cross-talk with other 
muscles. 
Definition of clinical change 
The lack of an objective measure to monitor clinical progress in the acute 
setting to allow comparative changes with EMGpara is an obvious limitation of 
this study.  All patients met an event based criteria for a severe exacerbation of 
COPD requiring hospital admission.290, 291  It is acknowledged that there is no 
‘gold standard’ to predict or measure acute clinical progress in an exacerbation 
of COPD,291 and therefore we compared EMGpara to standard clinical 
parameters and the summary opinion of the supervising senior physician.  
Whilst this is a broad definition it is widely used in both research and clinical 
practice and is the benchmark by which other novel influential assessment tools 
have been judged.292  In validating the EXACT tool Leidy et al 292 used 
physician rated exacerbation severity and physician judged treatment response 
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to act as the benchmark comparators i.e. physician’s clinical judgment was 
treated as the ‘gold standard’.  We, therefore, consider that despite the possible 
subjective nature of the definition of ‘improvers’ and ‘deteriorators’, this 
assessment genuinely represents the ‘gold standard’ to which this novel 
assessment tool of neural respiratory drive could effectively be judged.  In the 
current study, the physician judged treatment response was reported by the 
most senior clinician (Respiratory Consultant or Respiratory Specialist 
Registrar) reviewing the patient on that day and represents the summary 
assessment of the attending team, consisting of the junior medical team, nurses 
and specialist physiotherapists.  Clinical gestalt is the interpretation by 
physicians of the patient’s report of their clinical state as well as examination 
incorporating standard physiological variables and clinical parameters, which 
are subsequently processed as part of learnt complex clinical algorithm.  This is 
a robust clinical assessment tool and an adequate comparator.  Criteria to 
define ‘improvers’ and ‘deteriorators’ were not provided in this study as there is 
no clear consensus on a method to which this could be sufficiently defined.  The 
authors consider that providing set criteria, either based on patient symptom 
scores, physiological criteria or treatment changes, may interfere with the 
attending clinician assimilating the available information to produce a clinical 
summary opinion and would give an arbitrary, poorly understood and non-
validated method of defining treatment success.  In this study, patients admitted 
with an acute exacerbation of COPD were managed by respiratory specialist 
who would be expected to be able to produce a valid clinical assessment on 
patient response to treatment. 
Although there was no significant difference in specific physiological markers 
between ‘improvers’ and ‘deteriorators’, the trends were in the expected 
direction.  The ’improvers’ had statistically significant reduction in dyspnoea, 
respiratory rate and increase in FEV1 that support the physicians’ clinical 
judgment of treatment response.  This is also supported by the observation that 
there were no significant improvements in any physiological variables in the 
’deteriorators’ group. 
Despite the limitations inherent with this choice of outcome it allows the data to 
be easily interpreted. In order to have measured the performance of this novel 
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technique against a more definable objective marker the study population may 
have to be limited to those patients in hypercapnic respiratory failure. Such 
patients admitted directly to intensive care unit with severe respiratory failure 
were excluded from this study.  These patients were excluded as they represent 
a separate population from the cohort of patients recruited for this study.  3/30 
(10%) patients of the cohort received NIV as part of their acute exacerbation 
management, similar to previous published data.208  All these patients received 
NIV from admission and there were no patients that deteriorated sufficiently, 
following admission to the respiratory ward, to require initiation of NIV.  These 
data are consistent with published data that only 1 in 20 patients develop 
respiratory acidosis following admission.208  Had the study population been 
restricted to those with decompensated respiratory failure it would have limited 
the applicability of the study and it would have been difficult to demonstrate that 
measures of NRD added to already established and widely available techniques 
to measure clinical progress in this group. 
6.3.2: Significance of findings 
Dyspnoea 
Dyspnoea provides a significant symptom burden in COPD with its importance 
as a marker of disease severity recently noted by its incorporation into the 
GOLD guidelines.270  An objective method of assessing the severity of 
breathlessness has previously been lacking, with clinicians using subjective 
assessment tools.  Physiological indicators of disease severity in COPD, such 
as FEV1, are acknowledged to be poorly predictive of dyspnoea.
293  In contrast, 
changes in NRD have been shown to explain variance in exercise induced 
dyspnoea.243  In the current study, we observed a similar relationship between 
change in Borg score and change in EMGpara.  The initial measurements were 
recorded following initiation of emergency therapy, and in some patients there 
were relatively small changes in 2nd intercostal space parasternal muscle 
electrical activity and breathlessness, indicating that that the technique is 
sensitive enough to monitor relatively modest changes even after treatment 
initiation.  These data, therefore, support the use of non-invasive EMGpara as a 
physiological biomarker of NRD that reflects perception of dyspnoea severity 
during COPD exacerbations.  Furthermore, as FEV1 has a weak relationship 
141 
with dyspnoea, there is potential for EMGpara to be applied to patients in the 
stable state to monitor progression of disease and detect exacerbation onset, 
although more work is required to fully elucidate this relationship. 
Monitoring response to treatment 
NRD was shown to monitor response to treatment in patients admitted with 
acute exacerbations of COPD when calculated as EMGpara%max and NRDI.  The 
reproducibility data indicates that the ‘cut off’ chosen for maximum sensitivity 
and specificity of detection of clinical change (EMGpara%max >6.6%) represents a 
genuine and detectable change in NRD as it is above the 95% upper limit of 
agreement on the Bland-Altman plot for inter-occasion variabilty.  In this 
population of patients, this would have correctly tracked deterioration in 5 out of 
6 occasions.  This high sensitivity and specificity can be further improved with 
the addition of respiratory rate to produce the NRDI, which correctly identified all 
episodes of deterioration in this sample set.  This demonstrates the potential 
clinical utility of the test with the integrated physiological signal accurately 
reflecting the summary opinion of the senior attending respiratory physician in a 
way unable to be replicated by any of the standard clinical variables assessed. 
Re-admission 
In addition to the ability to track changes in NRD during acute exacerbations 
using this technique, the failure of NRD to fall in response to therapy identifies 
those patients who were likely to be readmitted within 14 days of discharge due 
to a further respiratory deterioration.  Whilst some biomarkers have allowed 
identification of COPD phenotypes during the stable state and that these can 
predict behaviour at the time of exacerbation294 there remains few clinically 
useful biomarkers that can predict readmission in these patients.295  Previous 
data has indicated that COPD patients with severe disease, as indicated by an 
FEV1 <1 L at discharge or >2 previous admissions in the preceding 12 months, 
reported that these patients were more likely to be readmitted following an 
exacerbation of COPD than those with less severe disease.296  The specificity 
of these particular predictors in the current cohort of patients was poor at <0.5 
and therefore these are not clinically useful.  Failure of NRD to fall in response 
to treatment provides an easy to apply novel physiological biomarker to predict 
readmission in high risk patients.  Data from the ECLIPSE study has suggested 
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the ‘frequent exacerbator’ is a distinct phenotype in COPD.297  The 
measurement of NRD in this context is not simply acting as a measure of 
disease severity or to identify the frequent exacerbator phenotype; if our 
analysis were limited to those patients with ≥2 previous admissions (n=22), the 
sensitivity and specificity to predict readmission at 14 days remained similar to 
the whole cohort at 63% and 64%, respectively.  The ability of this physiological 
tool to maintain its sensitivity and specificity in the higher risk group of patients 
increases its clinical utility, with the ability to further risk stratify the most high 
risk patients.  With the increasing role of early discharge and COPD outreach 
schemes to support patients in the community,198, 199 this technique could 
facilitate clinical selection to identify those patients that require greater 
community support or further hospital treatment prior to discharge.  This 
approach has increasing importance as the rising incidence of failed hospital 
discharge have been highlighted by the Department of Health as an area for 
improved performance.198  Although these observational data have 
demonstrated that measures of NRD can identify treatment failure and re-
admission risk in patients with acute exacerbations of COPD further validation 
of the technique is required with prospective interventional trials.  These could 
focus on the ability to identify treatment failure to allow patients to be 
discharged with standard or supportive care packages with the aim of reducing 
readmissions and the serious sequelae of repeated exacerbations. 
6.3.3: Conclusion 
Neural respiratory drive, measured from 2nd ICS parasternal electromyography, 
is an objective physiological biomarker in COPD patients hospitalised with acute 
exacerbations.  The technique is well tolerated and feasible in the acute care 
setting.  More importantly neural respiratory drive, in contrast to other standard 
clinical parameters, is able to provide an objective marker of dyspnoea, track 
the clinical state of patient during an exacerbation of COPD and predict risk of 
readmission at 14 days.  
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CHAPTER 7: PHYSIOLOGICAL SUB-STUDY OF THE HOME 
OXYGEN THERAPY VS. HOME MECHANICAL VENTILATION IN 
PATIENTS WITH PERSISTENT HYPERCAPNIA POST 
EXACERBATION OF COPD TRIAL (HOT-HMV UK TRIAL) 
7.1: Materials and Methods 
The background literature of this study can be found on Page 70 of this thesis.  
Patient recruitment is described earlier in this thesis on Page 76.  All subjects 
provided written informed consent prior to enrolment.  The study was approved 
by St Thomas’ Hospital Research Ethics Committee (09/H0802/2) and 
performed in line with local governance procedures (RJI 09/N070).  The study 
was registered prospectively on a publically accessible database 
(NCT00990132). 
7.1.1: Subjects 
Patients referred to the Lane Fox Respiratory Unit, St Thomas’ Hospital and the 
Sleep & Ventilation Unit, the Royal Brompton Hospital for consideration of 
domiciliary non-invasive ventilation (NIV) were screened for trial eligibility. 
7.1.2: Study design 
An open labelled randomised controlled design study was used.  
Randomisation was conducted independently of the study group at the Oxford 
Respiratory Clinical Trials Unit using minimisation. 
Minimisation variables were: 
 Age (<65 years/ ≥65 years), BMI (≤20 kgm-2/ >20 kgm-2) 
 Prior use of long term oxygen therapy (yes/no) 
 Number of previous COPD related admissions in the last 12 months (<3, 
≥3). 
7.1.3: Study intervention 
HOT and HMV were setup as described earlier in this thesis on page 92. 
7.1.4: Study measurements 
Patients underwent baseline assessment of anthropometrics including fat free 
mass measured by bioelectrical impedance analysis using a validated disease 
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specific regression algorithm.251  Pulmonary function tests including spirometry, 
static lung volumes, gas transfer and reversibility were performed according to 
international guidelines.264, 298  Health related quality of life questionnaires 
including SRI, SGRQ and ESS were completed.  Arterial blood gas analysis 
was performed with the patient in a seated position whilst breathing room air for 
20 minutes at least 4 hours after waking.  Patients underwent diagnostic limited 
respiratory polygraphy on either oxygen therapy or room air depending on result 
of daytime ABG.  Patients with severe resting hypoxaemia (PaO2 <7.3 kPa) 
were treated with nocturnal oxygen therapy and those with moderate 
hypoxaemia (PaO2 7.3-8 kPa) had the diagnostic respiratory sleep study 
performed on air to assess for nocturnal hypoxia and thus indication for HOT.  A 
subsequent oximetry-capnometry study was performed on an oxygen flow rate 
at the prescribed level.  Patients then had an early morning ABG performed to 
assess for respiratory acidosis on oxygen therapy.  A repeat oximetry-
capnometry was performed on the patients randomised to HMV. 
Pulmonary physiology  
Patients underwent full invasive pulmonary physiological testing, as described 
earlier in the Materials and Methods section on Page 80, including 
measurement of respiratory muscle strength, dynamic intrinsic positive end 
expiratory pressure (dynPEEPi), dynamic lung compliance (Cdyn), tidal breathing, 
neural respiratory drive (EMGpara, EMGdi, EMGsc and EMGabdo) and hypercapnic 
responsiveness testing using the rebreathe technique.234 
7.1.5: Follow up 
Patients underwent follow up assessment at 6 weeks, 3 months, and 6 months.  
The study plan with details of all the assessments performed at each visit is 
provided in Table 25. 
Table 25: Study plan for HOT-HMV UK trial 
 Baseline 
Follow up 
6 weeks 3 months 6 months 
Randomisation X    




6 weeks 3 months 6 months 
Demographics X    
Anthropometrics X X X X 
Clinical assessment X X X X 
Arterial Blood Gas X X X X 
Spirometry 
(full lung function) 
(X) X X (X) 
Respiratory Sleep studies X   X 
Exercise capacity X X X X 
HRQL X X X X 
Compliance  X X X 
Actigraphy (7 day) X X X X 
Pulmonary Physiology 
(invasive) 
(X) X (X) (X) 
7.1.6: Data analysis 
Previous work from our group has shown a pre-post treatment improvement in 
HCVR of 1.4 l/min/kPa with a test standard deviation of 2.0 l/min/kPa.137  Using 
an expected between group difference in HCVR of 2.0 l/min/kPa 40 patients are 
required (randomised on a 1:1 basis) to be 80% confident of detecting the 
difference at 6 weeks at the 0.05 level. 
Data were analysed using independent or paired t-test where appropriate, 
unless demonstrably not normally distributed in which case an appropriate non-
parametric equivalent was used.  Parametric data are presented as mean ± 
standard deviation and non-parametric data as median (inter-quartile range).  
Correlation analyses were performed using Pearson’s correlation test for 
parametric data and Spearman’s rank test for non-parametric data.  For all 
analyses, a p-value <0.05 was considered statistically significant.  Data 
analyses were conducted using PASW statistics 18 (SPSS, Chicago, IL, USA). 
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7.2: Results 
7.2.1: Patient recruitment 
A consort flow diagram showing screening failures is provided in Figure 28. 
Figure 28: Consort diagram detailing screening for HOT-HMV UK trial at St Thomas' 
(STH) and the Royal Brompton (RBH) Hospitals for the physiological sub-study 
Abbreviations: OSA – obstructive sleep apnoea, BMI – body mass index, PaCO2 – arterial 
partial pressure of carbon dioxide. 
A subset of 27 patients from the main study cohort were recruited with 23 
patients (HOT=10, HMV=13) able to undergo baseline physiological testing.  
Details on recruitment and retention are provided in Figure 29.  
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Figure 29: Patient recruitment and retention for physiological assessment in HOT-HMV 
UK trial 
Consort diagram detailing recruitment and follow up measurements with reasons for withdrawal 
or failure to complete testing. Numbers in brackets indicate those patients undergoing additional 
invasive measures of pulmonary mechanics with combined EMG and balloon oesophageal 
catheter.  Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation, 
EMG – electromyogram. 
7.2.2: Baseline data 
Comparisons of baseline anthropometric, arterial blood gas analysis, and lung 
function testing data for the 23 patients who were randomised and completed 
physiological evaluation at baseline are provided in Table 26. 
Table 26: Baseline data for patients undergoing physiological measurements in HOT-
HMV UK trial: [A] Anthropometric and [B] Lung function 
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Table 26A: Anthropometric 
 
 
HOT HMV p-value 
Centre (STH / RBH) 5 / 5 9 / 4 0.349 
Age (years) 67 ± 10 67 ± 11 0.959 
Gender 
(Male / Female) 
3 / 7 8 / 5 0.133 
Pack year history 55 ± 19 50 ± 17 0.520 
BMI (kgm
-2
)* 24.6 ± 6.7 20.2 ± 2.9 0.044* 
Weight (kg) 66.2 ± 21.3 54.0 ± 8.8 0.076 
Fat free mass (kg) 33.2 ± 5.4 30.2 ± 7.7 0.306 




12.4 ± 1.5 11.3 ± 2.6 0.237 
PaCO2 (kPa) 7.9 ± 0.7 8.0 ± 0.8 0.743 
PaO2 (kPa) 6.5 ± 1.1 6.6 ± 1.1 0.922 
*p<0.05. Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation, 
STH – St Thomas’ Hospital, RBH – Royal Brompton Hospital, BMI – body mass index, PaCO2 – 
arterial partial pressure of carbon dioxide, PaO2 – arterial partial pressure of oxygen.  
 
Table 26B: Lung function 
 
 
HOT HMV p-value 
PaCO2 (kPa) 
 
7.9 ± 0.7 8.0 ± 0.8 0.743 
PaO2 (kPa) 
 
6.5 ± 1.1 6.6 ± 1.1 0.922 
Bicarbonate (mmolL
-1
) 35 ± 3 38 ± 8 0.186 
FEV1 (L) 
(%) 
0.73 ± 0.34 
(30 ± 8) 
0.54 ± 0.18 





1.86 ± 0.49 
(66 ± 11) 
1.72 ± 0.82 
(52 ± 32) 
0.640 
(0.204) 









5.35 ± 0.86 
(105 ± 18) 
4.98 ± 0.87 







3.57 ± 1.27 
(65 ± 18) 
3.96 ± 0.74 







3.64 ± 0.67 
(172 ± 30) 
3.04 ± 0.83 







4.32 ± 0.82 
(149 ± 35) 
3.81 ± 0.67 
(130 ± 36) 
0.240 
(0.329) 




3.22 ± 2.15 
(39 ± 22) 
1.71 ± 1.35 




performed on HOT n=6, HMV n=8.  Abbreviations: HOT – home oxygen therapy, HMV – home 
mechanical ventilation, PaCO2 – arterial partial pressure of carbon dioxide, PaO2 – arterial 
partial pressure of oxygen, FEV1 – forced expiratory volume in 1s, FVC – forced vital capacity, 
TLC – total lung capacity, Va – alveolar volume, RV – residual volume, FRC – functional 
residual capacity, DLCO – diffusion capacity of carbon monoxide.  
The only statistically significant difference in baseline anthropometric and lung 
function characteristics was BMI (mean difference 4.4, 95%CI 0.1 to 8.7, 
p=0.044). There were no differences observed between groups at baseline in 
terms of respiratory muscle strength, resting breathing parameters, neural 
respiratory drive or hypercapnic response (Table 27) with the exception of 
parasternal muscle derived measures of neural respiratory drive which indicated 
higher levels of resting NRD in the group randomised to receive HMV 
(EMGpara%max mean difference -15%, 95%CI -1 to -28, p=0.035; NRDIpara 
mean difference -355 AU, 95%CI -23 to -686, p=0.037).  A non-significant trend 
towards a difference was present in EMGdi%max (mean difference -14%, 
95%CI 2 to -29, p=0.086) again, with higher levels of resting drive in the 
patients randomised to HMV. 
Table 27: Baseline measurement of: [A] Respiratory muscle strength, [B] Pulmonary 




Table 27A: Respiratory muscle strength 
 
 
HOT HMV p-value 
SNIP (cmH2O) 40 ± 13 36 ± 18 0.610 
Sniff Poes (cmH2O) 53 ± 20 43 ± 16 0.292 
Sniff Pdi (cmH2O) 66 ± 26 55 ± 19 0.341 
MIP (cmH2O) 28 ± 16 28 ± 15 0.946 
MEP (cmH2O) 46 ± 17 49 ± 22 0.755 
Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation, SNIP – sniff 
nasal inspiratory pressure, Poes – oesophageal pressure, MIP – mouth inspiratory pressure, 
MEP – mouth expiratory pressure. 
Table 27B: Pulmonary mechanics and ventilation parameters 
 
 
HOT HMV p-value 
IC (mL) 1342 ± 442 1339 ± 546 0.990 
MVV (Lmin
-1
) 19.8 ± 6.1 17.1 ± 4.4 0.247 
dynPEEPi (cmH2O) 3.9 ± 2.3 3.9 ± 4.4 0.992 
Cdyn (ml/cmH2O) 181 ± 103 134 ± 75 0.325 
Vt (ml)* 515 ± 114 587 ± 172 0.268 
RR  
(breaths per minute) 
23 ± 6 21 ± 7 0.536 
Ve 11.6 ± 3.2 11.6 ± 3.3 0.993 
Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation, IC – 
inspiratory capacity, MVV – maximum voluntary ventilation, dynPEEPi – dynamic intrinsic positive 
end-expiratory pressure, Cdyn – dynamic compliance, Vt – tidal volume, RR – respiratory rate, Ve 
– minute ventilation. 
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Table 27C: Neural respiratory drive and hypercapnic response testing 
 
 
HOT HMV p-value 
EMGpara%max (%)* 17 ± 9 32 ± 19 0.035* 
EMGdi%max (%) 30 ± 16 44 ± 13 0.086 
NRDIpara (AU)* 359 ± 135 714 ± 487 0.037* 
NRDIdi (AU) 804 ± 497 925 ± 365 0.596 
HCVR (Lmin
-1
/kPa) 2.76 ± 3.14 1.46 ± 1.14 0.213 
HCEMGpara%maxR 
(%/kPa) 
8.58 ± 5.23 6.94 ± 5.66 0.499 
HCEMGdi%maxR 
(%/kPa) 
10.66 ± 11.98 8.81 ± 6.29 0.712 
*p<0.05. Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation, 
EMGpara%max – percentage of maximum obtainable parasternal electromyogram, EMGdi%max – 
percentage of maximum obtainable diaphragm electromyogram, NRDIpara – neural respiratory 
drive index of the parasternal muscle, NRDIdi – neural respiratory drive index of the diaphragm, 
HCVR – hypercapnic ventilatory response, HCEMGpara%maxR – hypercapnic parasternal muscle 
electromyogram response, HCEMGdi%maxR – hypercapnic diaphragm electromyogram response. 
7.2.3: Assessment of severity of sleep disordered breathing 
There were no significant differences demonstrated between patients 
subsequently randomised to HOT or HMV on either diagnostic limited overnight 
respiratory polygraphy or oximetry-capnometry performed on prescribed oxygen 
level (Table 28). 
Table 28: Comparison of pre-randomisation limited overnight respiratory polygraphy: [A] 
Diagnostic testing and [B] Oxygen safety testing 
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Table 28A: Diagnostic testing 
 
 
HOT HMV p-value 
Diagnostic study 
performed on 
(oxygen / room air) 
7 / 2 11 / 2 0.683 
AHI (events/hour) 5 ± 8 10 ± 20 0.473 
4%ODI 
(events/hour) 
19 ± 21 17 ± 34 0.861 
Mean SpO2 (%) 89 ± 9 93 ± 5 0.181 
Min SpO2 (%) 64 ± 22 68 ± 16 0.609 
%TST SpO2<90% 
(%) 
35 ± 39 22 ± 26 0.352 
Mean tcCO2 (kPa) 9.0 ± 0.9 9.0 ± 1.5 0.925 
Max tcCO2 (kPa) 10.1 ± 1.1 10.4 ± 1.8 0.587 
Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation, AHI – 
apnoea-hypopnoea index, ODI – oxygen desaturation index, SpO2 – oxyhaemaglobin 
saturation, TST – total sleep time, tcCO2 – transcutaneous carbon dioxide. 
Table 28B: Oxygen safety testing 
 
 





1.3 ± 0.8 1.1 ± 0.6 0.514 
4%ODI 
(events/hour) 
17 ± 20 10 ± 16 0.369 
Mean SpO2 (%) 90 ± 9 93 ± 5 0.204 
Min SpO2 (%) 66 ± 21 68 ± 17 0.761 
%TST SpO2<90% 
(%) 
31 ± 38 20 ± 26 0.447 
Mean tcCO2 (kPa) 9.1 ± 0.9 9.3 ± 1.4 0.622 
Max tcCO2 (kPa) 10.1 ± 1.1 10.8 ± 1.7 0.331 
Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation, AHI – 
apnoea-hypopnoea index, ODI – oxygen desaturation index, SpO2 – oxyhaemaglobin 
saturation, TST – total sleep time, tcCO2 – transcutaneous carbon dioxide. 
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There were no significant correlations demonstrated between nocturnal hypoxia 
(mean nocturnal SpO2 and %night time SpO2<90%), nocturnal hypercapnia 
(mean tcCO2 and max tcCO2) on prescribed oxygen therapy and measurements 
of hypercapnic responsiveness (HCVR, HCEMGparaR and HCEMGdiR), 
pulmonary mechanics and resting neural respiratory drive.  Daytime resting Ve 
demonstrated an inverse correlation with mean nocturnal tcCO2 (r=-0.556, 
p=0.006) and max nocturnal tcCO2 (r=-0.424, p=0.044).  As expected mean 
nocturnal tcCO2 correlated with daytime PaCO2 whether performed on room air 
(r=0.449, p=0.028) or on prescribed oxygen therapy (r=0.422, p=0.040).  
Nocturnal mean SpO2 correlated with daytime SpO2 on prescribed oxygen 
(r=0.536, p=0.007) but there was no correlation between nocturnal mean SpO2 
and daytime SpO2 on room air (r=0.018, p=0.934). 
7.2.4: Repeatability of hypercapnic responsiveness testing 
The slopes of sequential HCVR tests performed during a single session showed 
good repeatability with a bias of -0.1 Lmin-1/kPa, 95%CI 1.7 to -2.0 and 
acceptable levels of repeatability for EMGpara%max (HCEMGpara%maxR) with a bias 
of 0.8 %/kPa, 95%CI -10.3 to 11.8 and EMGdi%max (HCEMGdi%maxR) with a bias 
of 2.4 %/kPa, 95%CI -14.6 to 19.4 (Figure 30). 
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Figure 30: Bland-Altman plots demonstrating reproducibility of hypercapnic 
responsiveness testing for [A] ventilation (HCVR), [B] percentage of maximum obtainable 
parasternal muscle electromyogram (HCEMGpara%maxR) and [C] percentage of maximum 
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7.2.5: Efficacy of HMV to control sleep disordered breathing and 
ventilatory settings 
9 patients were discharged with a Harmony 2 machine (Philips-Respironics, PA, 
US) and 4 patients with a VPAP III STa machine (ResMed, Bella Vista, 
Australia).  Discharge non-invasive ventilator settings for the HMV group were 
IPAP 26 ± 2 cmH2O, EPAP 4 ± 1 cmH2O and back up rate 15 ± 2 bpm.  All 
patients were discharged with a full face mask.  Oximetry-capnometry 
performed on discharge ventilator settings showed a significant reduction in 
tcCO2 and improvement in nocturnal saturations between diagnostic and 
therapeutic overnight limited respiratory polygraphy in the HMV group (Table 
29).  There were also significant between group differences in the severity of 
nocturnal hypoxia and hypercapnia between HOT and HMV groups (Table 29). 
Table 29: Comparison of oximetry-capnometry on home oxygen therapy (HOT) and home 
mechanical ventilation (HMV) 
 HOT HMV p-value 
4%ODI 10 ± 16 9 ± 9 0.866 
Mean SpO2 (%) 92 ± 6 96 ± 3
#
 0.060 























p<0.05 between group comparison (independent t-test); 
#
p<0.05 within group improvement 
from diagnostic sleep study (paired t-test).  Abbreviations: HOT – home oxygen therapy, HMV – 
home mechanical ventilation, ODI – oxygen desaturation index, SpO2 – oxyhaemaglobin 
saturation, TST – total sleep time, tcCO2 – transcutaneous carbon dioxide. 
Adequate levels of adherence with nocturnal ventilation were demonstrated 
throughout follow up in patients randomised to HMV (Figure 31). 
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Figure 31: Adherance with home mechanical ventilation (HMV) throughout follow up 
represented by [A] mean nightly ventilator usage and [B] percentage of nights with >4 
hours of ventilator use 




































































7.2.6: Changes in neural respiratory drive 
There were significant improvements in neural respiratory drive as 
demonstrated by increase in both HCVR and HCEMGpara%maxR between 
baseline and 6 week follow up that persisted at 3 month follow up for 
HCEMGpara%maxR although the treatment effect was attenuated in the HCVR 
(Table 30).  There were no within or between group changes in HCEMGdi%maxR 
at 3 month follow up. 
Table 30: Change from baseline to follow up at 6 weeks and 3 months in hypercapnic 
response testing in patients randomised to home oxygen therapy (HOT) or home 
mechanical ventilation (HMV) 






























































*p<0.05 within group paired change from baseline.  Abbreviations: HOT – home oxygen 
therapy, HMV – home mechanical ventilation, HCVR – hypercapnic ventilatory response, 
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HCEMGpara%maxR – hypercapnic parasternal muscle electromyogram response, HCEMGdi%maxR 
– hypercapnic diaphragm electromyogram response. 
Treatment effect on hypercapnic response testing was further attenuated at 6 
months (Figure 32). 
Figure 32: Changes in hypercapnic response testing between baseline and follow up for 
[A] hypercapnic ventilatory response (HCVR), [B] hypercapnic parasternal muscle 
electromyogram response (HCEMGpara%maxR) and [C] hypercapnic diaphragm 










































































































Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation, HCVR – 
hypercapnic ventilatory response, HCEMGparaR – hypercapnic parasternal muscle 
electromyogram response, HCEMGdiR – hypercapnic diaphragm electromyogram response. 
7.2.7: Changes in tidal breathing, respiratory cycle, pulmonary mechanics 
and gas exchange between baseline, 6 weeks follow up and 3 months 
follow up 
Patients randomised to HOT had a significant reduction in resting Ve at both 6 
weeks (Δ-3.3 Lmin-1, 95%CI 1.0 to 5.7, p=0.015) and 3 months follow up (Δ-2.0 
Lmin-1, 95%CI 0.6 to 3.4, p=0.014) that resulted in a significant between group 
difference in change in Ve from baseline to 6 weeks between HOT and HMV 
groups (Δ4.6 Lmin-1, 95%CI 2.2 to 6.9, p=0.001) and a trend towards a 
difference at 3 months (Δ2.5 Lmin-1, 95%CI -0.1 to 5.1, p=0.056).  There was a 
trend towards improved Vt (Δ126 mL, 95%CI -11 to 264, p=0.068) and RR (Δ-
1.8 bpm, 95%CI -3.4 to 0.8, p=0.055) in the HMV group at 6 weeks (Figure 33).  
The HOT group had a reduction in Vt at 6 weeks (Δ-83 mL, 95%CI -173 to 6, 
p=0.063) that further reduced at 3 months (Δ-92 mL, 95%CI -160 to -51, 
p=0.002).  These reductions in Vt in the HOT group coupled with the trends to 
improved Vt in the HMV group led to significant between group differences at 6 
weeks (Δ210 mL, 95%CI 29 to 390, p=0.026) and 3 months (Δ180 mL, 95%CI 3 
to 358, p=0.047). 
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Figure 33: Comparison between home oxygen therapy (HOT) and home mechanical 
ventilation (HMV) groups of changes from baseline at 6 week, 3 month and 6 month 






































































































Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation. 
There were no within or between group differences in changes in respiratory 
cycle, including inspiratory time (Ti), expiratory time (Te) or duty cycle (Ti/Ttot), 
between baseline and follow up at 6 weeks and 3 months.  Furthermore, there 
were no demonstrable changes in either Cdyn or dynPEEPi, resting EMGpara%max 
and resting EMGdi%max at 3 months follow up (Figure 34). 
160 
Figure 34: Changes in resting respiratory mechanics and neural respiratory drive 
between baseline and follow up in home oxygen therapy (HOT) and home mechanical 
ventilation (HMV) groups for [A] dynamic intrinsic positive end-expiratory pressure 


























































































































































































Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation, IC – 
inspiratory capacity, MVV – maximum voluntary ventilation, dynPEEPi – dynamic intrinsic positive 
end-expiratory pressure, Cdyn – dynamic compliance, EMGpara%max – percentage of maximum 
obtainable parasternal electromyogram, EMGdi%max – percentage of maximum obtainable 
diaphragm electromyogram. 
Significant within group improvement in PaCO2 occurred in the HMV group at 6 
weeks (∆-0.9 kPa, 95%CI -0.5 to -1.4, p=0.001) and at 3 months (∆-0.9 kPa, 
95%CI -0.4 to -1.5, p=0.004).  There was no significant change in PaCO2 in the 
HOT group at 6 week (∆-0.3 kPa, 95%CI -1.7 to 1.1, p=0.621) and 3 months (∆-
0.7 kPa, 95%CI -1.5 to 0.2, p=0.101).  A trend towards improved PaO2 was 
shown in the HMV group at 6 weeks (∆0.6 kPa, 95%CI 0.0 to 1.1, p=0.059) that 
became a significant improvement by 3 months (∆1.0 kPa, 95%CI 0.2 to 1.7, 
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p=0.016).  There were no significant improvements observed in PaO2 in the 
HOT group at 6 weeks (∆0.2 kPa, 95%CI -0.9 to 1.3, p=0.720) and 3 months 
follow up (∆0.5 kPa, 95%CI -0.8 to 1.8, p=0.372).  Despite the within group 
changes there were no significant between group differences demonstrated 
during follow up. 
7.3: Discussion 
These data represent the first randomised controlled physiological study to 
investigate long term effects of home mechanical ventilation and home oxygen 
therapy compared to home oxygen therapy alone.  The data have demonstrated 
the addition of nocturnal domiciliary NIV to oxygen therapy improves central 
respiratory drive and leads to augmented diurnal tidal volume. 
7.3.1: Critique of the method 
Patient recrui tment  
The study failed to recruit the pre-specified number of patients leading it to be 
underpowered to detect a difference between the groups in terms of change in 
hypercapnic ventilatory response.  The trial started on schedule, but patient 
recruitment to the trial was slow although it must be highlighted that these are 
an extremely sick group of patients that often declined recruitment to the 
physiological sub-study, even if they agreed to be enrolled in the clinical trial.  
This slow accrual persisted despite numerous attempts to increase local 
referrals as well as maximising in-house recruitment.  The reasons that 
contributed to the low recruitment rate are detailed below: 
1. There were more patients than expected, from our own previous pilot 
data, that had clinically improved by the 2 week screening period and 
subsequently had a PaCO2 less than 7.0 kPa. 
2. There was a higher than expected proportion of patients with obesity and 
obstructive sleep apnoea, reflecting general population trends. 
3. There was a larger than expected refusal by the patients to take part in 
the trial and as highlighted above there was further refusal to be part of 
the physiological sub-study.  This refusal to be part of the trial was driven 
by the patients’ negative experience of non-invasive ventilation during 
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the acute illness, which contributed to their reluctance to trial the therapy 
at home. 
4. A large proportion of patients died prior to screening both during the 
acute episode and following discharge. 
5. Recruitment rate was affected by a fall in COPD patients receiving non-
invasive ventilation for management of acute hypercapnic respiratory 
failure period.  Specifically, at St Thomas, there were 58 COPD patients 
in 2010 and only 44 patients in 2011 that were managed with acute use 
of non-invasive ventilation. 
Patient retention 
There was a significant loss of follow up data due to patient death or severe 
inter-current illness preventing assessment.  The magnitude of lost patient 
follow up data is perhaps not surprising given the acknowledged high morbidity 
and mortality in this patient population.146, 147, 149  Combined with the poor 
recruitment, the poor patient retention contributed to the under powering of the 
study.  Previous studies have used stable patients to investigate the 
physiological mechanisms of HMV in this patient population in order to 
overcome this problem.135, 235  Despite this approach, there has been no clear 
clinical efficacy demonstrated in this infrequent exacerbator phenotype93, 138, 140 
and as such a patient population considered to have the greatest potential for 
clinical benefit was selected for this trial.  Notwithstanding these factors, the 
primary outcome of the study was a change in hypercapnic ventilator response, 
which was shown to have a significant within group difference from baseline in 
the HMV group that translated to a treatment effect when compared to the 
control group at 6 weeks.  The magnitude of this change was similar to that 
observed in earlier uncontrolled studies,137 although the small patient numbers 
resulted in a less accurate prediction of the true treatment effect than would 
have been achieved had the study reached full recruitment. 
Control of nocturnal hypoventilation  
A critique of much of the published data, that fails to show a clear clinical or 
physiological advantage of using domiciliary NIV in hypercapnic COPD, is the 
failure of the studies to demonstrate a clear therapeutic effect on nocturnal 
hypoventilation.133  Studies that have shown a therapeutic effect have included 
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those in which a high pressure strategy was adopted and nocturnal 
hypoventilation improved.136  We have demonstrated a clear within and 
between group treatment effect of NIV on the control of nocturnal tcCO2 with 
high pressure NIV.  Interestingly, in contrast to published data in less severe 
patients there was no relationship demonstrated between hypercapnic 
ventilatory response and nocturnal hypoxia, measured as either mean oxygen 
saturation or percentage of total sleep time less than 90%.241  This is perhaps to 
be expected given that all patients in the current study had a reduced 
hypercapnic ventilatory response with more severe airflow limitation and worse 
gas exchange than patients in the earlier study by Vos et al.  The relationship 
between daytime ventilation and nocturnal hypoventilation can be inferred to 
show that the cause of the profound nocturnal hypoventilation is the result of the 
normal changes that occur during sleep being imposed on an respiratory 
system with severely abnormal pulmonary mechanics. 
Techniques to measure neural respiratory drive and hypercapnic 
ventilatory response 
The measurement of NRD using EMGdi has been previously shown to be 
reproducible and reflect disease severity in COPD.53  The use of EMGpara to 
represent NRD in stable COPD has been described in detail earlier in this work 
and it has been shown to have acceptable levels of reproducibility in this patient 
population.  The measurement of the HCVR via the rebreathe technique has 
been shown to be reliable and reproducible even in the presence of airway 
obstruction, as occurs in COPD.237  Inconsistent approaches have been 
adopted in an attempt to ‘normalise’ the HCVR in COPD to reflect the 
mechanical constraints on the respiratory system that limit changes to minute 
ventilation.  Such approaches have included dividing the slope of the HCVR by 
FEV1, measured MVV and predicted MVV.
137, 299  In the current study, it was not 
felt that adjusting the raw HCVR was warranted.  This was because the use of 
EMGpara and EMGdi would reflect central respiratory drive, negating the need to 
control for airflow obstruction and respiratory mechanical limitation.  In addition, 
the use of a randomised controlled design allows for direct comparison between 
the two groups without the need to normalise the data for comparison to a 
healthy population.  The values for HCVR in the study population were lower 
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than those reported in earlier work for eucapnic and hypercapnic COPD.137, 237  
The strength of the relationship between end-tidal carbon dioxide and minute 
ventilation was also weaker than earlier reports with some patients not showing 
a linear response to the hypercapnic challenge.  This could be explained in a 
number of ways principally that either the test was inadequate to demonstrate 
the hypercapnic ventilatory response or the patient no longer has a genuine 
linear response to progressive hypercapnia.  The former relates to the 
established phenomenon of a ‘dog leg’ between minute ventilation and level of 
carbon dioxide observed in the HCVR test.  This occurs because arterial carbon 
dioxide needs first to rise to a threshold level in order to stimulate central 
respiratory centres.234  It is possible that these patients with non-linear 
responses had yet to reach the ‘threshold’ level of hypercapnia.  However, 
patients were subjected to a significant degree of hypercapnia until completion 
of the rebreathe period, or more commonly, patient intolerance.  All traces were 
visually inspected to ensure a significant and linear rise in end-tidal carbon 
dioxide over time to be classed as technically adequate.  There would be 
significant clinical safety concerns from attempting to produce more pronounced 
hypercapnia or to continue testing beyond patient tolerance in this group with 
severe COPD and recent exacerbation.  Furthermore, several patients 
demonstrated a linear negative response to hypercapnic challenge, in that they 
had a decrease in both minute ventilation and markers of neural respiratory 
drive (EMGpara%max and EMGdi%max) with progressive rise in end tidal carbon 
dioxide.  An example hypercapnic challenge test of such a patient is provided 
for illustration (Figure 35). 
165 
Figure 35: Individual patient hypercapnic responsiveness testing demonstrating a 
negative relationship between end-tidal carbon dioxide (etCO2) and both minute 
ventilation (Ve) and neural respiratory drive (NRD) 
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Abbreviations: EMGpara%max – percentage of maximum obtainable parasternal electromyogram, 
EMGdi%max – percentage of maximum obtainable diaphragm electromyogram, etCO2 – end-tidal 
carbon dioxide. 
It can be presumed therefore that these patients have a hypercapnic ‘threshold’ 
that is sufficiently high as to be ineffective in response to an insult such as an 
acute exacerbation of COPD. 
7.3.2: Changes in central respiratory drive 
The use of domiciliary NIV to control nocturnal hypoventilation led to an 
improvement in both mechanical (hypercapnic ventilatory response) and neural 
(hypercapnic parasternal electromyogram response) response to carbon 
dioxide at the 6 week follow up stage.  The improvement in neural respiratory 
drive was greater than that of mechanical respiratory drive and persisted for 
longer during follow up.  This is to be expected given the particularly severe 
phenotype of COPD recruited for this study, specifically, patients with persistent 
severe hypercapnic respiratory failure as a consequence of severe airways 
obstruction following a recent hospital admission requiring acute non-invasive 
ventilation.  The magnitude of improvement in the HMV group was similar to 
that seen in previous studies.137   
Of interest, a non-significant reduction in both neural and mechanical 
respiratory drive was observed in the control group.  Reductions in hypercapnic 
ventilatory response have been demonstrated in COPD patients following 
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administration of oxygen therapy.300  However, the majority of our patients were 
already established on LTOT and thus this is less likely to have been a 
significant factor.  The study design randomised patients in the weeks that 
followed an acute decompensated exacerbation necessitating treatment with 
NIV.  As has been shown previously, re-setting of central respiratory drive 
occurs rapidly, within 5 days, with the administration of nocturnal NIV in the 
setting of chronic respiratory failure and a similar effect can be expected in the 
acute setting.137  The attenuation of this improvement may be responsible for 
the loss of hypercapnic responsiveness in the control group during follow up 
contributing to the significant between group differences seen in this study.   
Both the intervention and control groups experienced a reduction in PaCO2 
during follow up, although this was only significant in the HMV group suggesting 
that changes in hypercapnic response were not purely due to altered resting 
PaCO2 levels.  To provide further clarity, individual traces are provided for 
patient in the control and treatment groups demonstrating the changes in 
hypercapnic challenge testing (Figure 36).  The traces illustrate the decrease 
both in slope and volume of response, indicating that patients in the control 
group have not only a reduced response to rising end-tidal carbon dioxide but 
also have a lower level of either ventilation or NRD at a given end-tidal carbon 
dioxide.  In contrast, the opposite changes occur in the HMV group with both a 
higher level of both ventilation and NRD for a given end-tidal carbon dioxide 
with an enhanced response to rising hypercapnia. 
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Figure 36: Individual response to hypercapnic challenge in an example patient from [A] 
home oxygen therapy (HOT) and [B] home mechanical ventilation (HMV) groups 
Closed circles represent data from single hypercapnic challenge test at baseline.  Open circles 
represent repeat testing at 3 month follow up.  Abbreviations: EMGpara%max – percentage of 
maximum obtainable parasternal electromyogram, EMGdi%max – percentage of maximum 
obtainable diaphragm electromyogram, etCO2 – end-tidal carbon dioxide. 
7.3.3: Changes in tidal breathing mechanics 
There are conflicting current data on the changes in respiratory mechanics 
following domiciliary NIV in COPD.  Studies have shown reduction in gas 
trapping,134, 137 improved FEV1,
135, 236 and reduced dynamic intrinsic PEEP.236  
The current study did not demonstrate a clear difference between groups in any 
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of these parameters.  Changes in gas trapping were designed to be evaluated 
at 6 month follow up in the current study protocol but insufficient patient 
numbers reached this stage to allow meaningful use of inferential statistics, 
although the raw data shows trends in line with the published data.  The 
changes in spirometry have been present only in the studies from Diaz et al135, 
236 and are not replicated in work by other groups.137, 235  Changes in spirometry 
were also not seen in the recently published work by Funk et al151 which utilised 
a similar patient population but adopted a different study design to our current 
study.  Funk and colleagues recruited patients established on NIV following an 
acute exacerbation requiring mechanical ventilation 6 months following 
stabilisation and randomised them to either withdrawal or continuation of NIV.  
The use of this frequent exacerbator phenotype and the longer duration of our 
study than that of the previous work by Diaz et al or Nava et al leads to the 
confounding influence of inter-current exacerbations on lung function and other 
physiological parameters.  Recent data has suggested that even a single 
exacerbations can cause deterioration in lung function and therefore potentially 
influence the findings of such studies.301  In addition, changes in dynamic 
intrinsic PEEP have only been demonstrated in a single sham study that utilised 
diurnal rather than nocturnal NIV and thus may represent a specific effect of the 
therapy utilised in this modality.  Also analysis of the data from this study 
demonstrates a large number of data points clustered with little change in either 
PaCO2 or dynamic intrinsic PEEP and a small number of outlying data points 
driving the treatment effect. 
A clear treatment effect was demonstrated in the HMV group by improved 
minute ventilation during follow up.  The magnitude at 6 weeks in the current 
study (Δ1.2 L/min, 95%CI -0.2 to 2.7, p=0.091) was similar to that seen in the 
Diaz study at 4 weeks (Δ1.2 L/min, 95%CI 0.1 to 2.3, p<0.05).  Changes in tidal 
volume in the current study at 6 weeks (Δ126 mL) were also consistent with the 
data published by Nava et al (Δ148 mL)235 and Diaz et al (Δ181 mL)236.  These 
changes in tidal breathing were not mirrored by changes in the respiratory cycle 
or in changes in measured load during the current study.  As explained above, 
the study design using frequent exacerbators and the high loss of follow up data 
during the study may be responsible, in part, for this effect. In particular, it is 
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noteworthy that the effects demonstrated in the earlier studies were at a shorter 
follow up interval with the current study assessment of load was designed to be 
evaluated later at 3 months (Cdyn, dynPEEPi and spirometry) and 6 months (Cdyn, 
dynPEEPi and spirometry, gas trapping) when these treatment effects had been 
attenuated. 
Surprisingly, the study did not demonstrate changes in resting NRD as reflected 
by either EMGpara%max or EMGdi%max.  This is in contrast to the clear changes in 
central respiratory drive during the hypercapnic challenge tests.  Again, the 
assessment of EMGdi%max at 3 months follow up when other measures had 
started to attenuate may, in part, explain this finding.  However, EMGpara%max 
was assessed at the 6 week stage when the other parameters of both tidal 
breathing and hypercapnic responsiveness showed demonstrable change.  
Whilst EMGpara%max reflects changes in respiratory load during acute 
exacerbations in COPD, via changes in lung volume and in particular inspiratory 
capacity, which in the current study did not significantly alter during follow up 
and explains the failure to demonstrate change at this time.302  Although not 
significantly different due to the large spread of data, the group means moved in 
opposite directions with a reduction in EMGpara%max in the HMV group and an 
increase in the HOT group.  Again, the small number of data points may have 
led to the failure to translate this into a significant between group difference. 
7.3.4: Changes in respiratory muscle strength 
In line with much of the previously published work there was no evidence of 
changes in respiratory muscle strength in the current study.  Although the 
hypothesis that the mode of action of NIV is the result of resting of fatigued 
muscles is superficially appealing, there are few data to support this view.  It 
has not even been shown that COPD patients have clear respiratory muscle 
weakness, once values have been  corrected for the mechanical disadvantage 
produced by hyperinflation.57  Furthermore, respiratory muscle fatigue has also 
not been clearly demonstrated in vivo, even in those patients mechanically 
ventilated within critical care.247, 303  In summary, the low values of respiratory 
muscle strength demonstrated in this cohort are likely to be a marker of disease 
severity and hyperinflation with the failure of these values to change despite the 
improvement in gas exchange and central respiratory drive leaving little scope 
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for them to be considered an important mediator of the action of domiciliary NIV 
in this patient group. 
7.3.5: Attenuation of treatment effect during follow up 
The majority of physiological studies in this area have involved short term follow 
up in the most stable patients.135, 235  Other studies have used a long follow up, 
again selecting the most stable patients for investigation.134, 137  The study 
design, selecting the patients considered to have the potential for most clinical 
benefit has allowed an assessment of the real physiological treatment effect but 
has had the unintended consequence of causing significant loss of follow up 
data due to patient death or severe inter-current illness.  In addition to the loss 
of statistical power at longer follow up there is the potential for a ‘survivor’ effect, 
in that those patients from both groups reaching longer follow up may be those 
with favourable physiological response following the initial insult of a severe 
hypercapnic exacerbation of COPD. 
7.3.6: Conclusion 
The use of domiciliary NIV in patients with persistent hypercapnia following an 
acute exacerbation of COPD is associated with improvement in central 
respiratory drive which is greater than that achieved with the use of intermittent 
NIV at the time of decompensated exacerbations only.  The treatment also 
produces a favourable change in daytime resting gas exchange and tidal 
breathing.  Although the confounding effect of both inter-current exacerbations 
and loss of follow up data may have influenced the precision of the results of 
the study, the design has allowed a pragmatic assessment of a genuine 




CHAPTER 8: PHYSIOLOGICAL SUB-STUDY OF THE HOT-HMV 
TRIAL:  EFFECTS OF HOME MECHANICAL VENTILATION ON 
SLEEP QUALITY AND PHYSICAL ACTIVITY IN PATIENTS 
WITH HYPERCAPNIC RESPIRATORY FAILURE PERSISTENT 
POST EXACERBATION OF COPD 
8.1: Materials and Methods 
The background literature of this study can be found on Page 70 of this thesis.  
The study utilised patients recruited for the UKCRN multicentre HOT-HMV trial 
and a full description of the patient recruitment is described earlier in this thesis 
on Page 76 in the Materials and Methods section.  Any deviations from that 
protocol are provided below. 
8.1.1: Subjects 
Patients enrolled into the HOT-HMV UK trial were eligible.  Four of the sites 
participated in actigraphy analysis including the Lane Fox Unit, St Thomas’ 
Hospital; Sleep and Ventilation Unit, Royal Brompton Hospital; the Sleep Unit, 
Leeds University Hospital; and the Ventilation Unit, Aintree University Hospital.  
Inclusion and exclusion criteria were as detailed in the previous chapter on 
Page 143 and Page 76. 
8.1.2: Trial assessments 
Actigraphy 
Patients completed a 14 day monitoring period following each assessment, with 
the exception of the 12 month assessment when the preceding 2 week period 
was used.  The monitoring period included use of an Actiwatch Spectrum 
(Philips-Respironics, Murrysville, PA, US) with contemporaneous completion of 
a sleep hygiene diary.  The Actiwatch Spectrum device was secured to the non-
dominant wrist and patients were asked to wear it throughout the monitoring 
period with only short breaks for washing and personal hygiene.  Sleep periods 
were set using a combination of activity pattern on actigrams, sleep diary and 
light sensor readings. 
8.1.3: Follow up 
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Patients underwent follow up assessment at 6 weeks, 3 months, 6 months and 
12 months.  The study plan with details of all assessments performed at each 
visit is provided in Table 25. 
8.1.4: Data analysis 
From published data the standard deviation for sleep efficiency in COPD is 
10%, therefore a sample size of 60 patients randomised on a 1:1 basis would 
provide 80% power at the 0.05 significance level to detect a difference in sleep 
efficiency between groups of 7.5%.  This level of difference was chosen as it 
was considered to be a clinically significant effect that would be perceptible to 
patients. 
8.2: Results 
8.2.1: Patient recruitment and baseline measures 
34 patients were randomised and completed baseline actigraphy.  Recruitment 
and retention data are provided in Figure 37. 
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Figure 37: Recruitment and retention for study assessing sleep disruption with high 
pressure non-invasive ventilation in COPD 
Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation. 
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Despite randomisation and minimisation baseline characteristics of the 2 groups 
varied with significant between group differences in gender and anthropometric 
measures (Table 31A and Table 31B).  There were no significant differences 
observed between groups in severity of sleep disordered breathing on oxygen 
therapy (Table 32). 
Table 31: Baseline comparison for randomised patients in actigraphy analysis of sleep 
disruption of high pressure non-invasive ventilation compared to home oxygen therapy: 
[A] Anthropometric data and [B] Physiological data 
Table 31A: Anthropometric data 
 HOT HMV p-value 
Centre 
STH 7 10  
RBH 5 4  
AUH 3 2  
LUH 2 1  
    
Age (years) 66 ± 11 68 ± 10 0.659 
Gender 
Male / Female* 
6/11 12/5 0.039* 
BMI (kg/m
2
)* 24.6 ± 5.4 20.2 ± 2.8 0.006* 
Weight (kg) 66.2 ± 17.4 56.3 ± 10.7 0.053 
Fat free mass (kg) 33.0 ± 5.4 31.9 ± 7.3 0.608 
Fat free mass index (kg/m
2
) 12.3 ± 1.4 11.5 ± 2.4 0.242 
Neck circumference (cm) 38 ± 5 36 ± 4 0.161 
Waist circumference (cm)* 94 ± 15 85 ± 9 0.047* 
Hip circumference (cm)* 99 ± 8 91 ± 6 0.002* 
Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation, STH – St 
Thomas’ Hospital, RBH – Royal Brompton Hospital, AUH – Aintree University Hospital, LUH – 
Leeds University Hospital, BMI – body mass index. 
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Table 31B: Physiological Data 
 HOT HMV p-value 
Incremental shuttle walk test (m) 91 ± 111 76 ± 85 0.682 
PaCO2 on air (kPa) 8.0 ± 0.7 7.9 ± 0.8 0.736 
PaO2 on air (kPa) 6.3 ± 1.1 6.7 ± 1.1 0.393 
Bicarbonate on air (mmol/L) 34 ± 3 37 ± 8 0.172 
FEV1 (%) 29 ± 8 24 ± 10 0.121 
FVC (%) 62 ± 18 54 ± 29 0.313 
FEV1/FVC 0.38 ± 0.10 0.33 ± 0.07 0.115 
TLC (%)
# 
104 ± 18 91 ± 23 0.221 
Va (%)
#
 65 ± 18 71 ± 14 0.568 
RV (%)
#
 172 ± 30 135 ± 39 0.056 
FRC (%)
#
 149 ± 35 126 ± 31 0.083 
DLCO (%)
#
 39 ± 22 26 ± 10 0.210 
SRI-SS (/100) 50 ± 13 46 ± 17 0.461 
SGRQ-total 67 ± 12 71 ± 14 0.401 
MRC (/5) 4 ± 1 5 ± 1 0.060 
ESS (/24) 9 ± 5 6 ± 5 0.052 
*
p<0.05 between group comparison (independent t-test); 
#
performed on HOT=11, HMV=9.  
Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation, PaCO2 – 
arterial partial pressure of carbon dioxide, PaO2 – arterial partial pressure of oxygen, FEV1 – 
forced expiratory volume in 1s, FVC – forced vital capacity, TLC – total lung capacity, Va – 
alveolar volume, RV – residual volume, FRC – functional residual capacity, DLCO – Diffusion 
capacity of carbon monoxide, SRI-SS – severe respiratory insufficiency questionnaire summary 
score, SGRQ-total – St George’s respiratory questionnaire total score, MRC – Medical 
Research Council dyspnoea score, ESS – Epworth sleepiness score. 
Similar levels of nocturnal hypoxia and hypercapnia were demonstrated during 
limited respiratory sleep studies performed on the prescribed oxygen therapy 
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prior to randomisation (Table 32).  There were no cases of significant 
obstructive sleep apnoea syndrome diagnosed. 
Table 32: Comparison of baseline overnight oximetry-capnography performed prior to 
randomisation in groups subsequently randomised to home oxygen therapy (HOT) and 
home mechanical ventilation (HMV) 
 HOT HMV p-value 
Oxygen prescription (Lmin
-1
) 1 ± 1 1 ± 1 0.573 
AHI (/hr) 4 ± 7 10 ± 18 0.399 
4%ODI 9 ± 14 9 ± 15 0.963 
Mean SpO2 (%) 89 ± 8 94 ± 4 0.071 
Min SpO2 (%) 69 ± 24 70 ± 16 0.693 
%TST SpO2<90% (%) 34 ± 39 19 ± 24 0.184 
Mean tcCO2 (kPa) 8.6 ± 1.1 9.1 ± 1.4 0.294 
Max tcCO2 (kPa) 10.3 ± 1.3 10.4 ± 1.8 0.838 
Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation, ODI – 
oxygen desaturation index, SpO2 – oxyhaemaglobin saturation, TST – total sleep time, tcCO2 – 
transcutaneous carbon dioxide. 
Anthropometric measures as well as daytime PaCO2 and SpO2 on O2 therapy 
correlated with severity of nocturnal hypoxia (Table 33).  The severity of 
nocturnal hypercapnia correlated with daytime PaCO2 performed on room air 
(mean tcCO2 r=0.489, p=0.004; max tcCO2 r=0.522, p=0.002) but less strongly 
when performed on prescribed oxygen therapy (mean tcCO2 r=0.250, p=0.161; 
max tcCO2 r=0.524, p=0.002).  There were no significant relationships between 
anthropometric measures and severity of nocturnal hypercapnia.  Finally, there 
was no relationship demonstrated between spirometry and severity of nocturnal 
hypoxia or hypercapnia. 
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Table 33: Correlation between severity of nocturnal hypoxia during treatment with 
prescribed oxygen therapy and anthropometric measures 
 
Mean nocturnal SpO2 (%) %night time SpO2<90% 
r p value r p value 
BMI (kg/m
2
) -0.468 0.006 0.313 0.076 
Fat free mass (kg) -0.443 0.010 0.402 0.020 
Waist circumference (cm) -0.383 0.028 0.256 0.151 
Neck circumference (cm) -0.523 0.002 0.535 0.002 
PaCO2 on oxygen therapy 
(kPa) 
-0.349 0.047 0.448 0.009 
Daytime SpO2 on oxygen 
therapy (%) 
0.544 0.002 -0.493 0.007 
Abbreviations: SpO2 – oxyhaemaglobin saturation, BMI – body mass index, PaCO2 – arterial 
partial pressure of carbon dioxide. 
8.2.2: Ventilator settings and efficacy of nocturnal non-invasive ventilaiton 
12 patients received nocturnal NIV with the Harmony 2 ventilator (Philips-
Respironics, Murrysville, PA, US) and 5 patients received nocturnal NIV with the 
VPAP IIISTa ventilator (ResMed, Bella Vista, Australia).  The ventilator settings 
for patients randomised to home mechanical ventilation in addition to home 
oxygen therapy were an IPAP 25 ± 2 cmH2O, EPAP 4 ± 1 cmH2O, a back-up 
rate of 14 ± 2 breaths per minute.  15 patients used a full face mask (10 x 
ComfortFull 2, Philips-Respironics, Murrysville, PA, US; 5 x Mirage Quattro, 
ResMed, Bella Vista, Australia), 1 patient used a nasal mask (ProfileLite, 
Philips-Respironics, Murrysville, PA, US) and 1 patient used a total face mask 
(FitLife, Philips-Respironics, Murrysville, PA, US).  As expected, patients 
randomised to nocturnal NIV had superior control of nocturnal hypoxia and 
hypercapnia (Table 34). 
Table 34: Oximetry-capnography at baseline on allocated treatment 
 HOT HMV p-value 
4%ODI 7 ± 13 8 ± 8 0.744 
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 HOT HMV p-value 
Mean SpO2 (%)* 91 ± 6 95 ± 3 0.010* 
Min SpO2 (%) 70 ± 21 80 ± 10 0.115 
%TST SpO2<90% (%) 26 ± 31 9 ± 13 0.053 
Mean tcCO2 (kPa)* 8.6 ± 1.0 7.5 ± 1.3 0.010* 
Max tcCO2 (kPa)* 10.4 ± 1.2 8.8 ± 1.6 0.003* 
*
p<0.05 between group comparison (independent t-test).  Abbreviations: HOT – home oxygen 
therapy, HMV – home mechanical ventilation, ODI – oxygen desaturation index, SpO2 – 
oxyhaemaglobin saturation, TST – total sleep time, tcCO2 – transcutaneous carbon dioxide. 
8.2.3: Exercise capacity and daytime physical activity 
Baseline exercise capacity as measured by the incremental shuttle walk test 
distance correlated with anthropometric measures (weight r=0.425, p=0.014; 
BMI r=0.371, p=0.034; FFMI r=0.536, p=0.001; FFM r=0.592, p<0.001; waist 
circumference r=0.463, p=0.007) but there was no relationship observed 
beween ISWT distance and objective measures of daytime physical activity 
measured by actigraphy in the week following randomisation (mean activity 
r=0.238, p=0.182; max activity r=0.289, p=0.103; percentage of day spent 
mobile r=0.138, p=0.443).  The only objective measure of daytime physical 
activity that correlated with an anthropometric measure was maximum activity 
count which showed a weak correlation with FFMI (r=0.352, p=0.044).  Low 
levels of activity were present in both groups at baseline with high levels of 
sedentary behaviour (Table 35).  These low levels of activity persisted 
throughout follow up with no significant change in activity pattern occurring in 
either group (Figure 38). 
Table 35: Comparison of daytime physical activity in 2 weeks following randomisation 
between home oxygen therapy (HOT) and home mechanical ventilation (HMV) groups 
 HOT HMV p-value 
Mean activity counts 
(counts/min) 
117 ± 48 113 ± 46 0.797 
Max activity counts 882 ± 269 993 ± 293 0.270 
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 HOT HMV p-value 
Mobile time (minutes) 639 ± 135 663 ± 124 0.607 
%daytime spent mobile (%) 69 ± 15 68 ± 14 0.811 
Immobile time (minutes) 292 ± 142 316 ± 142 0.635 
%daytime spent immobile (%) 31 ± 14 34 ± 13 0.583 
Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation. 
Figure 38: Changes in objective measures of physical activity during follow up in home 
oxygen therapy (HOT) and home mechanical ventilaiton (HMV) groups for [A] mean 
activity, [B] maximum activity, [C] percentage of daytime period spent mobile and [D] 


































































































































































































































Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation. 
8.2.4: Differences in actigraphy measured sleep parameters and sleep 
quality 
Analysis of actigraphy data showed similar levels of sleep disruption but 
demonstrated a significantly longer total sleep time in the HOT group compared 
to the HMV group (Δ67 min, 95%CI 6 to 127, p=0.032) in the week following 
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randomisation (Table 36).  Sleep efficiency was non-significantly lower in the 
HMV group at baseline analysis (Δ6%, 95%CI -5 to 18, p=0.279) with no 
differences in self-reported sleep quality (Table 36). 
Table 36: Actigraphy measured sleep parameters in 7 days following randomisation 
Sleep quality measure on a 3 point scale (1=poor, 2=average, 3=good).  Abbreviations: HOT – 
home oxygen therapy, HMV – home mechanical ventilation, TST – total sleep time, WASO – 
wake after sleep onset. 
Actigraphy analysis of sleep parameters at 6 weeks follow up showed no 
between group differences in sleep quality or quantity (Table 37).  A small, but 
statistically significant, difference in sleep latency occurred in the HOT group 
(Δ3 min, 95%CI 0 to 7, p=0.045) with a trend to reduced sleep latency in the 
HMV group (Δ-13 min, 95%CI -30 to 3, p=0.094). 
Table 37: Comparison of actigraphy measured sleep parameters in the 2 weeks following 
6 week follow up between home oxygen therapy (HOT) (n=6) and home mechanical 
ventilation (HMV) (n=11) groups 
 HOT HMV p-value 
Sleep efficiency (%) 65 ± 20 58 ± 14 0.279 
TST (min)* 322 ± 103 255 ± 67 0.032* 
WASO (min) 161 ± 105 153 ± 73 0.814 
Sleep latency (min) 12 ± 9 19 ± 29 0.329 
Sleep quality 2 ± 1 2 ± 1 0.935 




Sleep efficiency (%) 65 ± 17 59 ± 14 
6 
(-10 to 22) 
0.451 
TST (min) 304 ± 110 261 ± 67 
43 
(-48 to 134) 
0.330 
WASO (min) 151 ± 101 165 ± 77 
-15 
(-108 to 77) 
0.736 
Sleep latency (min) 12 ± 7 10 ± 12 
2 
(-9 to 14) 
0.648 
Sleep quality 2 ± 1 2 ± 1 
0 
(-1 to 1) 
0.930 
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Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation, TST – total 
sleep time, WASO – wake after sleep onset. 
Over the duration of longer term follow up (3, 6 and 12 month), there were no 
significant between group differences observed in either absolute or change 
from baseline sleep efficiency, TST, WASO or sleep latency (Figure 39), albeit 
there was a trend to a difference in change in total sleep time and wake after 
sleep onset. 
Figure 39: Comparison of changes in actigraphy measured sleep parameters from 
baseline to 1 year follow up between treatment groups for [A] sleep efficiency, [B] total 












































































































































































































































Abbreviations: HOT – home oxygen therapy, HMV – home mechanical ventilation. 
8.2.5: Analysis of sleep data by centre 
A higher rate of follow up data loss occurred at peripheral (Aintree University 
Hospital, Leeds University Hospital) rather than central (St Thomas’ Hospital, 
Royal Brompton Hospital) study sites (data loss at 6 week follow up, Fisher’s 
exact test p=0.003).  Baseline comparison shows the groups were similar in 
terms of anthropometrics, exercise capacity and severity of spirometric deficit 
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(Table 38).  However, despite similar levels of PaCO2 and PaO2 there were 
significantly lower bicarbonate levels in the patients recruited from peripheral 
sites (∆7 mmol/L, 95%CI 2 to 11, p=0.006). 
Table 38: Comparison of patients enrolled in actigraphy sub-study from central or 
peripheral recruiting sites 
 Central sites Peripheral sites p-value 
Treatment allocation (HOT / 
HMV) 
12/14 5/3 0.419 
Age (years) 68 ± 10 65 ± 11 0.583 
Gender (Male / Female) 13 / 13 5 / 3 0.536 
BMI (kg/m
2
) 22 ± 5 23 ± 3 0.772 
Fat free mass (kg) 32 ± 7 34 ± 4 0.325 
Incremental shuttle walk test (m) 86 ± 109 74 ± 48 0.754 
PaCO2 on air (kPa) 8.0 ± 0.8 7.7 ± 0.5 0.312 
PaO2 on air (kPa) 6.6 ± 1.1 6.2 ±1 .1 0.357 
Base excess (mmol/L)* 9 ± 3 6 ± 2 0.006* 
FEV1 (%) 26 ± 10 27 ± 8 0.758 
FVC (%) 56 ± 25 64 ± 23 0.131 
FEV1/FVC 36 34 0.470 
*
p<0.05 between group comparison (independent t-test).  Abbreviations: HOT – home oxygen 
therapy, HMV – home mechanical ventilation, BMI – body mass index, PaCO2 – arterial partial 
pressure of carbon dioxide, PaO2 – arterial partial pressure of oxygen, FEV1 – forced expiratory 
volume in 1s, FVC, forced vital capacity. 
Despite the similar baseline characteristics, there were significant differences in 
sleep and activity patterns in the 2 weeks following randomisation.  Patients 
recruited from peripheral sites had longer sleep times (TST central 274 ± 96 
minutes, peripheral 338 ± 55 minutes, ∆-65 minutes, 95%CI -138 to 9 minutes, 
p=0.081) with significantly lower levels of sleep disruption (WASO central 178 ± 
87 minutes, peripheral 89 ± 64 minutes, ∆89 minutes, 95%CI -22 to -157 
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minutes, p=0.011) translating to significantly higher levels of sleep efficiency 
(central 57 ± 16%, peripheral 76 ± 12%, ∆19%, 95%CI 7 to 32%, p=0.003).  
Both groups had similar levels of sleep latency (central sites 15 ± 24 minutes, 
peripheral 17 ± 11 minutes; p=0.857).  Despite poorer sleep quantity and quality 
patients from the central sites spent a greater proportion of the day mobile (% 
daytime mobile central 72 ± 11%, peripheral 59 ± 18%, ∆12%, 95%CI 1 to 23, 
p=0.028) and a lower proportion of the day sedentary (% daytime immobile 
central 30 ± 12%, peripheral 42 ± 17%, ∆-12%, 95%CI -1 to -23, p=0.031). 
8.3: Discussion 
8.3.1: Recruitment and data retention 
As discussed earlier, with the physiological sub-study the analysis of actigraphy 
data has been limited by not reaching the pre-specified sample size and by 
suffering from a larger than expected patient drop-out rate and data loss during 
follow up.  Again, as with the physiological sub-study, inferential statistics have 
been limited to earlier follow up (baseline to 3 months) but not for longer follow 
up (6 to 12 months) but all data is quantitatively displayed to fully inform the 
reader.  In addition to the loss of follow up data from patient death and severe 
inter-current exacerbations there was a loss of follow up data due to technical 
difficulties.  This predominantly occurred in the peripheral centres (Aintree and 
Leeds) and further contributed to under-powering of this study.  This was a 
consequence of limited manpower for the day to day running of the trial at these 
peripheral sites, which is a common problem with multicentre trials.  Patients 
from peripheral centres had similar baseline characteristics, but had markedly 
different sleep and activity profiles in the two weeks following randomisation.  
Although the reasons for this disparity are unclear, this difference appears 
independent of body composition or severity of airflow obstruction.  If the data 
analysis is confined to patients recruited from the central sites, there was no 
effect on the data interpretation.  Due to the patient retention issues and loss of 
data, the difference in total sleep time between home oxygen therapy and home 
oxygen therapy combined with home mechanical ventilation groups does not 
achieve significance, but there is a trend towards a difference.  The primary 
endpoint was pre-specified as sleep efficiency at 6 weeks, as it was expected 
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there may be an acclimatisation effect in the home oxygen therapy and home 
mechanical ventilation group in the days following NIV setup.  All data analysed 
at this point was from the central sites and in addition to manpower issues for 
trial delivery at the peripheral sites, there were technical difficulties with the 
actigraphy software and device failure.  Interestingly, there were no reported 
cases of patient intolerance of the wrist-worn actigraphy device. 
8.3.2: Limitations of methods of assessment 
Previous data collected of the disruptive effects of nocturnal oxygen therapy 
and NIV on sleep quality have focussed on the interpretation of single night 
multichannel polysomongraphy, whilst data for longer term measurement of 
sleep quality has been lacking.  The relative merits of actigraphy and 
polysomongraphy to measure sleep quality in sleep disordered breathing are 
discussed earlier in this thesis (page 115).  Furthermore, the accuracy of the 
different physical activity monitoring devices for measuring daytime physical 
activity, rather than sleep quality, has recently been investigated in COPD 
patients as part of the European PROActive project (clinicaltrials.gov 
NCT01388218).  Despite the activity count output of the Actiwatch Spectrum 
device being shown to only moderately correlate with metabolic measures of 
energy expenditure in severe COPD, it was reliable in detecting a clinically 
significant improvement in walking speed.304  This is not unexpected as the 
Actiwatch Spectrum is a tri-axial accelerometer which quantifies activity counts 
as a reflection of change in speed and does not measure energy expenditure. 
8.3.3: Actigraphy assessed sleep disruption 
The primary outcome of the study was to investigate sleep quality at 6 weeks.  
As already discussed, the study was underpowered to confidently exclude a 
significant difference in sleep efficiency at this time point.  However, the 
longitudinal nature of the data collected allows for meaningful analysis of the 
effect of home mechanical ventilation in addition to home oxygen therapy on 
sleep quality in severe COPD complicated by hypercapnic respiratory failure.  
There appears a significant effect of home mechanical ventilation on sleep 
quantity and objective sleep quality in period immediately following home 
mechanical ventilation setup.  However, this effect did not significantly impair 
subjective sleep quality and the between group difference consistently narrowed 
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during the study follow up.  This has important implications for interpreting the 
other published data.  The work by Dreher et al investigated sleep quality, using 
multichannel polysomnography, comparing a high and low intensity non-
invasive ventilation approach, albeit in patients already established on a high 
intensity (high pressure and high back up rate) non-invasive ventilation.142  The 
current data supports the view that these patients were already acclimatised to 
the treatment and thus the findings may not reflect those observed in a group of 
COPD patients naïve to non-invasive ventilation.  It could be inferred that sleep 
disruption in high and low intensity non-invasive ventilation may relate to the 
device and interface issues rather than the ventilatory settings and so both 
strategies may induce sleep disruption initially following non-invasive ventilation 
setup.  These data are clinically useful; the clinician can inform the patient that 
although they may have an initial deterioration in both sleep quantity and 
quality, this negative effect is short lived. 
8.3.4: Control of nocturnal hypoventilation 
Earlier work has shown a clear relationship between nocturnal hypoventilation 
and daytime resting gas exchange and anthropometric measures in patients 
with less severe chronic hypercapnic respiratory failure (mean PaCO2 6.5 ± 0.9 
kPa) who were not on LTOT.305  De Angelis et al investigated the relationships 
between nocturnal oximetry and anthropometrics, spirometry and daytime gas 
exchange.  The patients studied by De Angelis and colleagues were of a similar 
age (65.2 ± 8.1 years) with slightly higher BMI (26.1 ± 2.7) and a less severe 
phenotype in terms of spirometry and gas exchange when compared to the 
current study (FEV1 43 ± 15%, PaO2 9.1 ± 0.8 kPa, PaCO2 6.5 ± 0.9 kPa).  The 
De Angelis study protocol performed nocturnal oximetry on air rather than on 
oxygen therapy as was the protocol in HOT-HMV UK.  However a similar 
inverse relationship was demonstrated between mean nocturnal SpO2 and body 
mass index (De Angelis et al r=-0.452, p<0.01; HOT-HMV r=-0.468, 
p=0.006).305  The degree of correlation between mean nocturnal SpO2 and body 
mass index was significant in the data reported by De Angelis et al and the 
current data presented in this thesis in patients with mild to severe chronic 
hypercapnic respiratory failure, whereas the relationship has been shown to be 
weak in COPD patients without chronic hypercapnic respiratory failure (r=-0.26, 
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p<0.02).306  Interestingly, there was no relationship between body mass index 
and measures of nocturnal hypercapnia (mean tcCO2 p=0.817, max tcCO2 
p=0.721) indicating that patients suffering from COPD and OSA overlap had 
been successful excluded from the HOT-HMV trial cohort.  The finding in the 
current study of strong relationships between daytime PaCO2 and SpO2 on 
oxygen therapy and nocturnal hypoxia is in disagreement with earlier data 
supporting a relationship with hypercapnia, but not daytime arterial partial 
pressure of oxygen.306  However, differences in the patient population are 
responsible, in part, for this observation.  The earlier work by Chaouat et al 
investigated nocturnal desaturations in patients without established hypoxic 
respiratory failure (PaO2 >7.3 kPa) and these patients will be positioned on the 
more favourable portion of the oxyhaemoglobin dissociation curve and as such 
SpO2 will be less affected by small changes in PaO2 occurring due to sleep 
hypoventilation than patients with more severe hypoxic respiratory failure.306   
Whilst it is unsurprising that measures of daytime gas exchange on oxygen 
therapy correlate with the severity of nocturnal hypoxia and hypercapnia on the 
same flow rate level of oxygen therapy, the similarity in the strength of 
relationship with body mass index is perhaps unexpected given the different 
severity of the patient groups. 
Many of the previous published clinical trials reporting the limited effect of home 
mechanical ventilation in COPD patients have been criticised for their failure to 
improve daytime gas exchange.93, 140  This has largely been attributed to the low 
airway pressures delivered by the non-invasive ventilator used and the failure to 
clearly demonstrate an improvement in nocturnal hypoventilation.  Meecham-
Jones et al demonstrated the importance of the control of nocturnal 
hypoventilation in a small randomised crossover study that showed a direct 
correlation between the change in nocturnal tcCO2 and improved daytime 
PaCO2.
136  The group in this trial had similar severity of nocturnal hypoxia and 
hypercapnia on oxygen therapy alone but the home mechanical ventilation 
group showed a significant improvement following initiation of nocturnal non-
invasive ventilation.  Patients allocated to home mechanical ventilation also had 
enhanced control of nocturnal hypoxia and hypercapnia than patients allocated 
to home oxygen therapy alone.  This study allowed for the true effect of 
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nocturnal non-invasive therapy, administered with adequate ventilator pressure, 
to control nocturnal hypoventilation rather than sub-therapeutic home 
mechanical ventilation and therefore address some of the concerns regarding 
interpretation of the data raised by earlier trials.  As researchers involved in 
clinical trials, we need to distinguish between the failure of intervention to 
provide clinical benefit and the failure of an intervention to be delivered 
effectively as the outcome will be the same. 
8.3.5: Physical activity and exercise capacity 
Patients in the home oxygen therapy group and home mechanical ventilation in 
addition to home oxygen therapy group had profoundly low levels of physical 
activity in the two weeks following randomisation with activity levels in both 
groups being lower than those observed in patients following hospital admission 
for an acute exacerbation of COPD that was not complicated by acute on 
chronic respiratory failure requiring acute non-invasive ventilation.307  This low 
level of activity did not significantly alter in either group throughout the duration 
of follow up.  This is in contrast to previous data showing improved levels of 
physical activity at 1 month follow up compared to immediately following 
hospital discharge.109  The data reported by Pitta et al was collected on a similar 
sized patient group (n=17) with a similar degree of airflow limitation (FEV1 29% 
(20-48)) but without chronic respiratory failure.  The presence of respiratory 
failure is an established poor prognostic feature in COPD and is associated with 
increased morbidity including high rates of hospital readmission.147  Whilst Pitta 
et al showed an increase in walking time at one month following an acute 
exacerbation requiring hospitalisation, they also demonstrated that there were 
only modest, non-significant, improvements in other measures of physical 
activity (time spent standing, sitting, lying down or in weight bearing activity) and 
that those patients with less improvement at follow up were at higher risk of 
subsequent readmission.  It is rational to propose that the failure of activity to 
improve during recovery following an acute exacerbation is correlated to the 
severity of the cohort enrolled in our study.  Exercise capacity correlated with a 
range of anthropometric measures, most notably fat free mass and fat free 
mass index.  Both these measures of lean body mass have been shown 
previously to be strong predictors of quadriceps strength in COPD.308  Although 
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quadriceps force was not directly measured in this patient cohort it is 
established that lean body mass and quadriceps strength also correlate with 
exercise capacity in COPD.309  Earlier studies have demonstrated a relationship 
between physical activity and exercise capacity in large cohorts of COPD 
patients covering all GOLD stages.97  However, this relationship may vary with 
disease severity with recent data suggesting that whilst quadriceps strength is 
an important determinant of physical activity in early disease (GOLD stage I), it 
is the degree of airway flow limitation and hyperinflation during standard lung 
function testing rather than peripheral muscle weakness that dictates physical 
activity in more severe disease (GOLD IV).310  This may explain, in part, the 
apparent discord between the results detailed in this thesis from a select group 
of GOLD stage IV patients with hypercapnic respiratory failure and larger 
cohorts of patients that cover a complete cross-section of disease severity. 
8.3.6: Variation in sleep and activity by trial site 
Despite patients from the central and peripheral sites having similar clinical and 
anthropometric features there were pronounced differences in the sleep and 
activity characteristics collected in this study.  The only statistically significant 
difference in baseline features was a higher base excess in the central cohort, 
this was accompanied by a non-significantly higher PaCO2.  This could be 
interpreted as a chance finding or suggesting that with larger numbers in the 
cohort the central group may have been shown to have more severe 
hypercapnic respiratory failure.  Given this clinical trend it is therefore perhaps 
surprising that the central group had higher levels of daytime activity as 
measured by percentage of daytime spent mobile.  All of the sites involved in 
the study serve urban environments and thus the reason for this apparent 
discord is unclear.  London has high levels of migration and so one could 
hypothesise that patients in London may have less well established support 
networks and therefore are required to perform more activities of daily living 
than patients outside of London.  Despite the higher level of activity observed in 
the central cohort there was no statistically significant difference in the exercise 
capacity, as measured by incremental shuttle walk test, between groups.  More 
pronounced than the activity differences were the differences in actigraphy 
measured sleep parameters with patients outside of London achieving an extra 
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hours sleep per night than there comparators in the central cohort.  This 
improvement in sleep quantity was accompanied by an improvement in sleep 
quality with reduced sleep disruption and higher sleep efficiency in the 
peripheral cohort.  The reasons for this difference are not explained by the 
anthropometric or clinical characteristics of the patients and again it raise the 
possibility of the patients from outside of the central sites being phenotypically 
different to those from central sites.  Another potential explanation is that the 
difference has occurred due to the reduced data collection rates at the 
peripheral centres and that this has selected out a sleepier, less active cohort 
that the larger central cohort, although why these characteristics would have led 
you to be more likely to complete the actigraphy component of the study is not 
clear. 
8.3.7: Conclusion 
The study was unable to demonstrate a negative effect of home mechanical 
ventilation on actigraphy measured parameters of sleep quality and quantity 6 
weeks following initiation of home mechanical ventilation.  However, it cannot 
be concluded that there is no significant effect as poor recruitment means the 
study was underpowered to assess the primary outcome.  The study remains 
informative as it shows impairment in sleep quantity immediately following 
initiation of home mechanical ventilation that attenuates during follow up. 
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CHAPTER 9: DISCUSSION OF THE PHYSIOLOGICAL 
ASSESSMENT OF THE RESPIRATORY LOAD-CAPACITY-
DRIVE RELATIONSHIP IN RESPIRATORY FAILURE 
9.1: Physiological and clinical outcomes following HMV in the 
treatment of obesity hypoventilation syndrome 
The data presented in this thesis demonstrates the clinical importance of 
physiologically targeted ventilator setup.  The previous studies, indicating a 
superior control of nocturnal hypoventilation could be achieved when using 
volume targeted NIV were shown to be a result of study design rather than 
ventilator technology.  The study demonstrated the importance of targeting the 
setup of HMV to overnight physiological monitoring to ensure the abolition of 
upper airways obstruction and the amelioration of nocturnal hypoventilation, as 
measured by tcCO2.  The implementation of this strategy provided similar levels 
of delivered pressure support in both patients randomised to usual as opposed 
to volume targeted NIV.  Of equal importance was demonstrating that all of the 
important clinical and physiological parameters correlate to improvement in 
respiratory failure, as measured by daytime PaCO2.  This confirms current 
clinical practice and again stresses the importance of ensuring ventilator setup 
strategy is implemented in order to control sleep disordered breathing.  The 
study is the first to show a therapeutic effect of HMV on objective physical 
activity in OHS, a finding that warrants further evaluation given the importance 
of this endpoint in the underlying aetiology of obesity. 
9.2: A novel marker of neural respiratory drive to assess 
clinical change during exacerbations of COPD 
The data collected as part of this thesis has demonstrated the potential clinical 
utility of a novel physiological biomarker of clinical change during acute 
exacerbations of COPD.  EMGpara%max has been shown to have acceptable 
levels of reproducibility in stable disease and to accurate reflect response to 
treatment during hospitalised exacerbations of COPD.  This novel physiological 
assessment tool outperformed routine clinical and physiological parameters with 
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receiver operating curve analysis suggesting the discriminatory power of the 
test met clinically useful benchmarks.  In addition to the accurate monitoring of 
clinical course during an exacerbation, the failure of NRD, as reflected by 
EMGpara%max, to reduce between admission and discharge was associated with 
a significantly higher risk of readmission in the subsequent 14 days.  The ability 
to risk stratify patients at discharge for risk of subsequent readmission represent 
a potential advance in clinical care, which requires further evaluation in larger 
studies and in the primary care population. 
To move this novel physiological test into routine clinical practice would face a 
number of challenges.  There are basic technological issues of translating a 
research assessment delivered by a highly trained operator into a standard test 
that can be delivered by nursing or allied health professional staff.  If a robust 
and simple equipment protocol could be developed and staff trained there 
would still be a need to demonstrate unequivocal superiority of the use of neural 
respiratory drive over the routine clinical parameters.  Furthermore, the clinical 
benefit would need to provide a sufficient cost saving to justify the outlay on 
equipment and training.  Also the development and implementation of the NHS 
early warning score has advocated the use of a standardised dataset across the 
health service for the assessment of the unwell patient thus use of a neural 
respirator drive would need to be integrated alongside as a disease specific 
adjunct.311  A purported benefit of the NHS early waning score is that the same 
variables will be collected on different wards or hospitals facilitating training and 
making threshold triggering easier to implement.  The addition of disease 
specific markers such as neural respiratory drive will need to be carefully 
thought through to ensure that they do not detract from other aspects of patient 
assessment systems. 
9.3: Physiological changes in the load-capacity drive 
relationship following HMV in the treatment of hypercapnic 
COPD 
The data presented represents the first use of a randomised controlled trial 
design to evaluate the physiological action of HMV in hypercapnic COPD.  The 
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data indicates the improvement in gas exchange produced by HMV is mediated 
principally through changes in central respiratory drive and tidal breathing 
pattern.  Poor recruitment prevented a definitive evaluation of changes in 
respiratory muscle load although the trends were supportive of the previous 
data suggesting a lowering of threshold load.  In line with existing data there 
were no significant changes to respiratory muscle capacity following HMV. 
The serial measurements of respiratory drive in patients with recent use of NIV 
for an acute decompensated episode of hypercapnic respiratory failure allowed 
for a useful observation; the attenuation in central drive in patients on home 
oxygen therapy alone.  There is an acknowledged high readmission and 
mortality rate in patients who have survived an admission for an acute 
exacerbation of COPD complicated by decompensated hypercapnic respiratory 
failure with much of the morbidity and mortality happening within the first few 
weeks following discharge.148, 149  The rapid diminution of central respiratory 
drive by 6 weeks that occurred in the control group may in part explain this with 
patients less well able to respond to increases in CO2 that may occur with a 
repeat exacerbation.  This is encouraging for the clinical outcomes of the HOT 
HMV UK study that are currently awaited. 
9.4: Physiological and clinical outcomes following HMV in the 
treatment of hypercapnic COPD 
The use of a high pressure ventilatory strategy allowed significant improvement 
of nocturnal sleep disordered breathing without a demonstrable deleterious 
effect on either subjective or objective sleep quality.  There was, however, a 
significant if short term effect on sleep quality with the addition of HMV to HOT.  
Despite improvements in respiratory failure in the HMV group there was no 
significant effect on physical activity.  The study highlights the severe limitation 
to physical activity in these severe COPD patients and the minimal impact of 
home mechanical ventilation on this outcome.  The reasons for this may relate 
to the severity of the disease population studied but warrants further 
investigation to identify strategies, such as home rehabilitation, that could bring 
improvements in this important area.  The trial design did not include baseline 
pulmonary rehabilitation in all patients and recent data has suggested that 
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domiciliary NIV may augment the response of hypercapnic patients to 
rehabilitation.111  The failure of NIV to improve physical activity may relate to the 
severity of the phenotype chosen or the lack of a specific pulmonary 
rehabilitation element. 
9.5: Future work 
9.5.1: Obesity related respiratory failure 
The work described earlier in this thesis demonstrates the equivalence of gold 
standard care, a nurse led protocolised titration of NIV, compared to an 
automated titrating device in the management of obesity hypoventilation 
syndrome.  Due to the increasing obesity epidemic, OHS will become an ever 
more common indication for domiciliary NIV and the results of this study raise 
the possibility of using home setup with advanced ventilators to achieve 
optimum personalised NIV settings.  This has the advantage of not 
necessitating a prolonged hospital admission for all patients allowing a potential 
cost saving. 
9.5.2: Parasternal EMG measurement 
The data collected using EMGpara has demonstrated that the measurement of 
neural respiratory drive is feasible in acute hospital admissions and may provide 
clinically useful information.  A larger prospective study is required to confirm 
the pilot study findings and confirm the threshold levels that would allow 
patients to be categorised as high or low risk of readmission.  Further work may 
include a multi-centre cluster randomised study to identify whether the 
additional information provided by the measurement of neural respiratory drive 
to risk stratify patients presenting with acute exacerbations of COPD translated 
into reduced hospital readmissions, hospital length of stay and mortality.  The 
use of neural respiratory drive to assess patient response to treatment in other 
respiratory disorders is also a potential avenue for further research.  Most 
appealing would be asthma that is also characterised by hyperinflation that 
augments the activity of the upper parasternal muscles but there is also the 
potential to use neural respiratory drive in critical care to assist with weaning 
and to assess patient-ventilator synchrony. 
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9.5.3: HOT-HMV UK 
The lower than anticipated rates of recruitment means that this work is 
continuing and should either demonstrate or refute the clinical utility of 
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CHAPTER 12: APPENDIX 























































VENTILATOR SET UP 










Suggested Ti Setting 
VPAP 3 ST/A 
 Min 0.8 




VPAP 3 150ms 
Harmony 2 1-3 
 
START PRESSURES (cmH2O) 
IPAP 18cmH2O 
EPAP 4cmH2O 
ENTRAIN OXYGEN AT 
DAYTIME PRESCRIPTION 
 
Is TcCO2 falling? 
Aim to decrease peak or reduce 
rise in TcCO2 by 
0.5KPa – 1KPa overnight 
yes 
no 
Increase IPAP by 2 
Review after 1 hour 
 
SaO2 > 88%? 







Patient demonstrating upper 
airways obstruction or snoring? 
yes 
Increase EPAP by 2 
This may require an increase in 
IPAP to maintain differential 
Review after 1 hour 






Suggested Trigger Setting 
VPAP 3 medium 
Backup rate 
VPAP 14-16 bpm 
Harmony 14-16 bpm 
Check for leak and 




Appendix G: AVAPS overnight titration protocol 
Patients randomised to the fixed bi-level arm underwent daytime NIV 
acclimatisation using the initiation settings provided on the protocol below.  The 
daytime session was designed to provide the patient with time to familiarise 
themselves with the device and pressure settings but also to ensure adequate 
interface fitting.  The interface should be fitted to provide patient comfort and 
with an unintentional leak of <30 L/min, with the aim to obtain a consistent leak 
of <15 L/min.  Initial interface choice was a full face mask with nasal mask and 
chin strap used if full face mask was not tolerated.  During acclimatisation 
patient synchronisation should be noted and back up rate altered to 2 less than 
resting rate.  Rise time was modified to patient comfort.  Patients had a 
nocturnal study with pressures titrated using the protocol provided below to 
adjust inspiratory and expiratory pressures in response to oximetry-capnometry 






During overnight study hourly observations should be recorded in the nursing 
data sheet and attached to the downloaded respiratory sleep study report. 
 
 
Final setting adjustments will be made at the morning review performed by the 
supervising consultant along with decision on acceptability of overnight control 
of sleep disordered breathing and suitability for discharge. 
